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Résumé 
La voie de signalisation des Récepteurs Tyrosine Kinase (RTK) occupe un rôle central 
dans la régulation de la croissance cellulaire, la prolifération, la différentiation et la motilité. 
Une régulation anormale des RTKs mène à plusieurs maladies humaines telles que le cancer 
du sein, la seconde cause de mortalité chez les femmes à cause de l’amplification et la 
mutation fréquente de la protéine tyrosine kinase HER2 (ERBB2). Grb2-associated binder 
(Gab) 2 est une protéine adaptatrice qui agit en aval de plusieurs RTKs, y compris HER2, 
pour réguler de multiples voies de signalisation. En réponse à la stimulation par de nombreux 
facteurs de croissances et cytokines, Gab2 est recruté à la membrane plasmique où il 
potentialise l’activation des voies de signalisation Ras/mitogen-activated protein kinase 
(MAPK) et PI3K (phosphatidylinositol-3-kinase)/Akt (protein kinase B). En plus d’occuper 
un rôle essentiel durant le développement du système hématopoïétique, Gab2 est souvent 
amplifié dans les cancers, notamment le cancer du sein et les mélanomes. Cependant, les 
mécanismes moléculaires qui régulent le fonctionnement de Gab2 sont peu connus.  
 Il est établi que lors de l’activation des RTKs, Gab2 est phosphorylé au niveau de 
plusieurs résidus Tyrosine, menant à l’association de différentes protéines comme p85 et Shp2. 
En plus de la phosphorylation en Tyrosine, notre laboratoire ainsi que d’autres groupes de 
recherche avons identifié que Gab2 est aussi phosphorylé au niveau de résidus Ser/Thr suite à 
l’activation de la voie de signalisation MAPK. Cependant, la régulation des fonctions de Gab2 
par ces modifications post-traductionnelles est encore peu connue. Dans le but de comprendre 
comment Gab2 est régulé par la voie de signalisation MAPK, nous avons utilisé différentes 
approches. Dans la première partie de ma thèse, nous avons déterminé un nouveau mécanisme 
démontrant que la voie de signalisation Ras/MAPK, par le biais des protéines kinases RSK 
(p90 ribosomal S6 kinase), phosphoryle Gab2. Ce phénomène se produit à la fois in vivo et in 
vitro au niveau de trois résidus Ser/Thr conservés. Des mutations au niveau de ces sites de 
phosphorylation entrainent le recrutement de Shp2 menant à l’augmentation de la motilité 
cellulaire, ce qui suggère que les protéines RSK restreignent les fonctions dépendantes de 
Gab2. Ce phénomène est le résultat de la participation de RSK dans la boucle de rétroaction 
négative de la voie de signalisation MAPK. Dans la seconde partie de ma thèse, nous avons 
démontré que les protéines ERK1/2 phosphorylent Gab2 au niveau de plusieurs résidus 
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pS/T-P à la fois in vitro et in vivo, entrainant l’inhibition du recrutement de p85. De plus, nous 
avons établi pour la première fois que Gab2 interagit physiquement avec ERK1/2 dans des 
cellules lors de l’activation de la voie de signalisation MAPK. Par ailleurs, nous avons montré 
un nouveau domaine d’attache du module ERK1/2 sur Gab2. Des mutations sur les résidus 
essentiels de ce domaine d’attache n’entrainent pas seulement la dissociation de ERK1/2 avec 
Gab2, mais diminuent également la phosphorylation dépendante de ERK1/2 sur Gab2. 
 Ainsi, nos données montrent que la voie de signalisation MAPK régule les fonctions de la 
protéine Gab2 par le biais des kinases RSK et ERK1/2. Cette thèse élabore par ailleurs un 
schéma complet des fonctions de Gab2 dépendantes de la voie de signalisation MAPK dans le 
développement de nombreux cancers.  
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Abstract 
Receptor tyrosine kinase (RTK) signaling plays an essential role in modulating cell 
growth, proliferation, differentiation and motility. Abnormal regulation of RTKs results in 
many human diseases, including breast cancer, the second leading cause of cancer mortality in 
women by the frequent amplification and mutation of the HER2 (ERBB2) tyrosine kinase. The 
Grb2-associated binder (Gab) 2 is an adaptor protein that acts downstream of several RTKs, 
including HER2, to regulate multiple signaling pathways. In response to the stimulation of a 
number of growth factors and cytokines, Gab2 is recruited to the plasma membrane, where it 
potentiates the activation of the Ras/mitogen-activated protein kinase (MAPK) and PI3K 
(phosphatidylinositol-3-kinase)/Akt (protein kinase B) pathways. In addition to playing an 
important role in the hematopoietic system during development, GAB2 is often amplified in 
cancers including breast cancer and melanoma, however, little is known about the molecular 
mechanisms that regulate Gab2 function.  
It has been well established that upon RTKs activation, Gab2 becomes phosphorylated on 
several Tyr residues leading to diverse adaptor protein associations, such as p85 and Shp2. 
Aside from the tyrosine phosphorylation, our lab and other groups noticed that Gab2 is also 
phosphorylated on Ser/Thr residues upon activation of MAPK signaling. However, less is 
known about this post-translational modification in the regulation of Gab2 functions. In order 
to understand how Gab2 is regulated by the MAPK pathway, we used different approaches. In 
the first part of my thesis, we determined a new mechanism by which the Ras/MAPK 
pathway through RSK (p90 ribosomal S6 kinase) phosphorylated Gab2 on three conserved 
Ser/Thr residues, both in vivo and in vitro. Mutation of these phosphorylation sites promoted 
Shp2 recruitment leading to increased cell motility, suggesting that RSK restricts 
Gab2-dependent functions as a result of participation in the negative feedback loop of MAPK 
signaling. In the second part of the thesis, we found that ERK1/2 phosphorylated Gab2 on 
several potential pS/T-P residues, both in vivo and in vitro, resulting in inhibited p85 
recruitment. In addition, to the best of our knowledge, we established for the first time that 
Gab2 physically interacted with ERK1/2 in cells upon activation of the MAPK pathway. 
Furthermore, we revealed a novel ERK1/2 docking domain in Gab2. Mutation of the essential 
residues in this docking domain not only disrupted ERK1/2-Gab2 interaction, but also 
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diminished ERK1/2-dependent phosphorylation on Gab2.  
 Taken together, our data showed that the MAPK pathway regulates Gab2 functions 
through both RSK- and ERK1/2-dependent manners. Given that Gab2 is overexpressed in 
several cancers, this thesis decodes a complete figure of modulating actions of Gab2 by 
MAPK signaling in cancer development.   
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1.0 General Introduction 
Breast cancer is the second leading cause of cancer mortality in women and accounts for 
6.8% of all cancer deaths in 2014 (data from American Cancer Society). In most breast 
cancers, ductal carcinomas in situ (DCIS) are precursors, and their progression to invasive 
breast carcinoma (IBC) is a representative feature of tumor aggressiveness (Tamimi et al., 
2008). Classifications of tumor grades, stages and molecular subtypes of breast cancers are 
helpful to define the cancer-related types and target diagnosis. In general, by using several 
immunohistochemical (IHC) markers, including the estrogen (ER)/progesterone(PR) receptor, 
HER2/neu (a member of the epidermal growth factor receptor family) and Ki67 (a marker for 
proliferation rate), breast cancers are predominately classified into four subtypes, including 
luminal A, luminal B, the triple negative basal-like and HER2 types (Carey et al., 2006). To 
date, around 10~15% of breast cancer patients have been determined with aberrant regulation 
of HER2 by overexpression or mutation, which leads to the upregulation of multiple 
intracellular signaling pathways, such as MAPK (mitogen-activated protein kinase) signaling 
(Kurokawa et al., 2000).  
 Aside from being involved in breast cancers, MAPK signaling has also been implicated in 
the development of several human diseases, including inflammatory diseases and severe bone 
disorders (Lawrence et al., 2008). Given that the MAPK pathway, through specific 
downstream effectors, leads to diverse biological events such as cell survival, proliferation 
and motility, the determination of novel substrates of MAPK signaling, likely substrates of 
ERK (extracellular signal-regulated kinase) and RSK (p90 ribosomal S6 kinase), will reveal 
new therapeutic targets for the treatment of human diseases. While ERK and RSK often 
co-regulate common protein substrates, they both phosphorylate specific sequences within 
target proteins. Whereas ERK phosphorylates substrates on the Ser/Thr-Pro residues that often 
require protein-protein interactions, RSK is a basophilic kinase that phosphorylates substrates 
on Arg-Xxx-Xxx-pSer/Thr consensus sequences (Cargnello and Roux, 2011).  
 Gab2 (Grb2-associated-binding protein 2) has been identified as an “amplifier” in signal 
transduction from receptors to multiple downstream signaling pathways, including MAPK 
and PI3K (phosphatidylinositol-3-kinase) signaling, resulting in increased cell proliferation 
and migration (Liu and Rohrschneider, 2002). Intriguingly, Gab2 in turn can act as a substrate 
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of the MAPK and PI3K pathways, indicating that Gab2 is involved in feedback loops within 
these signaling pathways (Lynch and Daly, 2002; Arnaud et al., 2004). In many instances, 
MAPK and PI3K signaling-mediated Gab2 phosphorylation on Ser/Thr residues result in 
altered cell proliferation and migration (Lynch and Daly, 2002; Arnaud et al., 2004). Given 
that the Gab2 gene is located on chromosome 11q14.1, a region frequently amplified in breast 
cancer (Bocanegra et al., 2009), the understanding of how Gab2 is regulated at the molecular 
level will be useful for the treatment of breast cancer. 
1.1 Characteristics of carcinogenesis 
The behavior of a normal cell is governed by precise molecular mechanisms that respond 
to the external environment. Changes in the extracellular environment are often transduced to 
intracellular signaling cascades through specific receptor systems, such as ion channel-linked 
receptors, enzyme-linked receptors and G protein-coupled receptors. These receptor systems 
stimulate many different signaling pathways that are tightly regulated and act as an integrated 
network, driving cells to divide, differentiate, proliferate, undergo apoptosis or migrate (Hille, 
1994; Delcourt et al., 2007). During these processes, monitoring programs, such as cell cycle 
checkpoints, are executed to ensure cells are behaving properly (Topham and Taylor, 2013). 
However, a series of diseases such as cancer can occur when the monitoring programs in an 
individual cell are deregulated, and the cell behaves inappropriately. Cancer often originates 
from heritable genetic alterations or epigenetic changes within normal tissue, which results in 
the accumulation of genomic alterations that convert the cell’s behavior from normal to 
malignant. For instance, gene silencing, gene amplification and gene mutation affect the 
structure or function of the genome, and are possible inducers of cancer.  
Intriguingly, based on the common characteristics of carcinogenesis, Hanahan and 
Weinberg in 2011 proposed a paradigm in which a normal cell acquires six hallmark 
capabilities to become malignant, fostered by genome instability (Hanahan and Weinberg, 
2011). These six hallmarks include: (I) sustaining growth-stimulatory signals; (II) 
downregulating growth-inhibitory signals; (III) resisting cell death; (IV) enabling replicative 
immortality; (V) inducing angiogenesis; and (VI) activating invasion and metastasis (Hanahan 
and Weinberg, 2011). This description provides a solid foundation for a better understanding 
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of the molecular mechanisms related to cancer biology. In the following sections, the basic 
characteristics of the tumor are summarized.         
    1.1.1 Sustaining proliferation and evading growth suppressors 
  Normal tissues properly secrete and release growth-stimulatory signal molecules inducing 
cell proliferation. Tumor cells often upregulate these growth-promoting signals, which sustain 
chronic proliferation. Several mechanisms underlie the upregulation of these enabling signals. 
Firstly, aberrant regulation of receptor proteins on the cell surface by overexpression or 
mutation promotes cell proliferation. It may either allow a cell to hyper-respond to the low 
concentration of circulating growth factors or cause ligand-independent receptor activation by 
spontaneous receptor dimerization, such as occurs with the members of the receptor tyrosine 
kinase family (Foley et al., 2010). In addition, autocrine or paracrine signaling can affect 
cancer cell proliferation. In the former pathway, a cancer cell produces its own growth factors, 
such as interleukin (IL)-6, to stimulate its own proliferation (Gao et al., 2007); in the latter 
pathway, cell growth is dependent on cross-communication between different cell types. For 
instance, stromal cells adjacent to carcinoma tissue secrete stromal cell-derived factor-1 
(SDF-1) for cancer cell proliferation (Kojima et al., 2010). Moreover, alteration of 
components of intracellular signaling cascades, such as MAPK and PI3K signaling, is another 
mechanism underlying cancer cell proliferation. For instance, either Ras/Raf (regulator of 
α-fetoprotein) mutation or PTEN (phosphatase and tensin homolog) deletion leading to the 
upregulation of Ras/MAPK (mitogen-activated protein kinase) and PI3K 
(phosphatidylinositol-3-kinase)/Akt (protein kinase B) signaling have been observed in 
certain human tumors (Hollestelle et al., 2007; Hollander et al., 2011).  
Aside from sustaining growth-promoting signaling, tumor cells also have to circumvent 
powerful monitoring programs that negatively regulate cell proliferation, such as tumor 
suppressors. Two of the famous tumor suppressors are RB1 (retinoblastoma-associated) and 
p53, which act as central nodes in regulation of cell proliferation, senescence and apoptosis 
(Sherr and McCormick, 2002). The first tumor suppressor gene, RB1, was identified in 1988 
by studies of retinoblastoma, a rare childhood eye tumor (Dunn et al., 1988). When receiving 
physiological growth-inhibitory signals from the outside of a cell, such as transforming 
growth factor beta (TGF-β) or contact inhibition, pRb, the phosphorylation product of Rb, 
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interacts with E2F (the E2 factor family of transcription factors) leading to the inhibition of 
the cell cycle-related gene expressions, such as cyclinB (Zhang et al., 1999). Moreover, 
oncogene expression, DNA damage, or cellular stress can induce p53 stabilization and 
activation. If the DNA is excessively damaged, or if the levels of growth-stimulatory signals, 
glucose or oxygenation tend to be high, p53 arrests cell at different phases of the cell cycle 
until these abnormal events have been successfully addressed (Zilfou and Lowe, 2009). 
Otherwise, the p53 pathway promotes cellular apoptosis, through activation of the caspase 
proteases, such as caspase 9, or release apoptogenic factors such as pro-apoptotic proteins of 
the Bcl-2 family from mitochondria (Schuler and Green, 2001). In order to circumvent these 
anti-growth factors, cancer cells become insensitive to these factors by defection or the lack of 
some growth-inhibitory proteins related to the cell cycle or cell survival, such as p21Cip1, 
p27Kip1, p16INK4A, pRb, Smad3, or p53 (Grady, 2005; Schwartz and Shah, 2005).     
    1.1.2 Angiogenesis formation in the primary tumor site 
 Angiogenesis is a normal physiological process in which new blood vessels sprout from 
pre-existing vessels. The function of angiogenesis is to provide sustenance to support the 
active cells. Whereas the development of the vasculature in embryogenesis involves 
vasculogenesis and angiogenesis, the normal vasculature is quiescent in healthy adults (Patan, 
2004). On certain physiological conditions, angiogenesis is transiently “turned on”, such as 
tissue regeneration. However, in cancer development, an “angiogenic switch” always remains 
on and is hyperactivated leading to a continued sprouting of new vessels to supply nutrients 
for the neoplastic growth. In carcinogenesis, angiogenesis leads to excessive vessel branching 
in solid tumors. Because these blood vessels have an erratic blood flow, they become 
distorted and enlarged with endothelial cell fast proliferation and resistance to apoptosis 
(Ucuzian et al., 2010).  
Angiogenesis is a complex process that is modulated either by angiogenic stimulatory 
factors or inhibitory factors. One such angiogenic inducer is the vascular endothelial growth 
factor (VEGF) (Shweiki et al., 1992). Hypoxia and oncogene-induced signals, such as Ras 
proto-oncogenes, drive angiogenesis leading to VEGF secretion (Rak et al., 1995; Forsythe et 
al., 1996). Upon VEGF binding to its specific cell-surface receptor, the VEGFR-mediated 
downstream signaling pathways are activated leading to increased vascular endothelial cell 
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proliferation and migration.  
Angiogenesis is also a well organized stepwise process beginning with extracellular 
matrix (ECM) degradation by ECM degrading proteases, such as matrix metallopeptidase 9 
(MMP-9), which are secreted and released from VEGF-induced endothelial cells (Ghosh et al., 
2012). Next, the migrated endothelial cells undergo proliferation and differentiation to form 
new blood vessels; Finally, endothelial cells form a new basement membrane and produce 
growth factors such as platelet-derived growth factor (PDGF) to ensure the stability of the 
new blood vessel (Appelmann et al., 2009). In contrast, the angiogenesis process is 
counterbalanced by angiogenic inhibitory factors. For instance, thrombospondin-1 (TSP-1) is 
a critical antagonistic molecule of VEGF that blocks cell survival signals and drives cell 
apoptosis (Kaur et al., 2010). It has been shown that TSP-1 regulates cell survival by directly 
modulating the formation of the CD36 (a member of the class B scavenger receptor 
family)/CD47/intergrins/VEGFR complex (Neufeld et al., 1999; Rodriguez-Manzaneque et 
al., 2001; Lawler and Lawler, 2012). Together, these findings suggest that the understanding 
of angiogenic stimulatory and inhibitory factors may pave the way for developing novel 
therapeutic approaches and anti-cancer drug innovations.           
    1.1.3 Invasion and metastasis 
Aside from uncontrolled proliferation, cancer cells progressing from epithelial tissues to 
higher malignancy carcinomas require alterations of cell shape and de-attachment from the 
adjacent cells or the extracellular matrix (ECM). In addition, cancer metastases formation in 
the distant organs away from the primary site represents aggressive cancers and accounts for 
90% of cancer deaths (Mehlen and Puisieux, 2006). Metastasis is a well-organized process 
and consists of several consecutive steps: (I) local invasion by carcinomas; (II) migration into 
adjacent blood or lymphatic vessels; (III) trafficking in the lymphatic and hematogenous 
systems; and (IV) colonization of distant tissue.       
The epithelial-mesenchymal transition (EMT) enables cancer cells to become invasive 
One of the acquisitions of tumor cell invasion is the EMT program execution, which 
allows cells to survive, invade and disseminate. Activation of the EMT program is either 
transient or permanent depending on the cancer cell type and stage. 
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The EMT is induced by several signals, such as Wnt signaling and TGF-β signals, 
correlating with the alteration of adherence molecules (Taki et al., 2003; Xu et al., 2009). 
Among these adherence molecules, E-cadherin plays the predominant role in EMT 
progression, being responsible for maintaining cells in a proper position and assembling 
epithelial cell sheets. Decreased E-cadherin expression promotes cell migration and invasion, 
whereas increased expression of E-cadherin allows cells to resist metastasis (Onder et al., 
2008). Several transcription factors, such as Snail, Slug, Twist and Zeb1/2, affect EMT 
program execution (Cano et al., 2000; Bolos et al., 2003; Vesuna et al., 2008; Lau et al., 
2013). For example, Snail, Slug, Twist and Zeb1/2 negatively regulate E-cadherin expression 
in several cancer cell lines, resulting in reduced adherence junctions and alterations of cell 
morphologies from polygonal/epithelial to spindly/fibroblastic.  
Paracrine signaling from stromal cells promote tumor invasion and metastasis 
Many studies indicate that tumorigenesis is not solely a cell-autonomous behavior, and 
cannot be understood simply by analysis of the genomes of tumor cells. Alterations in the 
microenvironment, such as the cross-communication between stromal and tumor tissues 
(referred to as paracrine signaling) is required for cell invasion and metastasis. The stromal 
cell-derived factors influence the adjacent target cancer cell. For instance, macrophages in the 
tumor periphery produce matrix-degrading proteases such as the macrophage metalloelastase 
(MMP-12) and the cysteine cathepsin B (CB), leading to cancer cell invasion by degrading 
the cell matrix membrane (Dong et al., 1997; Vu and Werb, 2000; Vasiljeva et al., 2006). 
Notably, paracrine signaling is different from endocrine signaling. In the former, the secreted 
molecules cannot be diffused too far, and only reach the adjacent target cells; in the latter, the 
secreted hormones are distributed widely throughout the body by the blood circulation 
(Molecular Biology of The cell. 4th edition). 
In addition to tumor metastasis, chemoresistance which causes the failure of cancer 
treatment is affected by paracrine signaling. A network of endothelial-carcinoma-myeloid 
signaling interactions provides a mechanism linking chemoresistance and metastasis 
(Acharyya et al., 2012). Although chemotherapeutic agents kill cancer cells, under certain 
conditions they also induce TNF-α production by endothelial cells and other stromal cells. In 
turn, TNF-α acts on cancer cells and increases NF-κB activity, leading to the 
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chemotherapeutic resistance of cancer cells by upregulating of the CXCL1/2 (C-X-C motif 
chemokine 1/2)-S100A8/9 (protein S100-A8/A9) loop (Acharyya et al., 2012).  
Formation of metastatic colonies in anatomical sites 
Cancer metastasis consists of two steps: (I) tumor cells migrate from a primary site to 
distant organs and; (II) they settle down in foreign tissues. Colonization is a complex process 
and also a challenging step of tumor metastasis. Indeed, some disseminated cancer cells 
hardly survive in an external microenvironment. Hence, each disseminated cancer cell needs 
its own set of solutions for colonizing a particular organ (Gupta et al., 2005). On the one hand, 
disseminated cancer cells colonize foreign tissues through self-seeding, which are supported 
by stromal cells adjacent to the primary tumor. On the other hand, after residing in the distant 
tissue, cancer cells no longer benefit from EMT-inducing signals from primary tumors. In the 
absence of such signals, cancer cells may make this new home a noninvasive stage, and 
undergo the mesenchymal to epithelial (MET) process, which is the reverse of EMT, leading 
to new cancer colonies similar to the primary tumor (Elshamy and Duhe, 2013). Although 
these findings suggest the possible mechanisms regarding the metastases, the explanations 
likely remain simplistic. The precise mechanisms by which disseminated cancer cells settle 
down in secondary sites require in-depth analysis.             
1.2 Breast cancer and receptor tyrosine kinase  
    1.2.1 Grades, stages and types of breast cancer 
Tumor grade is a classification based on the morphological similarities between tumor 
and normal cells. In general, the more the morphological similarities between tumor cells and 
normal cells, the lower the tumor grade tends to be; the faster the growth rate of tumor cells, the 
higher the tumor grade tends to be. Based on these two factors, there are three tumor grades: (I) 
Grade 1 or low grade: the tumor cells look the most similar to normal cells, high differentiation 
and are slow-growing; (II) Grade 2 or intermediate/moderate grade: the tumor cells look 
different from normal cells and grow faster; and (III) Grade 3 or high grade: the tumor cells 
look very abnormal, poorly-differentiated and are fast-growing (http://ww5.komen.org/).  
In addition to tumor grade, staging of cancer is another key indicator in cancer prognosis. 
Cancer stage is different from tumor grade because it refers to many factors, such as a primary 
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tumor location, a tumor size, lymph node involvement, and metastasis formation in a secondary 
organ (Gannon et al., 2013). Among these, the high capabilities of invasion and metastasis are 
the most harmful factors in breast cancer prognosis. While colon carcinomas are likely to 
invade the liver, breast cancers promiscuously form metastases in many organs throughout the 
body, including lungs, bones, liver, and the brain. In the invasion-metastasis cascade of breast 
cancer, invasive ductal cancer begins in the milk ducts, spreads into the surrounding breast 
tissue, and invades the rest of the body through the lymph nodes and blood circulation. Given 
that the ability of cancer cells invasion from the primary tumor into surrounding tissues and 
blood vessels is different, ductal carcinoma in situ (DCIS, intraductal carcinoma) is described 
as non-invasive breast cancer (stage 0), and invasion of tumor cells into distant lymph nodes 
and other organs is classified as stage IV. In general, the higher the stage of invasive breast 
cancer, the poorer is the prognosis of survival.  
 The classification of breast cancer characteristics can be helpful to define the 
cancer-related types and diagnosis in the future. By using molecular and genetic tools, a 
complete profile of each subtype of tumor cell can be determined. Hormone receptor status 
(estrogen receptor or progesterone receptor), HER2/neu status and proliferation rate (Ki67) are 
the three major testing standards. Based on these factors, breast cancers are classified into 
four major molecular subtypes: (1) luminal A; (2) luminal B; (3) triple negative basal-like type 
and; (4) HER2 type (Tamimi et al., 2008). Additional details of the four cancer subtypes are 
shown in the Table 1. Notably, not all breast cancer types are included in this classification, 
such as apocrine molecular type (looks like normal breast cells but characterized by androgen 
receptor expression) and claudin-low type (Prat et al., 2010), indicating the complexity of 
breast cancer types. 
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Luminal tumor cells. Most breast cancers belong to luminal tumors, which normally start 
in the inner (luminal) cells of the mammary ducts. Luminal tumors consist of two types: 
luminal A and luminal B, both of which tend to be hormone receptors-positive (ER+/PR+). In 
some cases, luminal A tumors also tend to be HER2/neu-negative (HER2-) with low expression 
of Ki67, indicating that this type of cancer has a lower-growth rate (Sun et al., 2014). Most of 
the luminal A tumor cells are classified as tumor grade 1 or 2, and likely to have a good 
prognosis with high survival-rates. However, approximately 15% of luminal A tumors have 
p53 mutations leading to a poor prognosis (Carey et al., 2006). Unlike luminal A-type, luminal 
B-type tumors are positive for HER2+ and/or Ki67 and 30% of them have p53 mutations. The 
survival rates of luminal B patients are fairly high but not as good as those with luminal A 
tumors.  
Triple negative/basal–like tumor cells. This subtype of tumor cells is hormone receptors 
negative (ER-, PR-), and HER2 negative (HER2-). Most triple negative tumors are also 
basal-like tumors because of a similar feature to the outer cells of the mammary ducts. In 
patients, about 15~20% of breast cancer are triple negative or basal-like tumors, and most 
basal-like tumors have p53 mutations (Badve et al., 2010). Compared to luminal cancer 
subtypes, the triple negative and the basal-like tumors are often more aggressive and have a 
Table I Molecular subtypes of breast cancer 
Subtype Molecular marker Prevalence 
(approximate) 
Luminal A ER+ and/or PR+, HER2-, 
low Ki67 
40% 
Luminal B ER+ and/or PR+, HER2+ 
(or HER2- with high Ki67) 
20% 
Triple 
negative/basal-like 
ER-, PR-, HER2- 15-20% 
HER2 type ER-, PR-, HER2+ 
( HER2-) 
10-15% 
Note: ER: estrogen receptor; PR: progesterone receptor; HER2: neu receptor; 
Ki67: a cellular marker for proliferation 
(Data adapted from http://ww5.komen.org/BreastCancer ) 
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poor prognosis. The BRCA1 (breast cancer gene 1) gene is the most studied gene in triple 
negative cancer. BRCA1 encodes a tumor suppressor protein BRCA1, which is involved in 
DNA damage repair and transcriptional response to DNA damage by regulating the 
transcription of several genes, including p21(WAF1/CIP1), Gadd45 (growth arrest and 
DNA-damage inducible), Cyclin B1, XPC (xeroderma pigmentosum C), 14-3-3σ 
(Somasundaram, 2003). It has been shown that BRCA1 mutations lead to carcinogenesis by 
inducing DNA damage and genome instability (Foulkes and Shuen, 2013). However, the 
mechanisms by which BRCA1 mutations are likely to promote carcinogenesis in 
estrogen-responsive tissues, such as ovary and breast, remain elusive (Wang and Di, 2014).  
HER2 type. Around 10~15% of breast cancers fit this molecular profile, and 75% of 
HER2-type cancers have the p53 gene mutations. However, the HER2 type does not 
completely have HER2+ status because 30% of these cancers are also HER negative (HER2-). 
There are four common characteristics in HER2 type cancers, including ER-, PR-, lymph node 
involvement and higher tumor grade (Kim et al., 2006). The classification of breast tumor types 
helps to estimate the diagnosis and plan the best treatment for patients, and also provides 
information for developing novel therapies.        
    1.2.2 Treatments of breast cancer  
Based on patients’ conditions and stages of cancer progression, different treatments are 
available. Local and systemic therapies are the two major ways for treating cancers. The former 
therapy is to remove tumors at the original site without affecting the rest of the body, including 
surgery and radiation therapies. The latter treatment involves administering drugs via the 
bloodstream and lymph cycles, including chemotherapy, hormone therapy, and targeted 
therapy (http://www.cancer.org/).   
Chemotherapy is a treatment with drugs, which can reach cancer cells in most part of the 
body via the bloodstream. Given that cancer cells divide more quickly than normal cells, the 
purpose of these drugs is to attack cells with higher division rates. However, some cells in the 
body such as bone marrow cells also divide quickly. Hence, chemo drugs are prone to attack 
these normal cells as well, leading to severe side effects (Crozier et al., 2014). The most 
common used chemotherapy drugs are anthracyclines, taxanes, and the combination of 
fluorouracil (5-FU) and cyclophosphamide.   
 12 
 
Hormone therapy. Around 67% of breast cancers are the hormone receptor-positive type, 
which contain hormone receptors for estrogen and/or progesterone. The aim of hormone 
therapy is to inhibit tumor growth by interrupting the estrogen-mediated pathway. However, 
this kind of treatment only works in hormone receptor-positive breast cancers (ER+/PR+) 
rather than hormone receptor-negative tumors (Mustonen et al., 2014). Tamoxifen, fulvestrant, 
and toremifene are common drugs for this treatment.  
Targeted therapy. Since alterations of some related genes in tumorigenesis have been 
explored, scientists have been able to develop specific drugs based on their target proteins. 
Unlike chemo drugs, these drugs individually act on target proteins and have fewer side effects. 
One of the representatives is HER2 inhibitors (Li and Li, 2014). HER2/neu is overexpressed in 
10~15% of breast cancer cell surface and makes them more aggressive and highly metastatic. 
Alternatively, mTOR inhibitor and vascular endothelial growth factor (VEGF) inhibitor are 
also used in cancer treatment. Examples regarding targeted therapy are shown in Table II.   
     
 
 
 
 
 
Table II Drugs for targeted therapy in breast cancers 
Drug name Target protein Functions Side effects 
Trastuzumab 
(Herceptin) 
Lapatinib (Tykerb) 
Pertuzumab 
 
HER2 
 
Decreasing the tumor 
growth and stimulating the 
immune system to attack the 
cancer cells. 
 
Relatively mild. 
 
Everolimus 
 
Blocking mTOR 
Preventing cancer cells 
from growing and 
developing new blood 
vessels. 
Increase blood lipids, 
blood sugars and risk of 
infection. 
 
Bevacizumab 
Against vascular 
endothelial growth 
factor (VEGF) 
Preventing new blood 
vessel formation in tumors. 
Much more severe 
side effects with 
high-blood pressure. 
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1.2.3 ErbB2/HER2 in breast cancer   
       1.2.3.1 EGFR family 
  The epithermal growth factor receptor (EGFR) family is a major class of the receptor 
tyrosine kinase (RTK) superfamily, consisting of four members: EGFR (HER1), HER2 
(ErbB2), HER3, and HER4 (Foley et al., 2010). HER receptors are transmembrane 
glycoproteins containing a highly conserved extracellular domain, and an intracellular 
ATP-binding kinase domain (Figure 1.1) (Yarden, 2001). To date, several ligands binding to 
different HER receptors (HER1, HER3, HER4) have been identified. Upon binding to ligands, 
HER receptors form dimers followed by intracellular kinase domain phosphorylation and 
adaptor protein recruitments, leading to the activation of several downstream signaling 
pathways. Unlike other isoforms, HER2 is the only isoform of the EGFR family whose ligand 
is still unknown. However, HER2/HER3 heterodimerization, leading to the 
auto-phosphorylation of HER2, is the most relevant to HER2-dependent carcinogenesis. 
Abnormal regulation of HER2 by overexpression and mutation has been indicated in around 
10~15% of breast cancers.  
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Figure 1.1 Cross-cancer alteration summary for the ERBB2 gene. 
It has been found that the ERBB2 gene is located on human chromosome 17 (17q12), which is 
amplified in multiple cancers. Amplification and mutation of ERBB2 are the two major causes 
in ErbB2/HER2-induced carcinogenesis. In breast cancer, the ERBB2 gene set is amplified in 
13.5% of 482 cases. In addition, 6.3% of 127 cases in bladder urothelial carcinoma carried 
mutations in the ERBB2 gene set, indicating that the differences of ERBB2 gene alterations 
depend on the cancer types. (Adapted from http://www.cbioportal.org, Cerami et al., Cancer 
Discov. 2012 & Gao et al. Sci. Signal. 2013.) 
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       1.2.3.2 Activation mechanisms of HER2 receptor 
As indicated in Figure 1.2, the alternation of the ERBB2/HER2 gene set occurs not only 
in breast cancer but also in other cancers, such as bladder cancer. De-regulation of the 
 
Figure 1.2 Schematic representation of HER receptors-mediated downstream signaling 
pathways. 
Upon ligands binding, HER receptors dimerize in the plasma membrane. Notably, among these 
receptors, no ligands of HER2 have been determined, and the intracellular kinase domain of 
HER3 is impaired. But the dimerization of receptors (HER2/HER3) could induce 
phosphorylation of tyrosine residues in the cytoplasmic domain and thereby drives amplification 
of the MAPK and the PI3K pathways. Diverse signaling pathways converge in the nucleus. For 
instance, ERK1/2 translocate into the nucleus and phosphorylate some transcription factors, 
leading to cell proliferation, motility, and metastasis. Alternatively, cell apoptosis and cell 
differentiation are inhibited. 
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ErbB2/HER2 receptor by overexpression or mutation induces hyper-activation of the 
ligand-independent receptor through spontaneous receptor dimerization or allow a cell to 
hyper-respond to a low concentration of circulating growth factors (Yarden, 2001). Being 
upstream (inducer) of the RTK signaling cascade, activated HER2 receptor drives several 
downstream effector activations and amplifies signal transduction, leading cells to proliferate, 
migrate and invade. Based on the crucial function of HER2 in tumorigenesis, the 
understanding of the mechanisms of how HER2 functions is essential for cancer therapy 
innovation. 
After receptor dimerization, tyrosine residues of RTKs in the cytoplasmic domain 
become auto-phosphorylated leading to HER2-mediated complex formation. Src-homology 
(SH) 2 domains present in binding partners play crucial roles in HER2 association. One such 
example is p85, which binds to the pYXXM motif of HER2, through its SH2 domain. 
Moreover, Grb2 and phospholipase C (PLC) through their SH2 domains associate with 
specific phospho-tyrosine sites in HER2 (Yamazaki et al., 2002). Phosphotyrosine binding 
(PTB) domains presented in some adaptor proteins are also responsible for HER2 interactions. 
For instance, Shc through PTB domains interacts with the NPXpY motif in HER2 (Batzer et 
al., 1995).  
Even though the HER2-associated adaptor proteins Grb2 and p85 lack catalytic activities, 
they can still amplify the activation of HER2-mediated signaling cascades through binding to 
diverse enzymes such as the guanylnucleotide exchange factor (SOS) and the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (p110), separately. It has been shown that 
Grb2 through its SH3 domains constitutively binds to SOS. Upon recruitment to the activated 
receptor, Grb2 acts as a bridge linking activated receptor to the downstream signaling 
apparatus (Margolis and Skolnik, 1994). Alternatively, activated HER2 induces PI3K/Akt 
signaling activation through p85 recruitment (De Luca et al., 2012). p85 is a regulatory 
subunit of PI3K, which constitutively binds to the catalytic subunit of PI3K (p110). Upon 
binding to the receptor, p85 PI3K recruits p110 PI3K to the plasma membrane where p110 
promotes phosphatidylinositol (3,4,5)-trisphosphate (PIP3) production leading to the 
activation of Akt (Hu et al., 1992).  
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1.3 The Ras/MAPK/RSK signaling pathway   
    1.3.1 Background: Mechanisms of MAPK cascade activation 
Mitogen-activated protein kinases (MAPKs) are Ser/Thr kinases that transmit 
extracellular ligand-binding events to intracellular signaling transduction cascades, resulting 
in diverse cellular functions, such as cell growth, proliferation, survival and differentiation. In 
mammals, 14 MAPKs have been identified and divided into 2 types: conventional MAPKs 
and atypical MAPKs (Figure 1.3). Conventional MAPKs consist of four groups: the 
extracellular signal-regulated kinase1/2 (ERK1/2), p38 isoforms (α, β, γ and δ), c-Jun 
N-terminal kinases1/2/3 (JNK1/2/3), and ERK5 (Cargnello and Roux, 2011). Atypical 
MAPKs comprise ERK3/4, ERK7, and Nemo-like kinase (NLK), which have not been well 
documented. 
 
Figure 1.3 Schematic representation of two classifications of MAPKs: conventional 
MAPKs and atypical MAPKs.  
All MAPKs contain the kinase domain in the middle, as shown in blue. Additional regions as 
indicated: TAD: a transactivation domain; C34: a region conserved in ERK3 and ERK4; AHQr: 
a domain rich in Ala, His, and Glu. Notably, two putative nuclear localization sequences (NLS) 
are present in ERK5 and ERK7/8. (Adapted from Microbio.l Mol. Biol. Rev., 2011 
Mar;75(1):50-83) 
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Each conventional MAPK cascade consists of at least three conserved, successively 
acting kinases: a MAP kinase kinase kinase (MAP3K or MEKK), a MAP kinase kinase 
(MAP2K or MEK) and a MAP kinase (MAPK). The MAP3K is often activated by small 
GTP-binding proteins of the Ras/Rho family, such as Ras or Rap (Chong et al., 2003). 
Phosphorylated MAP3K emits a signal to MAP2K, a dual-specificity kinase, which 
phosphorylates both Thr and Tyr residues present in the activation loop of most MAPKs. 
Once phosphorylated and activated, the MAPK phosphorylates numerous substrates either in 
the cytoplasm or the nucleus (Deschenes-Simard et al., 2014).   
In some respects, atypical MAPKs behave differently from conventional MAPKs. 
Compared to the three-tiered conventional MAPK signaling cascades, it seems that atypical 
 
Figure 1.4 Activation of the conventional MAPK-mediated signaling pathways results in the 
phosphorylation of MAPKAPKs. 
MAPK signaling cascades are triggered upon stimulation by the diverse growth factors, cytokines and 
cellular stress. MAPKAPKs include five subgroups: RSK, MNK, MSK, MK2/3 and MK5. Each 
MAPKAPK is phosphorylated by its respective upstream kinase. (Adapted from Journal of Molecular 
Signaling 2012 7:9 and from Microbiol. Mol. Biol. Rev., 2011 Mar; 75(1):50-83.) 
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MAPKs are organized into two-tiered kinase cascades. In addition, atypical MAPKs have no 
conserved T-X-Y motif in their activation loop (Figure 1.3). It appears that these atypical 
MAPKs have only one residue in the kinase domain to be phosphorylated. For instance, 
ERK3 and ERK4 have an S-E-G motif, while NLK contains a T-Q-E motif (Deleris et al., 
2010; Ishitani et al., 2010). Although ERK7 has a T-X-Y motif in its kinase domain, it is 
auto-phosphorylated by ERK7 rather than an upstream MAP2K (Abe et al., 2001).                   
Accumulating evidence has shown the involvement of scaffold proteins, which hold the 
components of three-tiered kinase cascades together and keep the kinase close to its substrate, 
which is essential for maintaining the magnitude and duration in the conventional MAPKs 
signaling pathway. For example, in the ERK1/2 signaling cascade, the kinase suppressor of 
Ras (KSR) is responsible for the assembly of Raf, MEK1/2 and ERK1/2, and the MEK 
partner1 (MP1) holds MEK1/2 and ERK1/2 together (Therrien et al., 1995; Sharma et al., 
2005). In JNK signaling, the JNK-interaction protein 1 (JIP1) holds MLK, MKK7 and 
JNK1-3 together (Yasuda et al., 1999). In addition, β–arrestin 2 serves as a scaffold protein 
for both the ERK1/2 and JNK pathways. In the former signaling pathway, β–arrestin 2 
directly interacts with Raf and ERK1/2 but indirectly binds to MEK1/2; in the latter signaling 
cascade, β–arrestin 2 assembles ASK1, MKK4 and JNK3 together (Tohgo et al., 2002; Guo 
and Whitmarsh, 2008).  
Once phosphorylated and activated, MAP kinases phosphorylate substrates on 
Ser/Thr-Pro residues, which is a common characteristic of conventional and atypical MAPKs. 
The diverse consequences of MAPK activation in an individual cell are eventually determined 
by the specific substrates involved in the different cellular processes. Most notably, among 
these substrates, phosphorylation of the MAPK activated protein kinases (MAPKAPKs) is the 
additional enzymatic and amplification step of MAPK signaling. As indicated in Figure 1.4, 
MAPKAPKs include the p90 ribosomal S6 kinase (RSKs), mitogen- and stress-activated 
kinase (MSKs), MAPK-interacting kinases (MNKs), MAPK-activated protein kinase 2/3 
(MK2/3), and MK5 (Chung et al., 1991; Cargnello and Roux, 2011).  
    1.3.2 The ERK1/2 module  
       1.3.2.1 Identification of ERK1/2 and their physiological functions   
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The cDNAs of ERK1 and ERK2 were cloned in the early 1990s, and their products were 
originally found to be phosphorylated on Tyr and Thr residues upon growth factor stimulation 
(Boulton et al., 1990; Boulton et al., 1991). The amino acid identity between human ERK1 
and ERK2 is 84%. Given the high similarity of sequences between ERK1 and ERK2, these 
two proteins are traditionally designated as ERK1/2. ERK1 and ERK2 are co-expressed 
widely in many cells and tissues, with high levels in the brain, skeletal muscle, thymus and 
heart (Boulton et al., 1991). Whereas the activation of ERK1 and ERK2 are induced in 
parallel upon stimulation, few reports indicated that each ERK isoform could also be 
selectively phosphorylated (Papkoff et al., 1994). Moreover, other studies have shown that 
activation of ERK1 and ERK2 result in different biological events. For instance, in MCF-10A 
cells, Shin et al. observed that ERK2 (not ERK1) was required in the Ras-induced EMT 
process (Shin et al., 2010). Consistent with these results, it was also found that erk1-knockout 
mice (erk1-/-) could survive with a defect in thymocyte development, whereas erk2-null mice 
(erk2-/-) were embryonic lethal due to the severely impaired development of the placental 
vasculature (Pages et al., 1999). Why did erk1-/- mice and erk2-/- mice have such different 
phenotypes? Were they due to the different isoform functions or expression levels? These 
were addressed by Lefloch et al. in a series of gene ablation experiments (Lefloch et al., 
2008). It was shown that only a single erk allele expressed in mouse, regardless of erk1 or 
erk2, resulted in a lethal phenotype rather than the mice with two single alleles separate from 
erk1 and erk2, indicating that a particular dosage of erk is necessary for mouse survival. 
Given that ERK2 expression is higher than ERK1 in most cells, the unfavorable outcome of 
erk2 knockout mice may be due to the diminished total ERK content instead of its unique 
biological functions. Even though several studies have reported different pathological roles of 
ERK1 and ERK2, these two isoforms are still considered to possess the same functions in 
most biological processes.     
       1.3.2.2 Activation mechanisms and inhibitors of ERK1/2    
ERK1/2 are core components in the Ras/MAPK pathway, which regulate multiple 
biological processes such as cell proliferation, differentiation and migration. ERK1/2 are 
activated in response to different growth factors, cytokines, osmotic stress, hormones and 
microtubule disorganization (Xing et al., 1998; Conway et al., 1999; Naor et al., 2000; Komis 
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et al., 2011). The activation of ERK1/2 is caused mainly by a receptor on the plasma 
membrane, such as receptor tyrosine kinases (RTKs) or heterotrimeric G protein-coupled 
receptors (Porter and Vaillancourt, 1998). For instance, upon a ligand binding, tyrosine kinase 
receptors (RTKs) are activated by trans-phosphorylation on tyrosine residues in the 
intracellular kinase domain. The subsequent trans-phosphorylation of RTKs leads to the 
recruitment of various adaptor proteins, such as Src homology and collagen (Shc), growth 
factor receptor-bound protein 2 (Grb2) and phospholipase C-γ (PLCγ), which contain Src 
homology 2 (SH2) domains or phosphotyrosine-binding (PTB) domains. One of the 
well-characterized mechanisms of RTK-induced Ras activation is mediated by the Grb2-SOS 
complex. Upon RTK activation, the guanine-exchange factor SOS is recruited to the plasma 
membrane from the cytosol by constitutive association with Grb2 (Pruett et al., 1995). 
Membrane-bound SOS promotes Ras activity by catalyzing GDP/GTP exchange. Once bound 
to GTP and activated, two “switch domains” in Ras shift enabling Ras to interact with several 
downstream effectors, such as Raf. Furthermore, this physical association leads to Raf 
phosphorylation. Activated Raf transmits signals by phosphorylating the downstream 
effectors MEK1/2. MEK1/2 are dual-specificity protein kinases since they can phosphorylate 
substrates on both Thr and Tyr residues. As the only substrate of MEK1/2, ERK1/2 are 
phosphorylated by MEK1/2 on the Thr-Glu-Tyr motif, which is required for ERK1/2 
activation. This phosphorylation also induces an allosteric conformational change in ERK1/2, 
leading to MEK1/2 dissociation. Once phosphorylated and activated, ERK1/2 either 
translocate into the nucleus or stay in the cytoplasm, where they can phosphorylate many 
substrates such as transcription factors or cytoskeletal proteins.  
Appropriate regulation of Ras/Raf activity is essential for the proper maintenance of cell 
proliferation. Abnormal regulation of Ras/Raf leads to the hyperactivation of the MAPK 
pathway and cause many human diseases such as cancer. Many studies have already shown 
that mutation of KRAS or BRAF occurs in a wide range of cancers, including pancreatic, 
colorectal cancer, biliary cancer, melanoma, thyroid cancer and ovarian cancer (Brose et al., 
2002; Lee et al., 2003). Given its diverse modes of action in cancer development, a specific 
blockade of the ERK1/2 cascade by inhibitors represents an attractive target in cancer therapy. 
Since ERK1/2 are the only substrates of MEK1/2, MEK1/2 inhibitors are used to characterize 
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ERK1/2 function in a wide range of biological contexts. Unlike other kinase inhibitors, most 
of the MEK1/2 inhibitors are non-competitive ATP molecules such as PD184352 and U0126, 
which interact more strongly with an inactive form of MEK rather than an active form (Favata 
et al., 1998; Allen et al., 2003). This interaction blocks conformational transition of MEK1/2 
and thus prevents their enzymatic activities.  
One of the conundrums in cancer treatment is that a few cancer cells often survive and are 
resistant to chemotherapy, leading to a failure of the treatments. For example, B-Raf 
inhibitors can cause drug resistance in patients by re-activating MAPK signaling. Therefore, 
the combination of B-Raf and MEK inhibitors in cancer treatment could be more efficient 
than either alone. For instance, co-treatment of trametinib (the first MEK inhibitor in clinical 
treatment) and dabrafenib (a BRAFV600E inhibitor with ATP competitor), which was approved 
by the FDA in January of 2014, sustains melanoma patients progression-free survival (PFS) 
up to 9.4 months, whereas the average PFS of only trametinib-treated patients is 5.8 months 
(Menzies and Long, 2014).  
       1.3.2.3 Docking interactions from ERK1/2 to substrates  
In an individual cell, various molecules, independently or coordinately, fulfill their 
specific actions at a particular time and place. To avoid unfavorable outcomes, these 
molecules must be precisely arranged and regulated. As such, appropriate partner selection 
becomes one of the fundamental mechanisms to keep the high efficiency and fidelity of signal 
transduction. To date, several mechanisms underlying the precise signal transmission in the 
ERK-MAPK cascade have been determined. One such example is the docking interaction, 
which is achieved by the common docking domain (the CD domain) in ERK1/2 (Tanoue et al., 
2001). It has been shown that the CD domain, which locates outside of the catalytic region of 
MAPKs and consists of negatively charged (acidic residues) and hydrophobic amino acids, is 
crucial for forming electrostatic and hydrophobic interactions with substrates (Tanoue et al., 
2001). In addition, it has been found that the ED/TT motif in ERK1/2 forms a docking grove 
with the CD domain, and thus participates in the association with partner molecules (Tanoue 
et al., 2001).     
A docking interaction is unlike a transient enzyme-substrate interaction, which occurs in 
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the active center. Indeed, it takes place outside of the kinase domain. For instance, MEK1 
interacts with ERK1/2 through the N-terminus of MEK1/2, outside of its kinase domain. RSK 
binds to ERK1/2 through the C-terminus of RSK, away from its kinase domain. Given that 
one of the predominant functions of docking interactions is to maintain the specificity of 
kinase-substrate interactions, ERK2 associates with its specific phosphatase MKP-3 through a 
docking interaction (Camps et al., 1998), while JNK similarly interacts with another 
phosphatase, MKP-7 (Tanoue et al., 2001).       
Consistently, it has been shown that ERK1/2 associate with their substrates through two 
independently specialized docking domains present in substrates: a D-domain and a 
DEF-domain (Tanoue and Nishida, 2003). Notably, some substrates possess one domain or 
both domains, while others have neither domain. Since the docking interaction plays an 
important role in maintaining the fidelity and efficiency of the ERK-MAPK signaling 
pathway, the main features of docking interactions are discussed below.  
D-domain. The classical consensus docking motif, D-domain, comprises a core of 
positively charged amino acids followed by hydrophobic amino acids: (R/K)2–3-X2–6-Φ-X-Φ 
(Fantz et al., 2001) (Figure 1.5A). To date, it has been found that the D-domain exists widely 
in ERK1/2 activators, inactivators as well as the substrates, such as MEK1/2 (ERK1/2 
activators), MKP-1 and STEP (ERK1/2 inactivators) and ELK1 (ERK1/2 substrates) (Tanoue 
and Nishida, 2003). When the positively charged amino acids or the hydrophobic amino acids 
are substituted by neutral ones, both the interaction between ERK1/2 and the substrates and 
the efficiency of the enzymatic reactions are severely decreased, indicating that the D-domain 
is required for MAPK-mediated transfer of phosphate group to protein substrates.  
KIM domain. The KIM (kinase interaction motif) domain is a subgroup of D-domains, 
which contains a hydrophobic amino acid followed by two positively charged amino acids, 
likely Lys or Arg. As indicated in Figure 1.5, RSK binds ERK to via its KIM domain, which 
consists of L/VXXRR/KKXXXXXL. KIM domains are often found in the MAPKAPKs 
family members. However, MK5 is an exceptional because a region responsible for ERK3/4 
interactions does not match neither the classical D-domain, nor the KIM domain (Kant et al., 
2006).        
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DEF domain. The second major docking motif in MAPK substrates is referred to as the 
DEF domain (docking site for ERK, FXF). The DEF domain is characterized as an F/YXF/YP 
consensus motif. It appears that the DEF domain exists in certain MAPK substrates, such as 
transcription factors Elk1, c-FOS, Lin1, but not in MAPKAPKs (Jacobs et al., 1998; Murphy 
et al., 2002; Burkhard et al., 2010). In addition to ERK1/2, p38α also binds to the DEF 
domain of substrates, such as SAP-1(transcription factor) (Galanis et al., 2001).  
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       1.3.2.4 Subcellular localization of the ERK1/2 cascade and its             
biological functions  
The ERK1/2 module converts signals from extracellular stimuli into intracellular 
 
Figure 1.5 Alignment of MAPK-binding domains in substrates and molecular model of 
Lig-D bound to ERK2. 
A. Known ERK1/2 D-domains in substrates. The D-domain consists of positively charged 
amino acids followed by hydrophobic amino acids: (R/K)2–3-X2–6-Ѱ-X-Ѱ. This motif has been 
found to be conserved in different substrates such as Elk1, EC-PTP and HePTP; B. Molecular 
structural model of D-domain peptide ligand bound to ERK2. Lig-D (a peptide with 
FQRKTLQRRNLKGLNLNL) bound to the DRS of ERK2. The two hydrophobic Leu of Lig-D 
bind to hydrophobic sites of the CD-domain in ERK2. (Adapted from PLoS One. 2011 Apr 
11;6(4):e18594)(Lee et al., 2011). C. KIM, a D-domain like sequence in MAPKAPKs is 
responsible for ERK/MAPKAPKs interaction. 
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responses, and induces different biological events, such as cell proliferation, cell motility and 
cell differentiation. However, one conundrum remains to be answered: how activation of the 
same kinases ERK1/2 induces such different biological events. Accumulating evidence has 
demonstrated that the duration, magnitude and compartmentalization of activated ERK1/2 can 
affect cell fates. Current models suggest that there are five potential mechanisms of 
ERK1/2-mediated diverse biological functions: (i) difference in the duration and strength of 
ERK activity; (ii) interaction with various scaffold proteins; (iii) localization in the different 
compartments of the cell; (iv) regulation of a wide range of substrates; and (v) 
cross-regulation between diverse signaling pathways (Wortzel and Seger, 2011). In the 
following section, the first four mechanisms are described on the basis of ERK1/2 localization 
in different subcellular compartments. Since the last one is more crucial for clinical research 
and drug development, it will be addressed in more detail in an independent section below.        
         1.3.2.4.1 ERK1/2 in the nucleus and cell proliferation 
Although most ERK1/2 molecules are located in the cytoplasm of quiescent cells, they 
are able to shuttle between the cytoplasm and the nucleus. Upon stimulation by serum, Chen 
et al. observed that a large proportion of ERK1/2 translocated into the nucleus within 10 to 20 
minutes (Chen et al., 1992). Unlike classical mechanism, it was initially thought that ERK1/2 
contain neither an NLS (nuclear localization signals) nor an NES (nuclear export signals), and 
cannot freely diffuse into the nucleus via nuclear membrane pores because only small 
molecules and proteins can penetrate (up to 40 kDa) this barrier (Nardozzi et al., 2010). 
Binding of ERK1/2 to the NPC (nuclear pore complex) directed by energy-dependent 
transport machinery was one of the previous explanations (Ranganathan et al., 2006). In 2008, 
a novel nuclear transport signal (NTS) consisting of the Ser-Pro-Ser residues was identified in 
ERK1/2 (Chuderland et al., 2008). Phosphorylation of this sequence leads to ERK1/2 tightly 
binding to importin7 and further translocation into the nucleus (Lorenzen et al., 2001; 
Chuderland et al., 2008). Most notably, translocation of MEK1 and SMAD3 into the nucleus 
also is mediated by this residue (Chuderland et al., 2008).  
The nuclear translocation of ERK1/2 plays a crucial function in a wide range of cellular 
processes. Robinson et al. demonstrated that ERK2 was required for differentiation in PC-12 
cells and transformation in NIH-3T3 cells, respectively (Robinson et al., 1998). More 
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interestingly, after maintaining ERK1/2 in the cytoplasm by expression a catalytically inactive 
form of cytoplasmic MAP kinase phosphatase (MKP-3/Pyst-1), Brunet et al. observed that 
Elk1-dependent gene transcription was strongly inhibited as well as cell cycle re-entry 
(Brunet et al., 1999). Whereas ERK1/2 activity and their ability to phosphorylate substrates in 
the cytoplasm, such as RSK, were not altered, suggesting that the nuclear localization of 
ERK1/2 is required for cell cycle-related gene transcriptions and cell division (Brunet et al., 
1999).  
As mentioned above, ERK1/2 phosphorylate a number of substrates, most of which are in 
the nuclear. In general, the consequences of ERK1/2 acting on the nucleus substrates are: (1) 
modulation of transcription factor activities: positively or negatively (i.e., Elk-1, Erf-1); (2) 
impacting chromatin remodeling (i.e., PARP-1 regulation); (3) promoting substrate nuclear 
translocation (i.e., NUP50) (Babu et al., 2000; Le Gallic et al., 2004; Cohen-Armon, 2007; 
Kosako et al., 2009). One of the best characterized actions of ERK1/2 in the nucleus is that 
they are involved in cell cycle progression as well as cell proliferation. On the one hand, 
ERK1/2 modulate the activity of the transcription factor Elk-1, which controls the expression 
of immediate early genes (IEG), such as c-Fos. Alternatively, ERK1/2 directly phosphorylate 
c-Fos leading to its stabilization. Stabilized c-Fos is involved in transcriptionally active AP-1 
complex formation through interaction with c-Jun (Wang and Prywes, 2000). It has been 
shown that AP-1 is an essential transcription factor that controls the expression of cyclinD1, 
which interacts with cyclin-dependent kinases(CDKs) and allows G1/S transition (Shaulian 
and Karin, 2001). In addition, ERK1/2 modulate several mediators of apoptosis in the nucleus. 
FOXO3a (Forkhead box O 3a) is a transcription factor upregulating several tumor suppressor 
gene expressions, such as Bim (BCL2-like 11, apoptosis facilitator) and PUMA (p53 
upregulated modulator of apoptosis). It was found that ERK1/2 phosphorylated FOXO3a, 
thereby promoting MDM2-dependent FOXO3a degradation and leading to robustly 
upregulated cell proliferation (Yang et al., 2008).   
         1.3.2.4.2 ERK1/2 in the plasma membrane and regulation of cytoskeletal 
elements  
The first step in transmitting signals from extracellular stimuli into intracellular targets 
occurs at the plasma membrane. In response to stimuli, many components of the signaling 
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cascades shuttle at the plasma membrane where they receive inputs in response to 
extracellular signals. In this process, scaffold proteins play crucial functions during signal 
transduction, such as KSR (kinase suppressor of Ras) and 14-3-3 (Therrien et al., 1995; 
Fanger et al., 1998). KSR was the first identified scaffold protein in the ERK1/2 cascade. In 
quiescent cells, KSR constitutively binds to the inactivated MEK1/2. Meanwhile, KSR also 
associates with 14-3-3 via two phosphoserine residues (Ser297/392) and thereby retains KSR in 
the cytoplasm (Xing et al., 1997). Upon activation by agonists, protein phosphatase-2A 
(PP2A) dephosphorylates KSR leading to 14-3-3 disassociation and KSR tethering at the 
plasma membrane, where it forms a complex with Raf initiating the activation of MEK1/2. 
Furthermore, activated MEK1/2 phosphorylate ERK1/2, which in turn modulate a multitude 
of biological functions, including cell proliferation.   
ERK1/2 participate in the regulation of cell spreading and cell migration by modulating 
cytoskeletal components. ERK1/2 can bind either directly or indirectly to cytoskeletal 
elements. It was shown that ERK1/2 not only directly bind to actin or microtubules, but also 
indirectly interact with them through association with the actin-binding protein calponin 
(Appel and Morgan, 2010). In addition, it was found that activated ERK1/2 phosphorylate 
myosin light chain kinase (MLCK), which in turn phosphorylates myosin light chains (MLC) 
leading to actin-based cell motility (Klemke et al., 1997).  
Scaffold proteins are also involved in the mechanism by which ERK1/2 affect cell 
migration through regulating cytoskeletal components. Given that scaffold proteins tether the 
components of the signaling cascade to a particular cellular location, it seems that the 
involvement of scaffold proteins is an additional way to ensure the fidelity and magnitude of 
the ERK1/2 cascade. As a scaffold protein, Ras GTPase-activating-like protein IQGAP1 
interacts with B-Raf, MEK1/2 and ERK1/2, and recruits them to actin filaments, resulting in 
cell proliferation (Jadeski et al., 2008). Another scaffold protein, LSP1, enhances ERK1/2 
signals leading to inhibited cell apoptosis as a result of tethering MEK1 and ERK2 to 
peripheral actin filaments (Huang et al., 1997). Moreover, paxillin, a focal 
adhesion-associated adaptor protein, associates with ERK1/2 and guides them to the 
cytoskeleton. In mIMCD-3 (mouse inner medullary collecting duct) cells, it was found that 
activated Raf and MEK bound to paxillin and further induced activation of ERK1/2 by 
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cell-matrix interactions upon HGF stimulation (Ishibe et al., 2003). Disruption of 
ERK/paxillin interaction decreased HGF-induced cell spreading and branching, indicating 
that the association of these two proteins is crucial for HGF-induced epithelial morphogenesis. 
Consistent with these results, it has been shown that the depletion of paxillin downregulates 
ERK1/2 activity in human oral squamous carcinoma HSC-4 cells, suggesting that paxillin is 
indispensable in the ERK-MAPK signaling cascade (Takino et al., 2010).  
         1.3.2.4.3 ERK1/2 in endosomes and signal transduction 
The predominant functions of endosomes are to sort molecules and proteins for 
degradation, re-cycling, and signal transduction. Previous studies have shown that endocytosis 
and endosomes are crucial for proper receptor-signal transduction via the ERK1/2 module 
(Lavoie et al., 2002). More specifically, endocytosis of the GPCR β2-adrenergic receptor is 
necessary for ERK1/2 activity, which occurs in the early endosomes (Lavoie et al., 2002). In 
this process, scaffold proteins, such as β-arrestin, are indispensable for ERK1/2 activity. For 
instance, β-arrestin associates with ERK1/2 and directs them to clathrin-coated endosomes 
upon stimulation (Zhang et al., 1997). This irreversible association between activated ERK1/2 
and β-arrestin retains ERK1/2 in the cytoplasm, where they phosphorylate cytoplasmic 
substrates instead of nuclear target proteins. Aside from β-arrestin, another scaffold protein 
MP1 (MEK-1 partner) facilitates ERK1/2 localization in endosomes (Schaeffer et al., 1998). 
Intriguingly, MP1 preferentially associates with specific MEK or ERK isoforms. In late 
endosomes, MP1 interacts with MEK1 and ERK1 rather than MEK2 and ERK2. It was shown 
that MP1 interaction with p14, an adaptor protein, enhanced ERK1-induced cell proliferation 
(Teis et al., 2006). Downregulation or upregulation of p14/MP1 leads to reduced or increased 
activation of the ERK1/2-cascade. An alternative view suggests that ERK1/2 regulate 
endosomal trafficking through ADP-ribosylation factor 6 (Arf6) GTPase-regulated pathway, 
rather than the clathrin-dependent mechanisms. It was shown that inhibition of MEK1/2 by 
U0126 prevents Arf6 cargo expansion, correlating with accumulation of ERK1/2, MEK and 
KSR in the Arf6 recycling compartment (Robertson et al., 2006).   
 30 
 
Although a report indicates that ERK1/2 are involved in endosomal protein trafficking, it 
appears that one of the predominant functions of the endosome is to participate in the 
regulation of ERK1/2 activity and direct them to their proper substrates in the cytoplasm. 
 
Figure 1.6 Simplified overview of phosphorylated ERK1/2 (p-ERK1/2) and their 
substrates localization in distinct cellular compartments. 
① Upon RTK activation, ERK1/2 is phosphorylated by the Ras/Raf/MEK cascade, which is 
present at the plasma membrane; ② p-ERK1/2 bind to cytoskeletal elements through a 
scaffold protein termed LSP1; ③ Some p-ERK1/2 translocate to the mitochondria, where 
they phosphorylate the anti-apoptotic regulator Bcl-2; ④ Most p-ERK1/2 shuttle into the 
nucleus and affect transcription factor activities; ⑤ p-ERK1/2 binds to Sef, leading to 
ERK1/2 retention in the cytoplasm; ⑥ p-ERK is involved in GPCR recycling (more detail in 
the text). (Adapted from Genes Cancer. 2011 Mar; 2(3):195-209)(Yu et al., 2011)  
 31 
 
Notably, in the RTK and GPCR-mediated signaling pathways, a different set of 
scaffold/anchor proteins cooperate with ERK1/2 to maintain the specificity and efficiency of 
intracellular signal transduction.  
         1.3.2.4.4 ERK1/2 in other cellular compartments 
In contrast to phosphorylation-dependent events, most functions within the Golgi 
apparatus involve glycosylation and protein trafficking. GRASP55 is responsible for Golgi 
cisternal stacking and cell migration and can be targeted by ERK1/2 (Jesch et al., 2001; Wei 
and Seemann, 2009). It was shown that GRASP55 was phosphorylated by ERK1/2 at Ser277 
leading to the unstacking of Golgi cisternae, which is crucial for polarization of the Golgi, 
centrosome orientation and cell migration. Thus, these results indicate that ERK1/2 play a key 
role in the modulation of Golgi remodeling. In addition, the process of Golgi fragmentation, 
which is considered as a “mitotic checkpoint”, is regulated by the ERK1/2 cascade (Colanzi 
and Corda, 2007). Previous reports indicated that MEK1/2 inhibitors were able to inhibit 
Golgi fragmentation, suggesting that the ERK1/2 cascade is involved in the process of Golgi 
fragmentation. However, neither active ERK1/2 nor MEK1/2 have been detected in the Golgi. 
Furthermore, Inbal et al. demonstrated that monophosphorylation of the ERK1 splice variant 
ERK1c accumulated in the late G2 and mitosis of synchronized cells (Shaul and Seger, 2006). 
Since ERK1c was activated by MEK1b, depletion of either MEK1b or ERK1c had the same 
function in the reduction of mitotic Golgi fragmentation and preventing mitotic progression. 
Therefore, these results demonstrate that the activity of the MEK1b-ERK1c cascade is crucial 
for Golgi fragmentation during mitosis. Moreover, scaffold proteins are required in 
Golgi-mediated ERK1/2 signaling cascades. One such scaffold protein is Sef1, which is 
located on the outer surface of the Golgi and interacts with inactivated ERK1/2 in resting cells 
(Torii et al., 2004). Upon stimulation, Sef1 associates irreversibly with activated MEK1/2, 
and inhibits activated ERK1/2 nuclear translocation. Silencing of Sef1 leads to the 
accumulation of ERK1/2 in the nucleus and the upregulation of ERK1/2-mediated gene 
transcription, such as ELK1 (Torii et al., 2004). Taken together, the MEK1/2-Sef1-ERK1/2 
complex on the outer surface of Golgi apparatus allows activated ERK1/2 to remain in the 
cytoplasm instead of the nucleus.  
The function of the mitochondria is to integrate signals from the environment/cellular 
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stimuli leading to a wide range of biological events, such as energy production, apoptosis 
(programmed cell death) and cellular metabolism. By using pharmacological inhibitors of 
MEK1/2, it was found that the ERK1/2 cascade was able to modulate mitochondrial functions 
such as cell survival (Erhardt et al., 1999). In cisplatin-treated cells, retention of ERK1/2 in 
mitochondria inhibits oxidative phosphorylation leading to the upregulation of caspase-3 
activity and cell apoptosis (Nowak, 2002). Moreover, ERK1/2 colocalize and phosphorylate 
the anti-apoptotic mitochondrial protein Bcl-2, thereby suppressing cell apoptosis. Notably, 
this process can be reversed by serine/threonine phosphatase 2 (PP2A) (Breitschopf et al., 
2000).  
Localization of ERK1/2 to the mitochondria is important for developmental brain 
activities (Alonso et al., 2004). In mice model, it was shown that the peak level of ERK1/2 in 
mitochondria was at from stage E19 to P2, then decreased from P3 to adulthood (Alonso et al., 
2004; Wortzel and Seger, 2011), whereas the maximal presence of ERK1/2 in the nuclear 
occurred after stage P3. Given that the level of nuclear ERK1/2 is variable during brain 
development and ERK1/2 localization in mitochondria is sensitive to redox regulation (Chu et 
al., 2004), these results suggest that ERK1/2 nuclear localization induced by mitochondrial 
energetic and redox status is crucial for cell differentiation and proliferation. In addition, it 
was shown that activated ERK1/2 in mitochondria protects cancer cells from death (Rasola et 
al., 2010). However, how do ERK1/2 localize to the mitochondria, and which transporter 
protein is involved remain unknown. Although there is no convincing mechanism for ERK1/2 
translocation into mitochondria, proteomic study by Soledad et al. demonstrated that VDAC1 
might serve as a transporter protein to facilitate ERK1/2 localization to the mitochondria 
(Galli et al., 2009).  
       1.3.2.5 Regulation of the ERK1/2 cascade by feedback loops 
Activation of the Ras/MAPK pathway leads to different cellular outcomes. For example, 
activation of the same protein kinases ERK1/2, can elicit different cellular responses, such as 
cell proliferation vs. cell differentiation. This cannot be simply explained by the specificity of 
cell type, because even in the same cell type ERK1/2 activation results in distinct outcomes in 
response to different agonists. Accumulating evidence is demonstrating that the duration and 
the magnitude of ERK1/2 activity in response to different agonists lead to discrete biological 
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events. Modulation of Ras/MAPK signaling by feedback loops might be one of the 
explanations for these discrepancies (Mendoza et al., 2011). Given that oncogenes upstream 
of the MAPK pathway, such as K-Ras and B-Raf, lead to the hyperactivation of ERK1/2 
module and cause diseases such as cancers, a understanding of the regulatory mechanisms of 
the Ras/MAPK pathway is necessary for better targeting ERK1/2 activity in disease.    
Negative feedback regulation within the Ras/MAPK signaling pathway 
   Negative feedback loops occur in the same signaling pathway, in which downstream 
effectors inhibit their own upstream inducers. For instance, in the MAPK pathway, ERK1/2 
inhibit their own upstream activator Ras by directly phosphorylating SOS and resulting in 
Grb2 dissociation (Dong et al., 1996). ERK1/2 were also found to directly phosphorylate Raf 
on C-terminal SPKTP sequence leading to reduced biological activity (Brummer et al., 2003). 
One possible reason is that phosphorylated Raf by ERK1/2 dissociates from the plasma 
membrane and also its upstream activators. In addition, ERK1/2 induce the expression of 
certain Ser/Thr phosphatase proteins, such as the MAPK phosphatase MKP1, that in turn 
dephosphorylate and inactivate ERK1/2 (Wang et al., 2006). Moreover, it was shown that 
inhibition of RSK activity using pharmacological inhibitors increases ERK1/2 activity in 
certain types of cells, suggesting that RSK negatively regulates ERK1/2 activity (Saha et al., 
2012). One conceivable explanation is that RSK modestly upregulates MAPK activation by 
phosphorylating SOS, leading to 14-3-3 association (Saha et al., 2012). 
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Cross-inhibition or -activation between the Ras/MAPK pathway and other signaling cascades 
Inhibition of MAPK signaling activation by several signaling cascades. The 
PI3K-Akt-mTOR pathway negatively regulates MAPK signaling by phosphorylating Raf. 
 
Figure 1.7 Schematic representation of the cross-talk between the Ras/MAPK and 
PI3K/mTOR signaling pathways. 
Activated growth factor receptors trigger the parallel activation of the Ras/MAPK and 
PI3K/mTOR signaling pathways. Upon stimulation, the SOS/Grb2 complex is tethered to the 
plasma membrane and acts as a positive regulator by promoting GTP binding to Ras. ERK1/2 
and RSK create feedback loops by phosphorylating SOS. In order to prevent hyperactivation of 
the MAPK pathway, ERK1/2-modulated phosphatases such as MKP1, inactivate ERK1/2. 
Moreover, ERK1/2 directly phosphorylate Raf and inhibit Raf activity with an unknown 
mechanism. Akt also phosphorylates Raf leading to downregulated MAPK activity. 
Alternatively, the MAPK pathway positively regulates mTORC1 activity. On the one hand, 
ERK1/2 and RSK indirectly regulate mTOR signaling by limiting TSC2 activity. On the other 
hand, ERK1/2 and RSK directly regulate mTORC1 activity by phosphorylating Raptor. (more 
detail in the text).  
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Upon IGF1 stimulation, it was observed that Akt phosphorylated inhibitory sites in the 
N-terminal of Raf leading to downregulated Raf and ERK1/2 activities (Moelling et al., 2002). 
However, this inhibitory effect could be counteracted by PP1 or PP2 (PP: protein phosphatase) 
(Abraham et al., 2000). Moreover, Salazar et al. demonstrated that p85 negatively regulated 
the Ras/MAPK pathway upon FGF stimulation (Salazar et al., 2009). Using the yeast 
two-hybrid system, they confirmed that p85 directly interacted with FGFR3. Upon FGF 
stimulation, depletion of p85ߚ in multiple myeloma cells promoted ERK1/2 activity, 
suggesting that p85-FGFR3 association acts as a negative regulator of ERK1/2 activity. More 
intriguingly, mTORC1 has been found to negatively regulate activation of the MAPK 
pathway through stabilization of Grb10 with an unknown mechanism (Yu et al., 2011). PKA 
(protein kinase A) also involves in the regulation of MAPK activity. In response to cAMP 
agonists, phosphorylation of Raf by PKA promotes 14-3-3 interaction, leading to Ras and 
MEK1/2 dissociation (Dumaz and Marais, 2003).  
  Cross-activation between the Ras/MAPK and PI3K/Akt/mTORC1 pathways. The 
MAPK signaling cascade positively regulates mTORC1 activity at several nodes of the 
PI3K/Akt/mTOR pathway. On the one hand, Ras directly binds to the catalytic subunit p110 
of PI3K and enhances Akt activity, independently of the regulatory subunit p85 of PI3K 
(Gupta et al., 2007). On the other hand, ERK1/2 and RSK cooperate to upregulate mTORC1 
activity by phosphorylating TSC2, a GTPase-activating protein (GAP) toward Rheb (Ras 
homolog enriched in brain) (Roux et al., 2004; Ma et al., 2005). Moreover, ERK1/2 and RSK 
directly regulate mTORC1 activity by phosphorylating Raptor, leading to PI3K-independent 
4E-BP phosphorylation (Carriere et al., 2008; Carriere et al., 2010). 
Implication of pathway cross-talk in tumor development and cancer treatments 
During tumor progression from benign nevi to a melanoma, cross-inhibition between the 
Ras/MAPK and PI3K/Akt pathways plays an important role. In benign lesions, the first 
mutation of Ras or Raf induces such high and sustained activation of ERK1/2, resulting in cell 
cycle arrest and cell senescence. However, secondary mutations occurring in the PI3K/Akt 
pathway reduce over-activation of the Ras/MAPK pathway (Cheung et al., 2008). Eventually, 
cooperation of the Ras/MAPK and PI3K/Akt pathways induces cell transformation and 
promotes tumor progression. 
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   Understanding cross-talk between the Ras/MAPK and PI3K/Akt pathways has a 
significant implication in clinical research. For instance, given that treatment of melanoma 
cells which contain a BRAFV600E mutation induces drug resistance through re-activation of the 
P13K/Akt pathway, co-inhibition of both signaling pathways has been proposed (Chen et al., 
2012). Interestingly, these findings have been successfully characterized by studies in the 
mouse, whereby co-treatment with dual inhibitors of both the Ras/MAPK and PI3K/Akt 
signaling is found to be most effective in the inhibition of prostate and lung tumor growth 
(Kinkade et al., 2008; Meng et al., 2010). Although intense work is required in future to fully 
characterize the various modes of cross-talk between signaling pathways after a drug is 
administered, this work is helpful to expand our knowledge in cancer intervention. 
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    1.3.3 MAPK–activated protein kinase RSK (90 kDa ribosomal S6 kinase)  
       1.3.3.1 Discovery of RSKs, their tissue expression and physiological functions 
Understanding the regulated phosphorylation of rpS6, a ribosomal protein, has become an 
attractive research topic during the 1970s (Gressner and Wool, 1974). Given that 
phosphorylated rpS6 was initially thought to participate in protein synthesis by regulating 
binding of mRNA to 40S ribosomal subunits (Burkhard and Traugh, 1983), several research 
groups endeavored to identify kinases involved in rpS6 phosphorylation. In 1985, an 
intracellular kinase activity that phosphorylated rpS6 was purified from unfertilized Xenopus 
laevis eggs (Erikson and Maller, 1985). Initially, this activity was termed ribosomal S6K (S6 
kinase). In 1988, two protein kinases, ribosomal S6 kinase I and ribosomal S6 kinase II, were 
identified by biochemical purification from egg extracts of Xenopus laevis, resulting in the 
cloning of two cDNAs encoding highly homologous proteins which were renamed p90 RSKs 
or RSKs (Jones et al., 1988; Romeo et al., 2011). Upon insulin stimulation, it was found that 
S6KII (or p90 RSKs or RSKs) was phosphorylated by MAP2 (microtubule-associated 
protein-2) kinase (renamed ERK2) (Sturgill et al., 1988), providing the first evidence that 
S6KII (or p90 RSKs or RSKs) was phosphorylated by the ERK/MAPK pathway.  
The RSK family consists of four isoforms: RSK1, RSK2, RSK3 and RSK4. Whereas 
RSK1-3 mRNAs are widely expressed in every mouse and human tissue tested, the 
abundance of RSK4 mRNA is relatively low (Moller et al., 1994; Zeniou et al., 2002). More 
specifically, while RSK1 mRNA is mostly expressed in the lung, kidney and pancreas, RSK2 
and RSK3 mRNAs are predominately found in skeletal muscle, heart and pancreas (Zeniou et 
al., 2002). Although RSK4 mRNA is lower compared to that for RSK1-3, it can still be 
detected in certain tissues, including brain, heart cerebellum, kidney and skeletal muscle, 
rather than lung, liver, pancreas and adipose tissue (Dummler et al., 2005). To date, RSK1-4 
knockout mice have been generated, and they are all viable and fertile. Although no obvious 
phenotypes are observed in RSK1- and RSK3-deficient mice, RSK2 knockout mice display 
impaired learning and cognitive functions (Poirier et al., 2007). It is also found that RSK2 
knockout mice are ~14% shorter and have ~10% less weight compared to wild-type (WT) mice. 
Most interestingly, insulin treatment and exercise remarkably increase ERK1/2 
phosphorylation in skeletal muscle of RSK2 knockout mice (~2-fold compared to WT mice), 
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indicating that RSK2 participates in the negative feedback regulation of ERK1/2-cascade in 
skeletal muscle (Dufresne et al., 2001). Since the physiological function of human RSK2 is 
highlighted because mutations in Rps6ka3 is a cause of CLS (Coffin–Lowry syndrome), an 
X-linked mental retardation syndrome (Kesler et al., 2007), the studies from RSK2 knockout 
mice would be helpful to prevent Coffin–Lowry syndrome.   
       1.3.3.2 Structural features of RSKs  
The amino acid identity between the human RSK isoforms is around 80%, and the most 
divergent regions between them are the N- and C-terminal sequences (Figure 1.8). Notably, 
RSKs are most likely fusion proteins and composed of two different kinase domains (Fisher 
and Blenis, 1996): (1) the carboxyl-terminal kinase domain (CTKD) belongs to the CAMK 
family (Ca2+ /calmodulin-dependent protein kinase), including AMPK (AMP-activated 
protein kinase), MARK (MAP-regulation kinase/microtubule affinity regulating kinase), and 
DAPK (death-associated protein kinase). The role of the CTKD is to receive upstream signals 
from ERK1/2 and transmit them to the N-terminus of RSK. To date, no substrate of the 
CTKD has been determined aside from RSK itself; (2) the amino-terminal kinase domain 
(NTKD) belongs to the AGC family (protein kinases A, G and C) including Akt (protein 
kinase B), SGK (serum-and glucocorticoid-induced protein kinase) and S6K1/2. The function 
of the NTKD in RSK is to phosphorylate downstream substrates. Between the CTKD and 
NTKD there is a linker region of around 100 amino acids that, consists of a hydrophobic 
motif and a turn motif. The predominant function of this middle linker region is to transduce a 
signal from the CTKD to NTKD. 
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 As indicated above, the CTKD of RSK is responsible for receiving an output signal from 
ERK (Fisher and Blenis, 1996). ERK catalyzes downstream effectors through interaction with 
the D-domain or DEF-domain present in substrates. As a substrate of ERK, RSK also follows 
this rule. However, unlike classical docking domains, the ERK binding region in RSK does 
not match the well-characterized consensus sequences of either D-domains or DEF-domains. 
Instead, it fits a KIM (kinase interaction motif), a D-domain-related motif that consists of a 
hydrophobic residue with two adjacent positively charged lysine or arginine residues 
(Leu-Xaa2-Lys/Arg- Lys/Arg-Xaa5-Leu) (Gavin and Nebreda, 1999). Aside from the KIM 
domain, a PDZ domain-binding motif (Ser-Thr-Xaa-Leu) in the C-terminal tail of all four 
RSK isoforms has been found to be functional and may help recruiting RSK to its targets 
(Thomas et al., 2005).      
       1.3.3.3 Activation mechanisms and inhibitors of RSK  
Activation of RSK is a result of sequential phosphorylation of four critical sites (Ser221, 
 
Figure 1.8 Schematic representation of structural features in RSK isoforms. 
All RSK isoforms consist of the NTKD, the middle-linker region and the CTKD. Among these, 
the NTKD belongs to the AGC family and the CTKD belongs to the CAMK family. Only RSK3 
contains a putative NLS (nuclear localization sequence), but its biological function remains 
elusive. (Adapted from Microbiol Mol Biol Rev. 2011 Mar;75(1):50-83 and Cancer Research 
2013 Sep 1;73(17):5301-8)     
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Ser363, Ser380 and Thr573 in human RSK1), that are highly conserved in all RSK isoforms 
(Figure 1.9). Given that sequential phosphorylation is necessary for RSK activation, the 
model of RSK activation is reviewed in the following.  
The C-terminal end of RSK: interacts with ERK1/2 and promotes RSK phosphorylation on 
Thr573 
As an initial step upon mitogen stimulation, the interaction between ERK1/2 and the KIM 
domain in the C-terminus of RSK is required for activation. Following ERK1/2 docking, 
Thr573 in the activation loop segment of the CTKD is phosphorylated, leading to the 
auto-phosphorylation of RSK at other residues (Smith et al., 1999). Moreover, 
phosphorylation on Thr573 may play an additional function in RSK translocation to the plasma 
 
Figure 1.9 Schematic representation of human RSK1 kinase domains and phosphorylation 
sites. 
RSK1 consists of two kinase domains: the N-terminal and the C-terminal kinase domains, 
which are linked by a region of 100 aa. The KIM domain is located on the C-terminus, which is 
responsible for ERK1/2 docking to RSK. There are at least six phosphorylation sites in RSK1, 
which are all conserved from RSK1 to RSK4, suggesting the significance of these sites in 
evolution. Phospho-Ser/Thr residues are modulated by different kinases, including ERK1/2, 
PDK1, CTKD and NTKD, which are displayed in the above figure. (Adapted from Biochem J. 
2012 Jan 15;441(2):553-69.)   
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membrane (Richards et al., 2001).   
The Middle-linker region of RSK: “the turn motif” and “the hydrophobic motif” 
The “hydrophobic” and “turn” motifs, which contain Thr359/Ser363 and Ser380 sites 
respectively, are located in the linker region between the CTKD and NTKD (Vik and Ryder, 
1997; Richards et al., 1999; Newton, 2003). Whereas Thr359/Ser363 are phosphorylated by 
ERK1/2 directly, phosphorylation of Ser380 is a result of ERK1/2-dependent phosphorylation 
on Thr573 in the CTKD (Richards et al., 1999; Newton, 2003). Although the consequence of 
Ser363 and Ser380 phosphorylation is to enhance NTKD enzymatic activity, the mechanism by 
which Ser363 enhances NTKD activity remains unclear. One possible function of the turn 
motif is to modulate heat shock protein bindings, thereby ensuring the correct folding of AGC 
kinases, such as PKC (Gao and Newton, 2002). Phosphorylation of Ser380 by the RSK CTKD 
provides a docking site for PDK1 that further phosphorylates and activates the NTKD of RSK 
(Frodin et al., 2000). Moreover, aside from the CTKD, Ser380 may also be phosphorylated by 
other kinases, such as the NTKD and other heterologous kinases (Vik and Ryder, 1997). 
The N-terminus of RSK: Complete RSK activation by phosphorylation of Ser221 
    Phosphorylation of Ser221 is the last step in completing RSK activation. 
3-phosphoinositide-dependent protein kinase-1 (PDK1) belongs to the AGC family, which 
includes AKT, S6K and SGK (Arencibia et al., 2013). The fact that RSK1-3 cannot be 
activated in PDK1-deficient cells suggests that recruitment of PDK1 to the hydrophobic motif 
of RSK is required for Ser221 phosphorylation (Williams et al., 2000). Although structurally, 
the PH domain in PDK1 is crucial for PDK1-dependent Akt1 activation, it appears that the 
PH domain is unnecessary for RSK activation (Bayascas et al., 2008). Additionally, PI3K 
inhibitors have no effect on RSK activity, indicating that PDK1 modulating RSK activity is 
independent of the PI3K/Akt pathway (Williams et al., 2000). Collectively, these results 
suggest that PDK1 is indispensable in mitogen-induced RSK1-3 activity, independently of the 
PIP3–containing domain (PH domain) and the PI3K pathway. Notably, it seems that RSK4 is 
excluded from the PDK1-dependent activation mechanism, but the reasons for this are 
currently unknown.  
Phosphorylation of Ser221 stabilizes the NTKD in an active conformation, leading to the 
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synergistic full activation of RSK. Meanwhile, phosphorylation of Ser732 at the C-terminus of 
RSK by the NTKD releases ERK1/2 and allows translocation of activated RSK into different 
cellular compartments, where it can act on particular substrates (Roux et al., 2003). The 
substrates of RSK have the following two common phospho-motifs, which consist of 
minimum sequences: (i) an Arg/Lys-Xaa-Arg-Xaa-Xaa-pSer/Thr motif; (ii) an 
Arg-Xaa-pSer/Thr-Xaa-Pro motif. Notably, this consensus motif can also be recognized by 
other AGC kinases, such as Akt, indicating the redundant functions of AGC kinases on the 
same substrate, such as PDCD4 (programmed cell death protein 4) (Palamarchuk et al., 2005; 
Galan et al., 2014).       
RSK pharmacological inhibitors. To date, two types of RSK inhibitors have been 
generated on the basis of the different kinase domains: (i) a CTKD inhibitor: FMK is an 
irreversible inhibitor that covalently modifies the CTKD of RSK1, 2 and 4 isoforms with an 
in vitro IC50 (half maximal inhibitory concentration) of 15 nM (Cohen et al., 2005); (ii) 
NTKD inhibitors: these are ATP-competitive inhibitors of the RSK NTKD ATP-interacting 
sequence, including SL0101, BI-D1870, LJH685 and LJI308 (Smith et al., 2005; Sapkota et 
al., 2007; Aronchik et al., 2014). SL0101 is a natural product, purified from the plant 
Fosteronia refracta with an in vitro EC50 (half maximal effective concentration) of 50 nM and 
IC50 of 90 nM. It was shown that 10 μM of BI-D1870 was enough to inhibit phosphorylation 
of RSK substrates in cells. LJH685 and LJI308 are two recently identified RSK inhibitors. It 
appears that these two inhibitors also prefer to associate with the NTKD of RSK. A study 
determined that suppression of RSK by LJH685 and LJI308 resulted in reduced 
anchorage-independent cell growth (Aronchik et al., 2014).      
       1.3.3.4 Subcellular localization and RSK-mediated biological functions 
To date, few studies have been published regarding the subcellular localization of RSK 
isoforms in cells. In resting cells, RSK1-4 are usually distributed in the cytoplasm. Upon 
stimulation, a large proportion of RSK1-3 translocates into the nucleus whereas RSK4 
remains in the cytoplasm (Chen et al., 1992; Zhao et al., 1995). Interestingly, it was shown 
that RSK1 accumulated transiently at the plasma membrane within a few minutes of 
stimulation, indicating that this protein might require additional signals for activation before 
entering the nucleus (Richards et al., 2001). The mechanisms by which RSK accumulates in 
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the nucleus remain unclear. One possible explanation is that RSK interacts with some adaptor 
proteins, which either translocate or antagonize them into the nucleus. For instance, PEA-15, 
a small death effector domain protein, binds to RSK2 and inhibits its translocation into the 
nucleus (Vaidyanathan and Ramos, 2003). RSK3 is the only isoform that contains a putative 
nuclear localization sequence (NLS). However, the functionality of this region has never been 
tested.  
  Given that the mechanisms regarding RSK localization remain elusive and very few 
studies have been reported, RSK-mediated biological functions have always been determined 
through their specific target proteins under different conditions. In the following section, the 
predominant functions of the RSK family will be discussed.  
         1.3.3.4.1 Regulation of transcription factor activities 
RSK plays an important function in ERK1/2-regulated gene transcription. On the one 
hand, being a downstream amplifier of ERK1/2, RSK receives input signals from ERK1/2 and 
transmits them to the substrates. On the other hand, ERK and RSK coordinate together to 
regulate their common substrates. In MDCK (Madin-Darby canine kidney) cells, it was 
shown that around 20% of mRNAs controlled by ERK1/2 were also regulated by RSK 
(Doehn et al., 2009). One possible mechanism is that some ERK1/2-regulated transcription 
factors can also be regulated by RSK, such as ELK1 (ETS domain-containing protein) (De 
Cesare et al., 1998; Babu et al., 2000).  
RSK modulates a number of transcription factors, which are either the IEG 
(immediate-early gene) products or involved in the IEG response. It has been shown that RSK 
directly modulates c-Fos activity or its expression by phosphorylating or regulation of its 
transcription factor activities, such as the ELK1 (ETS domain-containing protein)/SRF (serum 
response factor) complex, and CREB (cAMP response element-binding protein) (Chen et al., 
1993; De Cesare et al., 1998). For instance, De Cesare D et al. demonstrated that both 
phosphorylation of CREB and c-Fos were downregulated in fibroblast cell lines that were 
established from a CLS (Coffin-Lowry syndrome) patient without functional RSK2 (De 
Cesare et al., 1998). Intriguingly, RSK is not the only kinase responsible for CREB 
phosphorylation. A study showed that MSK1 was also required for CREB phosphorylation in 
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mouse embryonic stem (ES) cells (Arthur and Cohen, 2000). Given that mitogens, such as 
PDGF (platelet-derived growth factor) and IGF-1 (insulin-like growth factor), induce CREB 
phosphorylation in the absence of RSK2, this suggests that other kinases, likely MSK1, 
cooperate with RSK to modulate CREB activity upon mitogenic stimulation (Arthur and 
Cohen, 2000; Bruning et al., 2000). In addition to directly modulating transcription factors, 
some studies suggested that activated RSK may bind to the transcriptional co-activators CBP 
(CREB binding protein) and p300, and cooperate with them to modulate transcription factor 
activities, including c-Fos, CREB, ERα, ER81, and NF-κB (Nakajima et al., 1996).   
Studies have shown that RSK is crucial for the regulation of growth-related gene 
transcription initiation (Wu and Janknecht, 2002; Zhao et al., 2003; Yamnik and Holz, 2009). 
Growth factor-induced RSK1 directly phosphorylates the estrogen receptor α (ERα) and 
further increases ERα-dependent transcription (Yamnik and Holz, 2009). Upon serum 
stimulation, RSK2 phosphorylates transcription initiation factor TIF-1A, which is required for 
RNA polymerase I transcription and rRNA synthesis (Zhao et al., 2003). RSK phosphorylates 
ER81, an ETS transcription factor, and increases ER81-dependent transcription (Wu and 
Janknecht, 2002). In malignant melanoma, RSK also phosphorylates another transcription 
factor Mi (microphthalmia) (Richards et al., 2001).  
Aside from controlling growth-related gene transcription, RSK also regulates 
inflammatory response-related gene transcriptions, such as NF-κB. In the presence of the 
hormone angiotensin II, It was found that activation of RSK increased NF-κB activity in the 
vascular smooth muscle cells (Doyon and Servant, 2010). Furthermore, Priscilla D. et al. 
oberseved that the MAPK/RSK pathway phosphorylats the T-loop of IKKβ, leading to its full 
activation. Given that IKKβ phosphorylates and mediates the degradation of IκB, an 
inhibitory moleculer of NF-κB, these results indicate that RSK impacts NF-κB activity 
through regualtion of the IKK complex.  
         1.3.3.4.2 Regulation of cell cycle progression and cell proliferation 
One of the well-characterized functions of RSK is to regulate cell cycle progression and 
cell proliferation. It was found that depletion of RSK1/2 inhibited melanoma cell proliferation 
and also tumor growth in mice (Romeo et al., 2012). Another piece of evidence with regard to 
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the importance of RSK in cell proliferation is that inhibition of RSK by the pharmacological 
inhibitor SL0101 prevents cell cycle progression in the breast cancer cell line MCF-7 (Smith 
et al., 2005). Consistent with these results, data from EST (expressed sequence tag) sources 
indicate that expression of RSK1 in tumors is higher compared to normal tissues (Romeo et 
al., 2011). However, RSK2 shows no obvious preference between human malignancies and 
normal tissues. By contrast, RSK3 and RSK4 were found in lower abundance in tumor cells. 
These evidence indicate that RSK isoforms may have different functions.  
Regulation of G1/S progression. RSK controls cell proliferation through 
phosphorylating downstream effectors which are mediators of the cell cycle. In G1/S 
progression, it has been shown that RSK either indirectly or directly regulates cyclinD1 or 
CKI (cyclin-dependent kinase inhibitor) activity. For instance, it was shown that RSK 
phosphorylated c-Fos at Ser362, a transcription factor that directly up-regulates cyclinD1 
expression (Chen et al., 1993). p27kip1 is an inhibitor of CDK2 activity in G1 phase 
progression. It was found that RSK phosphorylated p27kip1 at Thr198 and thus promoted 14-3-3 
association resulting in a blockage of p27kip1 translocation into the nucleus (Fujita et al., 2003). 
In addition, RSK has some indirect modes of actions in controlling cell cycle progression. 
GSK3 is a Ser/Thr kinase and acts as a negative regulator in tumor progression. The canonical 
GSK3 substrate is the oncogene β-Catenin. Phosphorylation of β-Catenin by GSK3 leads to 
its recognition by β-TrCP, an ubiquitin E3-ligase, and its degradation by the proteasome (Hart 
et al., 1999). Besides this canonical inhibitory mechanism of GSK3 in tumorgenesis, it was 
found that RSK phosphorylated GSK3 abrogated GSK3’s inhibitory function on c-Myc and 
cyclinD1, leading to G1/S progression (De Mesquita et al., 2001).  
Regulation of G2/M progression and metaphase-to-anaphase transition. RSK1 has 
been found to play a crucial role in accelerating G2/M transition and promoting cell 
proliferation (Nam et al., 2008). Upon HGF stimulation or in the presence of an active form 
of the HGF receptor M1268T, either the MEK inhibitor U0126 or a kinase-dead RSK can 
delay cell cycle progression, suggesting that RSK is required for G2/M transition (Nam et al., 
2008). RSK-promoted cell cycle progression may be due to the involvement of RSK in the 
regulation of checkpoint-related proteins such as Chk1 (checkpoint kinase 1) and Cdc25 (cell 
division cycle 25) (Ray-David et al., 2012). Chk1 is a G2/M checkpoint kinase, which 
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prevents cells entering into mitosis by phosphorylating Cdc25, a phosphatase activating the 
Cdk/cyclins by dephosphorylating Wee1. In melanoma cell lines, hyperactivated N-Ras or 
B-Raf by mutations lead to constitutive phosphorylation of Chk1 on Ser280, an inhibitory site 
promoting Chk1 ubiquitination (Ray-David et al., 2012). Interestingly, upon DNA-damaging 
agent treatments, a study found that inhibition of RSK upregulated Chk1 activity correlating 
with downregulation of phosphorylation of Ser280, indicating that the Ras/MAPK pathway 
modulates Chk1 action in response to DNA damage (Ray-David et al., 2012). Furthermore, it 
was observed that while activation of RSK impaired the G2/M DNA damage checkpoint 
through phosphorylation of Chk1, inhibition of RSK sensitized melanoma cells to 
DNA-damaging agents. These results suggest that RSK inhibitors could be used to modulate 
chemosensitivity, which is one of the major issues in melanoma treatment. Another potential 
mechanism for RSK modulating G2/M transition is through direct phosphorylation of Cdc25 
(Wang et al., 2010). In the human HEK293 and PC-3MM2 human prostate cancer cells, 
phosphorylation of Cdc25A and Cdc25B by RSK accelerates cell cycle progression entering 
M phase (Wu et al., 2013). Suppression of RSK-dependent phosphorylation of Cdc25 
abrogates G2/M transition. Furthermore, the high-phosphorylation status of RSK on the 
Thr359/Ser363 residues in mitotic cells indicates that RSK is more active in these cells 
compared to interphase cells (Wu et al., 2013). RSK is also involved in the spindle assembly 
checkpoint by phosphorylating Mad1 (mitotic arrest-deficient protein) and promoting its 
degradation, resulting in increased Myc-induced cell proliferation and transformation (Zhu et 
al., 2008). Moreover, RSK participates in metaphase II by phosphorylating and regulating 
mediators of APC (anaphase-promoting complex) inhibition, such as Bub1 (budding 
uninhibited by benzimidazoles 1) and Emi2 (early mitotic inhibitor 2) (Tunquist et al., 2002).  
Compared to RSK1 and RSK2, less is known about RSK3/4. Recently, it was reported 
that the expression level of RSK3 in ovarian cancer was reduced compared to normal ovarian 
epithelium (Bignone et al., 2007). Overexpression of RSK3 leads to G1 phase arrest in 
UCI101 cells (ovarian cancer cell lines) (Bignone et al., 2007). However, the mechanisms by 
which RSK3 negatively regulates cell cycle progression still remain unclear. RSK4 is the 
most enigmatic member with the lowest expression level in the RSK family. In breast cancer 
cell lines, it was found that exogenous expression of RSK4 inhibited cell proliferation as a 
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result of G0/G1 arrest, indicating that RSK4 is a negative regulator of cell proliferation 
(Thakur et al., 2007). RSK4 is also involved in p53-dependent cell cycle arrest and 
oncogene-induced senescence (Lopez-Vicente et al., 2009). Given that RSK3 and RSK4 have 
different functions compared to RSK1 and RSK2, further studies are needed to better 
understand their underlying mechanisms.                     
         1.3.3.4.3 Regulation of protein synthesis and cell growth  
RpS6 is a component of the 40S ribosomal subunit, and phosphorylation of rpS6 is 
thought to participate in regulation of cell size and glucose homeostasis (Meyuhas and 
Dreazen, 2009). Although S6Ks are the major kinases responsible for rpS6 phosphorylation, 
many reports have indicated that RSK is also involved in rpS6 phosphorylation leading to 
protein synthesis (Roux et al., 2007). In S6K1-/- S6K2-/- double knockout mice, it was found 
that the absence of S6K1/2 resulted in an almost complete loss of rpS6 phosphorylation 
(Pende et al., 2004). However, low levels of rpS6 phosphorylation could still be observed. 
Moreover, it was found that rpS6 was phosphorylated upon the activation of oncogene- or 
agonist-induced activation of the MAPK pathway when S6K1/2 were inactive (Pende et al., 
2004). To date, accumulating evidence has shown that S6K1/2 phosphorylate rpS6 on Ser235, 
Ser236, Ser240 and Ser244, whereas the MAPK pathway via RSK phosphorylates rpS6 on Ser235 
and Ser236 (Roux et al., 2007). Collectively, these findings suggest that both RSK and S6K1/2 
are required for phosphorylation of rpS6 leading to the assembly of the cap-binding complex 
and cap-dependent translation.       
Indirect regulation of mTORC1 activity. One potential mechanism of RSK 
participating in mRNA translation is through modulating the activity of mTORC1, an 
essential regulator of ribosome biogenesis, mRNA translation and cell growth. It has been 
shown that RSK directly phosphorylates TSC2, a negative regulator of mTORC1 activity by 
inhibiting Rheb GTPase activity (Roux et al., 2004). Alternatively, RSK phosphorylates 
Raptor (the regulatory associated protein of mTOR), resulting in increased mTORC1 activity 
(Carriere et al., 2008).  
Regulation of translation-initiation factors (mTOR-independent manner). RSK 
regulates translation-initiation factors in both indirect and direct manners. GSK3β is a 
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negative regulator of protein synthesis by inhibition of eIF2B, a small G-protein responsible 
for the exchange of guanine nucleotides on translation initiation factor 2 (eIF2). It was found 
that RSK phosphorylated GSK3β on Ser9, thereby releasing its inhibitory function on eIF2B 
and promoting mRNA translation (Welsh et al., 1998). Aside from this indirect mode of 
action on mRNA translation, RSK directly phosphorylates the translation initiation factor 
eIF4B (Shahbazian et al., 2006). RSK phosphorylation of eIF4B promotes its recruitment to 
the translation-initiation complex, thereby enhancing the translation of mRNAs encoding 
proteins which participate in cell growth and survival. Moreover, upon typeIII IFN receptor 
activation, it has been determined that RSK affects mRNA translation initiation by regulating 
the phosphorylation of 4E-BP on Thr37/Thr46 (Kroczynska et al., 2010), an eukaryotic 
translation initiation factor 4E (eIF4E)-binding protein, thereby releasing eIF4E and initiating 
mRNA translation.      
         1.3.3.4.4 Regulation of cell survival  
RSK1/2 promote cell survival. It has been shown that RSK2 promotes cell survival 
through regulating CREB-dependent gene transcriptions, such as Bcl-2, Bcl-xL and Mcl1 
(myeloid cell leukemia sequence 1) (Xing et al., 1996). On the other hand, RSK protects cell 
against death through direct phosphorylation and inactivation of pro-apoptotic proteins, such 
as Bad (Bcl-2-associated death promoter) (Tan et al., 1999). More recently, RSK was found 
to enhance cell survival by modulating the transcription factor NF-κB (Peng et al., 2010). In 
addition, it was shown that RSK1 and RSK2 inactivated the tumor suppressor DAPK 
(death-associated protein kinase) by phosphorylating it on Ser289, resulting in enhanced cell 
survival (Anjum et al., 2005).  
Mitochondria-mediated cell apoptosis is a canonical apoptotic pathway. During this 
process, cytochrome-c release results in caspase enzyme activation, thereby inducing cell 
apoptosis (Jiang and Wang, 2004). Kim et al. observed that activation of the MAPK pathway 
led to the suppression of cytochrome-c-promoted caspase activation (Kim et al., 2012). 
Furthermore, they found that this regulation was modulated by RSK-phosphorylated Apaf-1 
(apoptotic protease activating factor-1). Given that RSK and 14-3-3 have the same consensus 
phospho-motif: RXXpS/T, it was hypothesized that RSK-induced Apaf-1 phosphorylation led 
to 14-3-3ɛ association and further prevented cytochrome-c release. Alternatively, RSK can 
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also regulate caspase activities, independently of cytochrome-c. For instance, it was shown 
that inhibition of the MAPK/RSK pathway decreased stellate cell survival as a result of 
alteration of the MAPK-RSK-C/EBP (CCAAT/enhancer binding protein)-(β)FLIPL (a critical 
inhibitor of caspase 8)-caspase 8 signaling pathway (Buck and Chojkier, 2007). 
         1.3.3.4.5 Regulation of cell migration 
Inhibition of tumor invasion and metastasis by RSK pharmacological inhibitors suggests 
that RSK is a therapeutic target for the treatment of disseminated cancers (Sulzmaier and 
Ramos, 2013). The first evidence of RSK1/2 involvement in cell migration was the 
identification of the cytoskeleton-associated protein filamin A as a novel substrate of RSK. 
More specifically, RSK phosphorylated filamin A on Ser2152, the site identified previously as 
a PAK1 (p21-activated kinase-1) phosphorylation site and required for membrane ruffling 
(Woo et al., 2004). More recently, it was found that RSK phosphorylated KIBRA (kidney and 
brain expressed protein), a new regulator in the Hippo signaling pathway, leading to 
upregulated cell migration (Yang et al., 2013). In MDA-MB-231 breast cancer cells, Yang et 
al. determined that RSK and ERK1/2 phosphorylated KIBRA on Ser548 and Thr929/Ser947, 
respectively. Moreover, another report indicated that RSK modulated cell movement through 
mediating the expression of Fascin-1, a protein involved in cell movement by association with 
actin filaments (Li et al., 2013). By analyzing primary human tumor tissue samples from head 
and neck squamous carcinoma patients, Li et al. observed that silencing of RSK2 not only 
disrupted filopodia formation and cell invasion but also significantly reduced Fascin-1 
expression, indicating that RSK2 is a potential upstream regulator of Fascin-1 (Li et al., 2013). 
Furthermore, it was indicated that RSK-induced Fascin-1 expression depended on CREB 
activity. Taken together, these results indicate that the RSK2-CREB-Fascin-1 pathway is a 
novel mechanism by which RSK regulates cell invasion (Li et al., 2013). Moreover, RSK 
phosphorylates VASP (vasodilator-stimulated phospho-protein) on Thr278, leading to actin 
polymerization and cell migration (Doppler and Storz, 2014).     
Intriguingly, it was found that RSK2 was also involved in macrophage-stimulating 
protein (MSP)-induced EMT (Ma et al., 2011). Upon MSP stimulation, Ron (recepteur 
d'origine nantais), a receptor tyrosine kinase also referred to as MST1R 
(macrophage-stimulating protein receptor), is activated. It was observed that the treatment of 
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MSP promoted RSK2 translocation into the nucleus, relying on both Ron and ERK1/2 
activities. By using the RSK inhibitor SL0101, Ma et al. observed that RSK activation was 
completely blocked as well as the MSP-induced spindle-like cell morphology and cell 
migration (Ma et al., 2011). Moreover, whereas deletion of RSK2 inhibited MSP-induced 
EMT, overexpression of RSK2 in HT-29 cells (a human colorectal adenocarcinoma cell line 
barely expressing RSK2) led to the recovery of the EMT-like phenotype. These results 
suggest that RSK2 is a crucial regulator in MSP-induced EMT, and inhibition of RSK2 
activity can be a potential therapeutic target in Ron-mediated cancer cell migration and 
invasion. 
         1.3.3.4.6 Other substrates and functions 
Recently, an advanced mass spectrometry approach and a genome-wide screen have been 
adapted to identify novel substrates of RSK. Recently, by using the global quantitative 
phosphoproteomic screen, our group firstly characterized RSK-dependent phosphorylation 
events in melanoma (Galan et al., 2014). Also, by using the genome-wide RNAi screen, the 
Haber group identified a number of RSK substrates in human MCF-10A mammary epithelial 
cells, which involve in a wide range of intracellular events, such as signal transduction, 
metabolism, cellular trafficking (Smolen et al., 2010). In addition to classical functions in cell 
proliferation, growth, survival and migration, RSK has been determined to be involved in 
other cellular processes. For example, RSK2 knockout mice have impaired abilities of 
learning and coordination, suggesting that RSK2 is involved in neuron activity (Dufresne et 
al., 2001). Moreover, it was found that RSK2 phosphorylated nNOS (neuronal nitric oxide 
synthase) on Ser847 in rat hippocampal neurons and cerebellar granule cells, leading to 
inhibited nNOS activity in the brain (Song et al., 2007).  
In addition, several lines of evidence suggest that RSK participates in the negative 
feedback loop of the Ras/MAPK signaling pathway. First, inhibition of RSK by the 
pharmacological inhibitor BI-D1870 increases ERK1/2 activity in certain cell types (Saha et 
al., 2012). Second, consistent with this result, by in vivo experiments with RSK2 knockout 
mice, it was also found that ERK1/2 activity was increased in skeletal muscle tissue. One of 
the conceivable explanations is that RSK phosphorylates SOS, leading to Grb2 disassociation 
and thereby inhibiting ERK1/2 activity (Saha et al., 2012). Taken together, these findings 
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suggest that one of RSK functions may be to prevent hyperactivity of the ERK1/2 cascade.   
1.4 The Gab/Dos family of docking proteins 
RTK signaling plays a crucial role in modulating cell growth, proliferation, 
differentiation and motility. Aberrant regulation of RTKs by mutation or overexpression 
results in many human diseases, such as cancer, inflammatory diseases and severe bone 
disorders (Lemmon and Schlessinger, 2010). Upon extracellular stimulation by a ligand, 
RTKs typically form stabilized dimers, which result in the trans-phosphorylation of tyrosine 
residues in the cytoplasmic domains. The tyrosine phosphorylated residues on the receptors in 
turn provide several binding sites for multiple signal relay proteins, such as those containing 
SH2 and PTB domains, including PLCγ and adaptor proteins (Jorissen et al., 2003). These 
phospho-dependent binding domains enable the association of adaptor proteins to receptors in 
order to serve as platforms for the initiation of downstream signaling. Although adaptor 
proteins often lack intrinsic catalytic activities, such as Grb2-associated binder (Gab) proteins, 
Grb2 and p85, they typically interact with one or more enzymes to amplify upstream signals. 
In the following section, I will focus on how RTKs signal through the Gab family of adaptor 
proteins.   
    1.4.1 Discovery of Gab proteins and their biological functions in mice 
The Gab family consists of five members, including Gab1-3 in vertebrates, Dos in 
Drosophila and Soc-1 in C. elegans. Gab1 was the first identified Gab protein, which was 
characterized as a Grb2 SH3-domain binding protein (Holgado-Madruga et al., 1996). In 1998, 
Gu et al. cloned Gab2 as a binding protein and substrate of the SH2-domain containing 
tyrosine phosphatase Shp2 (Gu et al., 1998). Gab3 was later identified due to its sequence 
similarity to Gab1 and Gab2 (Wolf et al., 2002). In Drosophila, Dos was determined as a 
potential substrate of Csw (Corkscrew; Shp-2 ortholog in Drosophila) (Herbst et al., 1996). 
Soc-1 was identified from a screen for suppressors of Egl-15 (a fibroblast growth factor 
receptor in C.elegans) signaling (Schutzman et al., 2001). Whereas GAB1 is localized to 
human chromosome 4, GAB2 and GAB3 are located on chromosomes 11 and X, respectively 
(Yamada et al., 2001; Seiffert et al., 2003). In the mouse, Gab1 and Gab2 are expressed 
ubiquitously, but expression of Gab3 is mainly found in the hematopoietic system (Yamada et 
al., 2001; Seiffert et al., 2003).  
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All three mouse Gab knockouts have been generated and resulted in very different 
phenotypes. Deletion of GAB1 in the mouse results in embryonic lethality between 12.5 and 
18.5 days with defects in heart, placenta, liver, skin and muscle developments (Itoh et al., 
2000). Given that the phenotypes of mice that lack signals from EGF, PDGF, HGF and gp130 
pathways are similar to the ones observed in the GAB1-deficient mice (Itoh et al., 2000; Sachs 
et al., 2000), these results suggest that the phenotype of Gab1-/- mice may stem from the 
combined deficiencies in these signals. In contrast to GAB1-deficient mice, GAB2-deficient 
mice are viable but defective in the mast cell lineage (Nishida et al., 2002). It was shown that 
GAB2 knockout (Gab2-/-) mice displayed decreased mast cell numbers in different tissues, 
such as stomach and skin (Nishida et al., 2002). Moreover, Gab2-deficient mast cells grow 
poorly and show impaired Kit (a receptor tyrosine kinase)-induced signals. GAB2-deficient 
mice also have defects in IgE-induced allergic responses (Gu et al., 2001). GAB3-deficient 
mice have been generated, but no detectable defects have been observed in these animals 
(Seiffert et al., 2003).   
    1.4.2 Activation mechanisms of Gab protein-dependent signaling   
      1.4.2.1 Structural features of Gab proteins 
Although the biological functions of Gab family members are different and the overall 
amino acid identity between mouse Gab1-3 is only 38~42%, Gab proteins still have a similar 
topology (Figure 1.10). Each Gab protein contains an N-terminal pleckstrin homology (PH) 
domain, multiple proline-rich domains (PXXP), and several potential tyrosine and 
serine/threonine phosphorylation sites (Gu and Neel, 2003). In humans, the PH domains 
found in Gab1~Gab3 have 62-76% amino acid identity, suggesting that these domains 
perform a similar function between Gab isoforms (Wohrle et al., 2009). While the PH 
domains bind to membrane-associated phospholipids and mediate the membrane localization 
of Gab proteins, the proline-rich domains of Gab proteins constitutively associate with SH3 
domains-containing proteins, such as Grb2 (Zhao et al., 1999). Upon RTK activation, Grb2 
brings Gab proteins to the plasma membrane, where they become tyrosine phosphorylated and, 
in turn, mediates SH2 domain-containing protein associations, such as Shp2 (the SH2 
domain-containing protein tyrosine phosphatase 2) and p85 (regulatory subunit of PI3K) 
(Wohrle et al., 2009). Given the importance and complexity of Gab-mediated signals, more 
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details about how Gab proteins participate in the activation of intracellular signaling pathways 
will be described in the following section.  
      1.4.2.2 Role of the PH domain  
PH domains are found in a wide range of proteins that are involved in diverse cellular 
processes, including intracellular trafficking, cellular signaling transduction and cytoskeletal 
remodeling (Rebecchi and Scarlata, 1998). The three-dimensional structure of the PH 
domains has been determined to be highly conserved, suggesting that these domains have 
important functions. Structurally, PH domains consist of ~120 amino acids and share a 
 
Figure 1.10 Schematic representation of structural features of Gab proteins. 
The Gab family consists of five members, including Gab1-3 in vertebrates, Dos in Drosophila 
and Soc-1 in C. elegans. As the amino acid identity between mGab1 and mGab2 is only 41.5%, 
it suggests that Gab1 may have different biological functions from Gab2. All Gab proteins 
consist of several proline-rich domains responsible for SH3 domain-containing protein 
associations, such as Grb2. Meanwhile, several potential phosphotyrosine residues in Gab 
proteins provide binding sites for SH2 or PTB domain-containing protein. Notably, only Gab1 
has the MBD domain which is responsible for Gab1’s direct binding to the C-met receptor 
(HGF receptor) (Adapted from Int J Inflam. 2013 2013:141068 )(Nakaoka and Komuro, 2013).  
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common core fold formed from two near orthogonal beta sheets (β1/β2 loop) (Rebecchi and 
Scarlata, 1998). Within these domains, there is a well-defined binding site for the headgroup 
of phosphoinositides. Despite the remarkable conservation in their secondary structure, 
variations can be found in the loops that enable an individual PH domain to have binding 
affinities for specific phosphoinositides, such as PI-4,5-P2, PI-3,4-P2 or PI-3,4,5-P3 (PI: 
phosphatidylinositol; P: phosphate) (Chen et al., 1997). Furthermore, their association with 
phosphoinositides and localization on different cellular compartment membranes allow 
PH-domain-containing proteins to transmit signals from lipid messengers to downstream 
targets (Rebecchi and Scarlata, 1998).  
  The role of the PH domains in mediating Gab proteins localization has been well 
characterized. The Park group observed that truncation of the PH domain impaired Gab1’s 
translocation from the cytoplasm to the plasma membrane upon HGF stimulation (Maroun et 
al., 1999). They also found that this translocation of Gab1 was required for transducing 
HGF-induced intracellular signaling (Maroun et al., 1999). Upon EGF stimulation, the PH 
domain of Gab1 was shown to bind specifically to PI-3,4,5-P3 in the plasma membrane, where 
it enhanced EGFR signaling (Rodrigues et al., 2000). Overexpression of the Gab1 PH domain 
was dominant-negative and abolished activation of the EGFR/PI3K pathway, suggesting 
further that Gab1 is the primary mediator transducing a signal from EGFR to PI3 kinase 
(Rodrigues et al., 2000). In the case of Gab2, upon fibroblast growth factor (FGF) stimulation, 
deletion of the PH domain impaired its localization at the plasma membrane, abolished 
tyrosine phosphorylation and also p85 recruitment leading to decreased Akt activity (Mao and 
Lee, 2005). Taken together, these findings suggest that the PH domain is crucial for 
localization of Gab proteins on the plasma membrane where receptors are activated.   
      1.4.2.3 Role of the proline-rich domains in Gab2 
The SH3 domain was first identified as conserved residues in several tyrosine kinases 
such as Src and Abl (Pawson and Schlessingert, 1993). They are small peptide sequences of 
approximately 60 amino acids. Proteins having SH3 domains are likely to constitutively 
interact with proline-rich sequence (PXXP)-containing proteins (Alexandropoulos et al., 
1995). One such an example is Grb2 through its SH3 domains constitutive association with 
two proline-rich domains in Gab2. Grb2 is the predominant upstream regulator of Gab2. Upon 
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stimulation by diverse growth factors and cytokines, such as EGF and IL-2, Grb2 recruits 
Gab2 to the receptors at the plasma membrane where Gab2 becomes tyrosine phosphorylated 
and thus acts on its membrane-associated substrates such as Shp2. However, some receptors 
that lack Grb2 binding sites cannot directly bind to the Grb2/Gab2 complex, such as the β 
chain of IL-2 and IL-3 receptors (Gu et al., 2000). In these signaling pathways, adaptor 
proteins, such as Shc, are required to provide an additional link between the Grb2/Gab2 
complex and tyrosine-phosphorylated receptors (Gu et al., 2000).  
      1.4.2.4 Tyrosine phosphorylated Gab2 mediates Gab2-dependent complex 
formation and sustains its downstream signaling 
Upon RTKs activation, Gab2 becomes tyrosine phosphorylated and, in turn, provides 
numerous binding sites to different SH2- or PTB-domain-containing proteins such as Shp2, 
p85, PLCγ, RANK, Crk, Shc and SHIP (Gu et al., 1998; Bone and Welham, 2000; Wada et 
al., 2005; Mao et al., 2006). More details regarding how Gab2 interacts with binding partners 
leading to the activation of downstream pathways will be described in following.   
Roles in Shp2-dependent multiple signaling pathways 
Gab2 contains two conserved tyrosine motifs consisting of I/V/LXYXXI/V/L responsible 
for its association with Shp2 (Gu et al., 1998). Under basal condition, the phosphatase activity 
of Shp2 is very low due to allosteric inhibition of the PTP (protein-tyrosine phosphatase) 
domain by its N-terminal SH2 domains (Dance et al., 2008). Following association of SH2 
domains to Gab1/2, the PTP domain of Shp2 is released leading to the dephosphorylation of 
downstream targets, such as RasGAP (Agazie and Hayman, 2003; Montagner et al., 2005). 
The best-characterized function of the Gab2-Shp2 axis is its involvement in the activation 
of the Ras/MAPK pathway. Phosphorylation of Gab2 on tyrosine residues 614 and 643 is 
required for Shp2 SH2 domains recruitment (Gu et al., 1998). Mutation of Tyr614/643 to Phe in 
Gab2 not only prevents Shp2 association but also inhibits the downstream signaling, such as 
ERK1/2 phosphorylation. Co-expression of ErbB2 and Gab2 with a Shp2 binding mutant 
(ΔShp2) impairs cell proliferation as well as ErbB2-induced breast tumor growth in mice 
(Bentires-Alj et al., 2006).   
Aside from its involvement in the MAPK pathway, the Gab2-Shp2 complex also 
 56 
 
participates in the Rac/JNK pathway in mast cells (Yu et al., 2006). In response to stem cell 
factor (SCF) stimulation, deletion of Gab2 (Gab2-/-) in mast cells inhibits cell proliferation, 
indicating that Gab2 is required for SCF-induced mast cell proliferation. Furthermore, it was 
found that disruption of Shp2 binding to Gab2 decreased SCF-mediated Rac/JNK signaling. 
Taken together, these results demonstrate that the Gab2-Shp2 complex positively regulates 
signal transduction from the SCF receptor (Kit) to the Rac/JNK pathway leading to mast cell 
proliferation.   
Role in the PI3K/Akt pathway 
Another important downstream signaling event mediated by Gab2 is the PI3K/Akt 
pathway. Interaction of the p85 subunit of PI3K with phosphorylated Tyr452, Tyr476 and Tyr584 
of Gab2 results in the upregulation of Akt activity (Wang et al., 2011). Recently, many 
reports have indicated that Gab2 acts through the PI3K/Akt pathway to promote ovarian 
cancer formation (Wang et al., 2011). Using an in vivo multiplexed transformation assay, 
Dunn et al. found that amplification of GAB2 strongly induced immortalized ovarian 
epithelial cell transformation (Dunn et al., 2014). Furthermore, they determined that p85 
recruitment was necessary for Gab2-induced cell transformation, suggesting that the PI3K 
pathway is crucial for Gab2-mediated ovarian cancer development. Consistent with these 
results, it was shown that inhibitors of PI3K, LY294002 and GDC-0941, or an mTOR 
inhibitor, rapamycin, abrogated Gab2-induced cell migration and invasion. One possible 
mechanism for the Gab2-induced ovarian cancer cell migration is through the 
PI3K-upregulated Zeb1 expression, a transcription factor related to the EMT, leading to 
downregulated E-cadherin expression (Wang et al., 2011).  
Although many studies established that p85 recruitment is essential for Gab2-mediated 
PI3K/Akt signaling, others argued that p85 association is dispensable. To address this, using 
the MCF-10A cell line as model for understanding the molecular mechanisms of breast cancer 
progression, Bentires-Alj et al. demonstrated that co-expression of Gab2 with HER2 resulted 
in an invasive phenotype independently of p85 recruitment (Bentires-Alj et al., 2006). Given 
that Shp2 dissociation from Gab2 inhibited the acinar growth of epithelial mammary cells as 
well as Akt activity, it appears that Shp2 recruitment is more crucial than p85 binding in 
biological contexts (Brummer et al., 2006). However, the molecular mechanism regarding this 
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regulation is ill defined. It was shown that Gab2 recruited Shp2 to an inhibitory site of Lyn (a 
non-receptor tyrosine-protein kinase), leading to its activation (Futami et al., 2011). Given 
that Lyn is a predominant Src kinase in myeloid cells and Src induces PI3K to phosphorylate 
Akt, it is possible that the Gab2/Shp2 axis may regulate Akt activity through the Shp2/Src/Akt 
pathway.      
Other Gab2-dependent signaling pathways 
Gab2-STAT3 signaling. Gab2 has an important function in the hematopoietic system. It 
was found that Gab2-/- mice are viable and fertile, but the number of circulating mast cells is 
severely decreased (Itoh et al., 2007). For this reason, many research groups endeavored to 
understand the roles of Gab2 in mast cell growth and development. As such, several new PTB 
domain containing proteins have been identified. One of these is STAT3 (signal transducer 
and activator of transcription 3). In primary hematopoietic cells, it was found that upon 
activation of Stk/Ron (receptor tyrosine kinase), Gab2 directly interacted with STAT3 
resulting in hematopoietic cell transformation (Ni et al., 2007). Given that STAT3 is one of 
the major transcription factors in the regulation of mast cell growth (Sonnenblick et al., 2004), 
it is possible that Gab2 association with STAT3 in mast cells results in accelerated cell 
growth.  
Gab2-SHIP signaling. Studies have shown that Gab2 is required in FcεRI (lgE receptor) 
induced mast cell aggregation (Gu et al., 2001; Xie et al., 2002). In rat basophilic leukemia 
RBL-2H3 cells, FcεRI clustering induced translocation of Gab2 to the plasma membrane, 
where it became tyrosine phosphorylated. Then, tyrosine phosphorylated Gab2 associated 
with SHIP, an SH2-containing inositol 5’-phosphatase (Leung and Bolland, 2007). Given that 
the predominant function of SHIP is to convert PI(3,4,5)P3 to PI(3,4)P2, this raises the 
possibility that SHIP acts as a negative modulator in FcεRI/Gab2-mediated pathways. Indeed, 
it was shown that upon FcεRI engagement, SHIP interacted with Gab2 leading to the 
inhibition of microtubule polymerization (Leung and Bolland, 2007). Because microtubules 
participate in mast cell degranulation (Draber et al., 2012), these results suggest that 
FcεRI-mediated mast cell degranulation is inhibited by SHIP recruited to Gab2.  
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PLCγ-Gab2-RANK-NF-κB signaling. PLCγ2 (phosphoinositide phospholipase C 
gamma) is important for early osteoclast development (Mao et al., 2006). It was found that 
activated PLCγ2-induced Gab2 recruitment was necessary for osteoclastogenesis (Mao et al., 
2006). More specifically, PLCγ associated with Gab2 induced its tyrosine phosphorylation, 
resulting in RANK (receptor activation of NF-κB) recruitment that, in turn, activated the 
NF-κB pathway, Lacking of NF-κB has been found to cause severe osteopetrosis in mice, a 
disease with impaired osteoclastic bone resorption, indicating this signaling pathway is crucial 
for generating mature osteoclasts (Franzoso et al., 1997).  
        
      1.4.2.5 Other binding partners to Gab2 
14-3-3. Aside from phosphotyrosine residues, some phospho-serine/threonine residues on 
Gab2 also provide binding sites for protein interactions. One such Gab2 binding protein is 
 
Figure 1.11 Schematic representation of various binding proteins recruited to Gab2. 
Both phospho-Tyr and -Ser/Thr residues mediate Gab2-dependent complex formation. For 
instance, the former induces direct binding of Shp2 and p85 to Gab2, and the latter is 
responsible for 14-3-3 recruitment. Other proteins can also associate directly with Gab2, such as 
GC-GAP, CrkL and PLCγ. 
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14-3-3, a small adaptor protein of only 29kDa that frequently acts as a bridge between two 
molecules, resulting in the assembly of a complex and also the stabilization of its 
conformational state (Bridges and Moorhead, 2005). Upon EGF stimulation, phosphorylation 
of Gab2 on Ser210 and Thr391 promotes its interaction with 14-3-3 (Brummer et al., 2008). 
Binding of 14-3-3 was shown to terminate Gab2-dependent signaling by sequestering Grb2, 
disassociating it from Gab2 and thus preventing Gab2 recruitment to the receptors.  
GC-GAP. By using a yeast two-hybrid approach with hGab2 (120–587) as bait, Zhao et 
al. identified that GC-GAP, a GTPase-activating protein (GAP) of the Rho family, is a novel 
binding partner of Gab2 (Zhao et al., 2003). Expression of GC-GAP in HEK293T cells 
resulted in reduced activity of Rac1 and Cdc42 rather than RhoA (Zhao et al., 2003). 
Moreover, deletion of GC-GAP in C6 astroglioma cells inhibited cell proliferation. On the 
basis of these findings, it was suggested that Gab2 interacts with GC-GAP leading to 
decreased activity of Rac1 and Cdc42. Given that the expression of GC-GAP is specific in the 
nervous system, it also suggests that the Gab2/GC-GAP complex may play an important role 
in neural/glial cell proliferation.     
Shc and CrkL. Gab2 also interacts with some proteins whose functional significance is 
less established. In some cases, the Gab2/Grb2 complex lacks the capability to directly 
interact with receptors, such as the β chain of IL-2 and IL-3 receptors. In this situation, 
tyrosine phosphorylation of a small adaptor protein termed Shc plays a crucial role in 
Gab2/Grb2 recruitment to the receptors (Gu et al., 2000). CrkL is a Crk-like protein and 
participates in Bcr-Abl tyrosine kinase induced fibroblast transformation (Senechal et al., 
1996). By using a modified yeast two-hybrid system with the catalytic Lyn tyrosine kinase 
(belonging to the Src family), Crouin et al. found that Gab2 directly interacted with CrkL 
through phosphorylated Tyr266 and Tyr293 of Gab2 (Crouin et al., 2001). However, the 
biological function of the Gab2/CrkL interaction has not been fully determined.  
    1.4.3 Role of Gab2 in tumorigenesis  
Genetic and epigenetic changes are the two major causes of oncogene-induced 
carcinogenesis (You and Jones, 2012). Amplification of chromosome 11q13-14.1 is often 
found in human malignancies (Johnson et al., 2008). In 1995, amplification of the CCND1 
gene, that encodes the cell cycle regulatory protein cyclinD1, was first identified on human 
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chromosome 11q13 (Adelaide et al., 1995). Given that human chromosome 11q13-14.1 is a 
large region (around 9~10Mb), this raises the possibility that other potential proto-oncogenes 
also co-amplify with CCND1. To date, it has been determined that a number of genes, 
including EMS1, PAK1, RSF1 and GAB2, are located in this region and act as potential 
drivers of tumorigenesis (Brown et al., 2008).  
 
Figure 1.12 Cross-cancer alteration summary for the GAB2 gene. 
It has been found that the GAB2 gene is located on human chromosome 11 (11q14.1), which is 
altered in diverse malignancies such as breast cancer, ovarian cancer and melanoma. As 
displayed in the above figure, GAB2 is often found amplified in numerous cancers. 
Amplification of the GAB2 gene occurs in 8.5% of 482 breast tumor cases, and 16.1% of 311 
Ovarian Serous Cystadenocarcinoma cases. This suggests that GAB2 is a potential oncogene in 
these cancers. (Adapted from http://www.cbioportal.org, Cerami et.al., Cancer Discov. 2012 & 
Gao et. al., Sci. Signal. 2013.)    
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Compared to other isoforms of the Gab family, it appears that Gab2 is more closely 
related to cancer. As shown in 1.12, the alteration frequency of GAB2 is due to amplification 
rather than mutation, especially in ovarian cancer, breast cancer and lung cancer. Although 
CCND1 and GAB2 are located on the same chromosome, there is no evidence to indicate that 
focal amplification of GAB2 (11q14.1) is correlated with CCND1 (11q13.2) in breast cancers 
(Bocanegra et al., 2009). Aside from breast cancers, 11% of human metastatic melanomas 
harbor GAB2 amplification (Horst et al., 2009). Given that overexpression of Gab2 has been 
observed in several cancers including ovarian cancer, breast cancer, leukemia and melanoma 
(Bocanegra et al., 2009; Horst et al., 2009), it raises the possibility that GAB2 is a potential 
proto-oncogene.              
      1.4.3.1 Gab2 in breast cancer  
Breast cancer is the second leading cause of cancer mortality in women in the United 
States, and it has a poor prognosis. The contribution of Gab2 to breast cancer development 
has been well studied. Silencing of Gab2 in several breast cancer cell lines, such as SUM52, 
SUM44PE and MDA468, inhibits cell proliferation, survival and invasion (Bocanegra et al., 
2009). Deregulation of ERBB2 (HER2) is one of the primary causes of breast cancer, which 
was determined many years ago (Schechter et al., 1984). Recently, studies have revealed that 
Gab2 is required in ErbB2-overexpressed cancer cell lines (Bocanegra et al., 2009). For 
instance, in the breast cancer cell line BT474 with ErbB2 overexpression, it was shown that 
knockdown of Gab2 not only inhibited the activities of downstream effectors, such as ERK1/2 
and Akt but also reduced cell proliferation (Bocanegra et al., 2009).  
Understanding how GAB2 is regulated at the transcriptional level has attracted much 
attention. This can be answered by studies concerning microRNAs (miRNAs). These small 
non-coding RNA molecules (21~25 nucleotides) are natural products, that are partially 
complementary to one or more messenger RNA (mRNA) molecules in the 3’-untranslated 
region and inhibit gene expression by mRNA cleavage, deadenylation, and translational 
repression (Ling et al., 2013). By using in situ hybridization screening for the let-7 family of 
miRNA, one study has shown that let-7g is the only one in the let-7 family related to lymph 
node metastasis and the poor survival rate of breast cancer patients (Qian et al., 2011). 
Downregulation of let-7g expression promoted rapid metastasis of non-metastatic mammary 
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carcinoma cells, leading to increased expression levels of Gab2, fibronectin 1 (FN1), matrix 
metalloproteinases (MMPs) as well as upregulated ERK1/2 activity (Qian et al., 2011). These 
studies suggest that GAB2 may be a new target of let-7g miRNA, and provide a new insight into 
Gab2 regulation in breast cancer.   
Although considered as an “amplifier” in Neu/ErbB2-induced tumorigenesis, 
overexpression of Gab2 alone is insufficient to induce tumor in mice. To address this, the 
human MCF-10A mammary epithelial cell is widely used as a cell model for better 
understanding the underlying mechanisms of Gab2 in breast cancer development. It was 
shown that Gab2 cooperation with other oncogenes, including ErbB2 and Src, was necessary 
for mammary epithelial cell transformation (Bentires-Alj et al., 2006; Bennett et al., 2008). 
Furthermore, Ke et al. determined that ErbB2-mediated tyrosine phosphorylation of Gab2 was 
required for the Gab2-induced invasive phenotype (Ke et al., 2007). Consistent with these 
results, overexpression of ErbB2 with or without Gab2 was found to induce mammary 
carcinogenesis in mice, whereas overexpression of Gab2 alone was insufficient (Bentires-Alj 
et al., 2006). Notably, the tumor-free period in mice was found to be dependent on Gab2 
expression levels. The more Gab2 was expressed, the shorter the tumor-free period was in 
these mice (Bentires-Alj et al., 2006). Therefore, these results suggest that the contribution of 
Gab2 to tumor development depends on its upstream inducers and is also related to its 
expression level. Aside from being downstream of RTKs, Gab2 is also a substrate of the 
non-receptor kinase c-Src (Bennett et al., 2008). Coexpression of c-Src and Gab2 in 
MCF-10A cells promoted EGF-independent acinar growth. Consistent with this result, Gab2 
cooperation with an activated form of c-Src Y527F enhanced MCF-10A cells to a more 
dispersed phenotype. However, p85 recruitment is dispensable in this process. In addition, it 
appears that activation of Src-STAT3 signaling is another potential mechanism behind the 
Gab2/Src-induced invasive phenotype (Mira et al., 2009).  
Although Gab2-induced cell motility has been well characterized, the mechanisms by 
which Gab2 is involved remain elusive. Some studies have indicated that Gab2-mediated cell 
motility is regulated by RhoA activity (Herrera Abreu et al., 2010). RhoA belongs to the Rho 
GTPase family, which is involved in several cellular functions, such as cytoskeleton dynamics, 
cell polarity, and cell movement (Schwartz, 2004). Overexpression of Gab2 in MCF-10A 
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cells results in decreased RhoA activity, less cell spreading, and more migration (Herrera 
Abreu et al., 2010). Given that constitutive expression of active RhoA restores stress fibers 
and focal adhesions, it suggests that Gab2 is upstream of RhoA. In addition, Shp2 recruitment 
to Gab2 also modulates cell spreading, but the underlying mechanisms remain unclear. 
Together, these studies indicate new mechanisms by which Gab2 regulates cell motility, and 
shed light on the role of Gab2 in disease treatments. 
      1.4.3.2 Gab2 in melanoma  
Genetic alterations of BRAF, NRAS, and KIT by mutation frequently occur in metastatic 
melanoma patients leading to hyperactivation of the MAPK and PI3K pathways. In order to 
identify the genome-wide copy number of GAB2, bacterial artificial chromosome (BAC) 
array comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) 
arrays were adapted (Horst et al., 2009). Based on these approaches, it was shown that the 
gene copy level of GAB2 in metastatic melanoma tissues and melanoma cell lines was higher 
compared to melanocytic nevi, as well as melanoma cell lines with low metastatic potential, 
indicating that Gab2 acts as a diagnostic marker in melanoma. As the amplification level of 
the GAB2 gene correlates with protein expression levels, knockdown of GAB2 in metastatic 
melanoma cell lines was found to result in decreased cell invasion, whereas overexpression of 
Gab2 led to tumor growth and metastasis (Horst et al., 2009).  
In melanocytes, Gab2 cooperates with RasG12V to promote tumor development. Yang et al. 
observed that Gab2 accelerated tumor angiogenesis in NRAS-driven melanoma as a result of 
upregulation of HIF-1α (hypoxia-inducible factor 1-alpha) and VEGF (Yang et al., 2012). 
However, the molecular mechanisms with regard to these findings are ill-defined. RasG12V 
cannot induce Gab2 tyrosine phosphorylation; instead, it promotes Ser/Thr phosphorylation 
on Gab2. Compared to the well characterized mechanisms of tyrosine phosphorylated Gab2, 
less is known about Ser/Thr phosphorylation. Therefore, more in-depth studies are needed to 
better understand how Ser/Thr phosphorylation modulates Gab2 function.     
      1.4.3.3 Gab2 in leukemia  
Bcr-Abl is an oncoprotein associated with chronic myelogenous leukemia (CML) that 
results from a translocation between chromosomes 9 and 22 (Chu et al., 2007). This fusion 
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tyrosine kinase is hyperactivated even at basal level owing to its auto-phosphorylation on 
Tyr177. Phosphorylated Bcr-Abl associates with the Grb2/Gab2 complex, and thus initiates the 
activation of diverse downstream signaling pathways: Ras/MAPK, PI3K/Akt, and JAK/STAT 
(Sattler et al., 2002).  
Tyrosine phosphorylated Gab2 by Bcr-Abl induces Shp2 recruitment. Shp2 is a tyrosine 
phosphatase that behaves as an oncoprotein in tumorigenesis. In an inactive state, Shp2 is 
auto-inhibited since its SH2 domains bind to its phosphatase domain (PTP) resulting in a 
blockage of substrates to PTP (Li et al., 2012). Upon activation, SH2 domains of Shp2 bind to 
some tyrosine phosphorylated proteins such as Gab2, leading to PTP accessible to substrates. 
Being a scaffold protein, Gab2 serves as a platform for protein-protein interactions and 
amplifies signal transduction. Interaction between Gab2 and Shp2 enhances signals from 
upstream of Ras and tranduces them to downstream effectors, such as ERK1/2 and STAT5 
(Scherr et al., 2006). In Bcr-Abl-mediated CML, knockdown of GAB2, SHP2, or STAT5 
inhibits cell proliferation and colony formation (Scherr et al., 2006).        
Tyrosine kinase inhibitors (TKIs), such as imatinib and nilotinib, have been used in CML 
treatment for years. However, certain TKIs can cause unexpected upregulation of downstream 
signals, leading to drug resistance in CML treatment. One such example is a LYN 
(tyrosine-protein kinase) inhibitor that prolongs tyrosine phosphorylation of Gab2 and 
Bcr-Abl (Wu et al., 2008). Silencing of Gab2 results in increased TKI sensitivity in CML 
cells, suggesting that Gab2 participates in protecting CML cells from a variety of Bcr-Abl 
inhibitors (Wohrle et al., 2012). In addition, Ding et al. found that nilotinib was able to induce 
activation of the PI3K pathway (Ding et al., 2013). These results suggest that a combination 
of TKI inhibitors and PI3K/mTOR inhibitors would be a new strategy in the treatment of 
TKI-resistant BCR-ABL positive leukemia.       
    1.4.4 Feedback regulation of Gab2 function  
The roles of Gab2 in cancer cell proliferation and invasion suggest that Gab2 is a 
potential therapeutic target for cancer treatment. Tyrosine phosphorylation is crucial for 
Gab2-dependent functions. Tyrosine-phosphorylated residues in Gab2 mediate its interaction 
with several adaptor proteins, such as Shp2 and p85, resulting in activation of the MAPK and 
the PI3K pathways, respectively. In addition, some studies suggest that other 
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post-translational modulations, such as Ser/Thr phosphorylation, can also regulate 
Gab2-dependent functions. Details regarding this regulation will be discussed below. 
Negative regulation by the PI3K/Akt pathway 
Gab2 acts as a central node in transducing signals from receptors to downstream targets. 
Upon stimulation with Heregulin (HRG), tyrosine-phosphorylated Gab2 enhances activation 
of the PI3K pathway. Inhibition of Akt activation by a PI3K inhibitor, wortmannin, increases 
tyrosine phosphorylation of Gab2, suggesting that Akt negatively regulates Gab2-dependent 
signaling (Lynch and Daly, 2002). Furthermore, Gab2 is identified as a substrate of Akt, 
which phosphorylates Gab2 on Ser159. Mutation of Ser159 to unphosphorylatable Ala not only 
increases Gab2 tyrosine phosphorylation, but also promotes Shc and ErbB2 binding to Gab2, 
leading to the transformation of NIH 3T3 fibroblast cells (Lynch and Daly, 2002).    
Feedback regulation of Gab proteins by MAPK signaling 
In the Gab family, Gab1 was the first member identified as an ERK1/2 substrate (Roshan 
et al., 1999). In 1999, Gab1 was found to associate with activated ERK2 upon EGF or HGF 
stimulation (Roshan et al., 1999). It was also observed that the MBD (c-Met–binding domain), 
a domain directly involved in Gab1’s association with c-Met (hepatocyte growth factor 
receptor HGFR), was also responsible for the ERK1/2 interaction (Roshan et al., 1999). Later, 
several ERK1/2 phosphorylation sites in Gab1 were determined by a mass spectrometry 
approach (Lehr et al., 2004). Among these sites, mutation of Ser552 to Ala blocked Gab1 
localization at the plasma membrane (Eulenfeld and Schaper, 2009). Interestingly, it appears 
that phosphorylation of Gab1 by ERK1/2 has different functions in response to diverse forms 
of stimulation. For instance, whereas ERK1/2 phosphorylation of Gab1 upon EGF stimulation 
inhibits p85 recruitment (Yu et al., 2002), HGF-induced ERK1/2 phosphorylation of Gab1 
increases p85 interaction and its downstream effectors activity, such as Akt (Yu et al., 2001). 
Therefore, the roles of ERK1/2 in regulating Gab1 functions remain controversial, and more 
in-depth studies are required to fully understand the intricate mechanism by which Gab1 is 
regulated in response to different forms of stimuli.   
 Similar to Gab1, several Ser/Thr phosphorylation sites in Gab2 have been identified, 
suggesting that Gab2 is a potential target for Ser/Thr protein kinases (Halbach et al., 2013). It 
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was shown that inhibition of the MAPK pathway upregulates Gab2 tyrosine phosphorylation, 
indicating that the MAPK pathway negatively regulates Gab2 function (Arnaud et al., 2004). 
Mutation of the ERK-mediated phosphorylation site, Ser623, to unphosphorylatable Ala in 
Gab2 was shown to sustain Shp-2 recruitment concomitantly with a decrease in STAT5 
activity.    
Role of 14-3-3 in terminating Gab2 function 
14-3-3 proteins were the first known phospho-serine/threonine-binding proteins (Freeman 
and Morrison, 2011). It has been found that 14-3-3 proteins are widely expressed in all 
eukaryotic cells. Binding of 14-3-3 to a number of proteins are involved in diverse biological 
events including cell proliferation, cell migration, and the epithelial-to-mesenchymal 
transition (EMT) (Freeman and Morrison, 2011). In general, 14-3-3 proteins bind to many 
 
Figure 1.13 Schematic representation of feedback regulation of Gab2-dependent signaling. 
Upon RTKs activation, Gab2 is phosphorylated at tyrosine residues, leading to increased 
activation of the Shp2/MAPK and p85/PI3K pathways. However, phosphorylation of Gab2 by 
Akt on Ser159 attenuates Gab2-dependent signaling. Moreover, phospho-Ser/Thr residues 
mediate Gab2/14-3-3 interaction, which in turn terminates Gab2-dependent biological functions, 
such as cell transformation. 
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target proteins through two phospho-Ser/Thr modes: (1) an RXpS/TXP motif (mode I); (2) an 
RXXpS/T motif (mode II). Besides, certain ligands binding to 14-3-3 proteins is through the 
C-terminal binding consensus (mode III). Intriguingly, it was found that around 0.6% of the 
human proteome had 14-3-3 proteins engaged, suggesting that 14-3-3 proteins are key 
regulatory components in modulating normal growth and development in human (Jin et al., 
2004). Gab2 was identified as a binding protein to 14-3-3 upon EGF stimulation. 
Phosphorylation on Ser210 and Thr391 in Gab2 was found to be crucial for the Gab2/14-3-3 
interaction. Mutations of Ser210 and Thr391 to Ala in Gab2 enhanced Grb2 recruitment resulted 
in MCF-10A cell proliferation and transformation (Brummer et al., 2008). Meanwhile, 
constitutive 14-3-3 binding to Gab2 led to impaired Gab2-dependent biological functions such 
as cell proliferation, cell transformation and cell motility (Herrera Abreu et al., 2010). 
Taken together, these findings provide important information on the feedback regulation 
of Gab2-dependent functions. Based on the essential roles of Gab2 in the receptor-mediated 
signaling pathways, these findings also expand our knowledge and pave the way to develop 
novel therapeutics for cancer treatment.  
Implication of feedforward and feedback loops in diseases 
 Pathway cross-talk affects intracellular signal transduction, leading to decreased or 
increased target protein activities. Understanding feedforward and feedback loops has a 
significant implication in disease treatments, including cancer and inflammatory diseases. On 
certain conditions, such as drug treatments, pathway cross-talk results in upregulated 
compensatory signaling cascades. For instance, disruption of a feedforward loop of 
VEGF-VEGFR-Akt-mTOR-VEGF by an inhibitor (ZD6474) of VEGFR2 switches tumor 
cells from an angiogenic to a proliferative phenotype with feedback activation of the 
IRS/MAPK signaling cascade (Chatterjee et al., 2013). Hence, co-treatment of lung cancer 
patients with both VEGFR2 (ZD6474) and MEK1/2 (PD0325901) inhibitors is found to be 
more effective to inhibit tumor growth than either of them alone (Chatterjee et al., 2013). In 
addition, it has been found that inhibition of either the PI3K/Akt/mTOR or Ras/MAPK 
pathway leads to upregulation of its compensatory signaling cascade, allowing tumor cells to 
survive and evade apoptosis (Carracedo et al., 2008; Turke et al., 2012). Co-inhibition of both 
the PI3K/Akt/mTOR and Ras/MAPK pathways counteracts this feedback regulation and is 
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more efficient in cancer treatments. Interestingly, the balance between feedforward and 
feedback inhibition also plays a key role in normal regulation of macrophage activation. 
Whereas TLR (toll-like receptor) induces production of an inflammatory cytokine TNF 
(tumor necrosis factor) and an anti-inflammatory molecule IL-10 at the same time, IL-10, in 
turn, inhibits TNF secretion in a STAT3-dependent manner (Hu et al., 2008). Given that 
dysregulation of the balance between these feedforward and feedback loops leads to 
autoimmune diseases, such as high level of IL-10 inducing rheumatoid arthritis (RA), it is 
suggested that perturbation of IL-10 production would be a potential therapeutic target for this 
disease (Cush et al., 1995).  
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1.5 Rationale and objectives 
    1.5.1 Rationale 
GAB2 is located on chromosome 11q14.1, a region frequently amplified in breast cancers, 
melanomas, ovarian cancers and leukemia. As a scaffold protein, Gab2 serves as a platform 
that assembles multiple signal relay proteins together. In response to the stimulation of 
several growth factors and cytokines, Gab2 becomes phosphorylated by activated RTKs on 
Tyr residues, and thus associates with diverse adaptor molecules, such as Shp2 and p85, 
leading to the activation of MAPK and PI3K signaling, respectively. To date, the essential 
role of tyrosine-phosphorylated Gab2 in signal transduction has been well characterized. 
However, we noted that agonists also promote Gab2 phosphorylation on Ser/Thr residues 
independently of tyrosine phosphorylation, but the roles of these phosphorylation events, 
how they are regulated, and by which protein kinase(s) remains elusive. Therefore, the 
primary goal of my Ph.D. thesis was to determine how Gab2 is regulated at the molecular 
level by MAPK signaling, and how these events regulate Gab2 function, especially in the 
context of breast cancer cell growth, proliferation and migration.  
    1.5.2 Objectives 
There are three main objectives to this thesis:  
1. Given that the exact kinases in the MAPK pathway involved in phosphorylation of 
Gab2 are ill-defined, we intend to demonstrate that the MAPK pathway, through both 
ERK1/2 and RSK, phosphorylates Gab2 on several Ser/Thr residues.  
2. Less is known about the molecular mechanisms by which MAPK signaling regulate 
Gab2 functions. In this objective, we will characterize that RSK and 
ERK1/2-mediated feedback loops have different roles on stabilizing the 
Gab2-mediated complex.  
3. To further determine the physiological functions of these two feedback loops, we 
developed an in vitro cell model to fully understand the different impacts of 
phosphorylated Gab2 by RSK and ERK1/2 signaling.  
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Preface to Chapter 2 
Accumulating evidence has shown that Gab2 is overexpressed in several malignancies, 
such as breast cancer, melanoma, ovarian cancers and leukemia. Although the contribution of 
tyrosine phosphorylated Gab2 to signal transduction has been well characterized, it is still 
unclear how Gab2 is regulated at the molecular level. Upon stimulation by agonists, our group 
has found that activation of the Ras/MAPK pathway induces an electrophoretic mobility shift 
in Gab2. This result suggests that phosphorylation a protein kinase within this pathway 
directly regulate Gab2 phosphorylation. In this study, we determined that Gab2 is a novel 
substrate of the MAPK-activated protein kinase RSK by using pharmacological inhibitors and 
RNA interference. Using quantitative mass spectrometry and through the generation of 
unphosphorylatable mutants, we further defined that RSK phosphorylates Gab2 on Ser160, 
Ser211 and Ser620. Expression of an unphosphorylatable Gab2 mutant (S3A) in MCF-10A cells 
resulted in an invasive-like phenotype and increased cell motility, suggesting that RSK 
participates in a negative feedback loop to inhibit Gab2-dependent function. We found that 
Shp2 recruitment to Gab2 was affected by RSK-mediated phosphorylation, implicating RSK 
in the regulation of Gab2-Shp2 signaling.   
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Chapter 2 Gab2 phosphorylation by RSK inhibits Shp2 
recruitment and cell motility 
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ABSTRACT 
The scaffolding adapter protein Gab2 (Grb2-associated binder) participates in the signaling 
response evoked by various growth factors and cytokines. Gab2 is overexpressed in several 
human malignancies, including breast cancer, and was shown to promote mammary epithelial 
cell migration. The role of Gab2 in the activation of different signaling pathways is well 
documented, but less is known regarding the feedback mechanisms responsible for its 
inactivation. We now demonstrate that activation of the Ras/mitogen-activated protein kinase 
(MAPK) pathway promotes Gab2 phosphorylation on basic consensus motifs. More 
specifically, we show that RSK (p90 ribosomal S6 kinase) phosphorylates Gab2 on three 
conserved residues, both in vivo and in vitro. Mutation of these phosphorylation sites does not 
alter Gab2 binding to Grb2, but instead, we show that Gab2 phosphorylation inhibits the 
recruitment of the tyrosine phosphatase Shp2 in response to growth factors. Expression of an 
unphosphorylatable Gab2 mutant in mammary epithelial cells promotes an invasion-like 
phenotype and increases cell motility. Taken together, these results suggest that RSK is part of 
a negative-feedback loop that restricts Gab2-dependent epithelial cell motility. On the basis of 
the widespread role of Gab2 in receptor signaling, these findings also suggest that RSK plays 
a regulatory function in diverse receptor systems. 
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INTRODUCTION 
The binding of growth factors to receptor tyrosine kinases (RTKs) regulates a number of 
biological processes, such as cell cycle progression, migration, metabolism, survival, and 
differentiation (1). Upon activation, RTKs recruit several docking adapter proteins that play a 
key role in transducing extracellular signals to downstream signaling cascades, such as the 
Ras/mitogen-activated protein kinase (MAPK) pathway (2, 3). The adapter protein Grb2 
(growth factor receptor-bound protein 2) links the receptors to the MAPK pathway by binding 
to the Ras-specific guanine nucleotide exchange factor (GEF) son of sevenless (SOS). 
Recruitment of SOS to the plasma membrane leads to the activation of Ras, which results in 
the sequential phosphorylation and activation of Raf, MEK1/2, and extracellular 
signal-regulated kinase 1/2 (ERK1/2) protein kinases (4). Once activated, ERK1/2 
phosphorylate numerous cytoplasmic and nuclear substrates, including the p90 ribosomal S6 
kinase (RSK) family of Ser/Thr kinases (5, 6), which often collaborate with ERK1/2 to 
regulate cell growth, survival, and proliferation.  
In addition to SOS, Grb2 associates with a number of docking adapter proteins that 
modulate RTK signaling (7). Members of the Grb2-associated binder (Gab) family of proteins 
function downstream of a variety of RTKs and comprise three vertebrate members (Gab1 to 
Gab3) (8, 9). These proteins mainly function as RTK signal transducers that activate pathways 
involved in cell growth, proliferation, and motility. Gab proteins contain several highly 
conserved regions, including an N-terminal pleckstrin homology (PH) domain, a central 
proline-rich domain, and multiple phosphotyrosine residues (9). While the PH domain binds 
membrane-associated phospholipids, the proline-rich domain contains several PXXP motifs 
that serve as docking sites for Src homology 3 (SH3) domain-containing proteins, including 
Grb2 (10). The Gab proteins harbor several tyrosine residues that become phosphorylated 
upon RTK activation. Many of these phosphorylated tyrosines are capable of interacting with 
Src homology 2 (SH2) domain-containing proteins, including the protein tyrosine phosphatase 
Shp2 and the p85 subunit of phosphoinositide 3-kinase (PI3K). Recruitment of these proteins 
leads to the activation and potentiation of the Ras/MAPK and PI3K/Akt pathways, 
respectively (9). 
The Gab proteins perform important functions in normal physiology, and certain Gab 
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isoforms also contribute to human malignancies (11). The GAB2 gene is frequently amplified 
in human cancer and was identified to be a potential oncogene in breast and ovarian cancers, 
as well as leukemia and melanoma (12). While Gab2 appears to be insufficient to transform 
primary mammary epithelial cells, it was shown to cooperate with ErbB2 (Neu or HER2) to 
potentiate tumorigenic signaling (13–15). Gab2 seems to contribute to a metastatic phenotype 
in breast cancer, as its overexpression in human mammary epithelial cells results in increased 
proliferation, invasiveness, and motility (13–15). The mechanisms by which Gab2 contributes 
to breast cancer are not fully understood, but Shp2 recruitment and the subsequent 
activationof the Ras/MAPK pathway were shown to be required (14). Moreover, recent 
evidence indicates that Gab2 regulates cytoskeletal organization and mammary epithelial cell 
motility through the recruitment of Shp2 (16).  
The main role of Gab2 is to activate downstream signaling cascades via tyrosine 
phosphorylation and SH2 domain interactions, such as with Shp2. Conversely, Gab2 
phosphorylation on Ser/Thr residues was previously reported to play inhibitory roles. Akt was 
shown to regulate the phosphorylation of Ser159, resulting in reduced ErbB2-mediated 
tyrosine phosphorylation through unknown mechanisms (17). ERK1/2 also phosphorylates 
Gab2 on Ser613, which was found to modulate Shp2 recruitment in response to interleukin-2 
(IL-2) (18). More recently, phosphorylation of Gab2 on Ser210 and Thr391 by an unknown 
protein kinase was shown to promote 14-3-3 binding, resulting in reduced Grb2 binding and 
tyrosine phosphorylation (19). In the current study, we describe the regulation of Gab2 
phosphorylation on Ser/Thr residues in response to the Ras/MAPK pathway. Our results 
indicate that RSK directly phosphorylates Gab2 on three serine residues, both in vivo and in 
vitro. We show that RSK-mediated Gab2 phosphorylation inhibits Shp2 recruitment, 
suggesting that RSK mediates a negative-feedback loop that attenuates Gab2-dependent 
functions, including cell motility. 
 
 
 
 
 76 
 
MATERIALS AND METHODS 
DNA constructs and recombinant proteins. The plasmids encoding hemagglutinin 
(HA)-tagged murine Gab1 and Gab2 were provided by Morag Park (McGill University, 
Canada) and Isabelle Royal (University of Montreal, Montreal, Quebec, Canada), respectively, 
and described previously (20, 21). The vectors encoding constitutively active forms of Ras 
(G12V) and MEK1 (MEK-DD) and the inactive form of Ras (S17N) were described 
previously (22, 23). All HA-tagged RSK1 constructs were described previously (24). To 
subclone murine Gab1 and Gab2 into pcDNA3.0-6myc, HA-tagged Gab1 and Gab2 were 
amplified by PCR using these primers: primers Gab1-sense 
(5`-GCTTAGAATTCTATGAGCGGCGGCGAAGTGG-3`) and Gab1-antisense 
(5`-GCATAGAATTCCTACTTCACATTCTTGGTGGGTG-3`) and primers Gab2-sense 
(5`-GCTTACTCGAGTATGAGCGGCGGCGGCGGCGACGACGT-3`) and Gab2-antisense 
(5`-GCATACTCGAGTCATTACAGCTTGGCACCCTTGGAAG-3`), respectively. All 
murine Gab2 mutants were generated using the QuikChange methodology (Stratagene, La 
Jolla, CA). To subclone murine Gab2 into pBabe-puro and produce retroviral particles used in 
the generation of stable cell lines, Myc-tagged wild-type (wt) and mutant Gab2 were 
amplified by PCR using these primers: Gab2-sense 
(5`-GCTTAGGATCCATTTAAAGCTATGGAGCAAAAGC-3`) and Gab2-antisense 
(5`-GCATAGGATCCTCATTACAGCTTGGCACCCTTGGAAG-3`). 
Antibodies. Antibodies targeted against Arg/Lys-X-X-pSer/Thr (RXXpS/T; X is any 
amino acid) and Arg/Lys-X-X-pSer/Thr-X-Pro (RXXpS/TXP) consensus sequences, Gab2, 
RSK1 to RSK3, phospho-Akt (S473), Akt, phospho-Gab2 (S159), p85, ERK1/2, 
phospho-ERK1/2 (T202/Y204), phospho-RSK (S380), and Shp2 were purchased from Cell 
Signaling Technologies (Beverly, MA). The Shp2 antibody used for immunoprecipitation was 
purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). Anti-Myc and anti-HA 
monoclonal antibodies were purchased from Sigma-Aldrich (Oakville, Ontario, Canada). All 
secondary horseradish peroxidase (HRP)-conjugated antibodies used for immunoblotting 
were purchased from Chemicon (Temecula, CA).   
  Cell culture and transfection. HEK293 and mouse embryonic fibroblasts (MEFs) were 
maintained at 37°C in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/liter glucose 
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supplemented with 10% fetal bovine serum (FBS) and antibiotics. Wild-type and 
Gab2-deficient MEFs were described elsewhere (25). MCF-10A cells were cultured in 
DMEM–F-12 medium with growth medium (supplemented with 5% [vol/vol] horse serum 
[Invitrogen], 20 ng/ml human recombinant epidermal growth factor [EGF; R&D Systems, 
Minneapolis, MN], 0.5 μg/ml hydrocortisone [Sigma], 100 ng/ml cholera toxin [Sigma], 10 
μg/ml bovine insulin [Sigma], 50 U/ml penicillin G [Invitrogen], and 50 μg/ml streptomycin 
sulfate [Invitrogen]). Gab2-deficient MEFs and MCF-10A stable cell lines were generated 
using pBabe-puro-derived retroviral particles, and expressing cells were selected using 
puromycin (2 μg/ml). HEK293 cells were transfected by calcium phosphate precipitation as 
previously described (26). Cells were grown for 24 h after transfection and serum starved 
using serum-free DMEM where indicated for 16 to 18 h. Starved cells were pretreated with 
PD184352 (10 µM), U0126 (20 µM), or BI-D1870 (10 µM) (Biomol, Plymouth Meeting, PA), 
where indicated, and stimulated with FBS (10%), phorbol myristate acetate (PMA; 25 to 100 
ng/ml), or EGF (25 ng/ml) before being harvested. Unless indicated otherwise, all drugs and 
growth factors were purchased from Invitrogen (Burlington, Ontario, Canada). The 
proliferation rate was measured by the colorimetric 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. 
RNA interferences. For small interfering RNA (siRNA)-mediated knockdown of RSK1 
and RSK2, validated 21-nucleotide cRNAs with symmetrical 2-nucleotide overhangs were 
obtained from Qiagen. HEK293 cells were transfected using calcium phosphate and 50 nM 
siRNA per dish. At 24 h following transfection, cells were serum starved overnight before 
being harvested. 
Immunoprecipitations and immunoblotting. Cell lysates were prepared as previously 
described. Briefly, cells were washed three times with ice-cold phosphate-buffered saline 
(PBS) and lysed in CLB (10 mM K3PO4, 1 mM EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM 
-glycerophosphate, 0.5% Nonidet P-40, 0.1% Brij 35, 0.1% deoxycholic acid, 1 mM sodium 
orthovanadate [Na3VO4], 1 mM phenylmethylsulfonyl fluoride, and a cOmplete protease 
inhibitor cocktail tablet [Roche]). For immunoprecipitations, cell lysates were incubated with 
the indicated antibodies for 2 h, followed by a 1-h incubation with protein A–Sepharose 
CL-4B beads (GE Healthcare). Unless they were used for kinase assays, immunoprecipitates 
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were washed three times in lysis buffer and beads were eluted and boiled in 2×reducing 
sample buffer (5×buffer is 60mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 14.4 mM 
2-mercaptoethanol, 0.1% bromophenol blue). Eluates and total cell lysates were subjected to 8 
to 10% SDS-PAGE, and resolved proteins were transferred onto polyvinylidene fluoride 
(PVDF) membranes for immunoblotting. Densitometry analysis was conducted using 
identical areas for each lane of a given blot and inverted histograms in the Adobe Photoshop 
CS6 package. After subtracting the background, Shp2 levels were normalized to the levels of 
immunoprecipitated Gab2. 
Protein phosphotransferase assays. For RSK1 assays, transfected HA-tagged wt or 
kinase-inactive (kinase-deficient [kd]) RSK1 (K112/464R) was immunoprecipitated from 
cells lysed in BLB buffer, as previously described (26). Immunoprecipitates were washed 
thrice in BLB and twice in kinase buffer (25 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 5 mM 
β-glycerophosphate). Kinase assays were performed with immunopurified full-length 
Myc-tagged wt Gab2 or the S160/211/620A mutant (from here on termed the S3A mutant) as 
the substrates under linear assay conditions. Assays were performed for 10 min at 30°C in 
kinase buffer supplemented with 5 μCi [λ-32P]ATP per reaction. All samples were subjected to 
SDS-PAGE, and incorporation of radioactive phosphate (32P) was determined by 
autoradiography using a Fuji PhosphorImager with Multi-Gauge (version 3.0) software. The 
data presented are representative of at least three independent experiments. 
Digestion, TMT labeling, and mass spectrometry analysis. Following SDS-PAGE 
separation with Coomassie staining, bands corresponding to Gab2 were excised and digested 
in gel with sequencing-grade trypsin (Promega, Madison, WI) as described previously (27). 
Labeling with sixplex iobaric tandem mass tag (TMT6) reagents (Thermo Scientific) was 
accomplished as published previously with minimal modifications (28, 29). Labeled peptides 
were then mixed and underwent C18 solid-phase extraction as described previously (30). 
Finally, combined samples were resuspended in 5% acetonitrile–5% formic acid for mass 
spectrometry analysis. All liquid chromatography (LC)-mass spectrometry (MS) experiments 
were performed on an LTQ-Velos-Orbitrap column (Thermo Fisher Scientific) equipped with 
a Famos autosampler (LC Packings) and an Agilent 1100 binary high-pressure liquid 
chromatography pump (Agilent Technologies) essentially as described previously (29). The 
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LTQ-Velos-Orbitrap was operated in the data-dependent mode and collected high-resolution 
Orbitrap MS/MS spectra after higher-energy C-trap dissociation for the top 10 most intense 
ions following each survey scan collected in the Orbitrap. 
Peptide, protein, and phosphorylation site identification. Following acquisition, 
individual MS/MS spectra were assigned to peptides using the Sequest program (31). To 
maximize phosphorylation site identifications, a two-stage database searching strategy was 
employed. In the first stage, all MS/MS spectra were searched against a database containing 
all protein sequences from the human International Protein Index database (version 3.6) in the 
forward and reverse orientations as well as sequences of common contaminants. Initial 
searches were performed with the following parameters: 25-ppm precursor ion tolerance; 
0.02-Da product ion tolerance; fully tryptic digestion with up to two missed cleavages; static 
modifications Cys alkylation (57.021464) and TMT labeling of Lys and peptide N termini 
(+229.162932); and dynamic modifications Met oxidation (+15.994915) and phosphorylation 
of Ser, Thr, and Tyr (+79.966330). The target-decoy approach (32) was then used to 
distinguish correct and incorrect peptide identifications using linear discriminant analysis 
based on several parameters, including Xcorr, dCn`, peptide length, precursor ion mass error, 
numbers of missed cleavages, peptide length, and charge state (33). After filtering to an initial 
1% peptide-level false detection rate (FDR), peptides were then assembled into proteins, and 
proteins were scored and filtered to a final protein FDR of 1% (33). 
In the second stage, relaxed parameters were used to match additional MS/MS spectra 
against a filtered database. Sequest was again employed, but this time the database was 
filtered to include only forward and reverse sequences for proteins that were identified in 
stage 1. Stage 2 search parameters included a 3.1-Da precursor ion tolerance; a 0.02-Da 
product ion tolerance; no enzyme specificity; static modifications Cys alkylation (+57.021464) 
and TMT labeling of Lys and peptide N termini (+229.162932); and dynamic modifications 
Met oxidation (+15.994915) and phosphorylation of Ser, Thr, and Tyr (+79.966330). The 
resulting peptides were again filtered via linear discriminant analysis, but this time, the 
number of tryptic ends was included as an additional feature and peptide mass errors were 
corrected to account for occasional incorrect monoisotopic mass assignments. To evaluate 
phosphorylation site localization, all phosphopeptides matching Gab2 were scored using the 
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Ascore algorithm (34) and peptides were grouped according to the phosphorylation sites that 
they contained. A minimum Ascore of 13 was required for phosphorylation site localization (P 
<0.05), and phosphorylation site assignments were manually validated to ensure reliability.  
Phosphorylation site quantification. Relative quantification of each peptide was 
accomplished on the basis of the intensities observed for all six reporter ions from 
high-resolution Orbitrap MS/MS spectra, after correcting for batch-specific isotopic 
enrichments of each TMT reagent. Each peptide was required to have a minimum isolation 
specificity of 0.75 (29) and a summed reporter ion intensity of at least 500 with no more than 
four missing reporter ions. Individual sites were quantified on the basis of the summed 
reporter ion intensities for all matching peptides. Nonphosphorylated peptides matching Gab2 
were combined to estimate unmodified protein abundance. Quantitative profiles for all 
phosphorylation sites were normalized to account for slight changes in Gab2 abundance. 
Finally, analysis of variance (ANOVA) was used to identify statistically significant, 
site-specific changes in protein phosphorylation. Within each experiment, all P values were 
adjusted to account for multiple-hypothesis testing via the method of Hochberg and 
Benjamini (35). 
Epifluorescence microscopy. For immunofluorescence analyses, 5×104 MCF-10A cells 
were seeded in 12-well plates containing coverslips. Twenty-four hours later, cells were 
washed twice in PBS and fixed in 3.7% formaldehyde for 10 min at room temperature. Cells 
were washed twice in PBS, permeabilized for 5 min in PBS containing 0.2% Triton X-100, 
and blocked with PBS containing 0.1% bovine serum albumin for 30 min. Cells were 
incubated for 2 h with anti-Myc antibodies, washed twice with PBS, and incubated for 1 h 
with a secondary Alexa Fluor 488-conjugated goat anti-mouse antibody (Invitrogen), Texas 
Red-phalloidin, and DAPI (4`, 6-diamidino-2-phenylindole) diluted in PBS. Images were 
acquired on a Zeiss Axio Imager Z1 wide-field fluorescence microscope using a ×40 
oil-immersion objective. 
Proliferation assays. For proliferation assays, MCF-10A cells were grown in medium 
supplemented with 10% FBS. The relative number of viable cells was measured every 24 h 
during four consecutive days using the 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
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inner salt (MTS), cell proliferation assay from Promega, as shown elsewhere (36). The 
absorbance was measured at 490 nm using a Tecan GENios Plus microplate reader, and the 
results displayed represent the mean of triplicates ± standard error (SE). 
Cell migration assays. For the Transwell assays, MCF-10A cells stably expressing wt 
Gab2 or the S3A mutant were starved overnight, and 4×104 cells suspended in 100 μl of 
EGF-free medium were seeded in the top chamber of polyethylene terephthalate Transwells 
(24-well insert; pore size, 8 m; Becton, Dickinson). Cells were allowed to migrate toward 20 
ng/ml EGF for 24 h at 37°C in the presence of dimethyl sulfoxide or PD184352 (1 μM), fixed 
with 10% Formalin, and stained with hematoxylin-eosin (H&E). Cells that did not migrate 
(top side of the filter) were wiped with a cotton swab. Filters were scanned, and migrated cells 
were automatically counted using the VisiomorphDP tool (Visiopharm). 
 For the live-cell-imaging wound-healing assays, an Oris cell migration assay kit (Platipus 
Technologies) was used. Cells were seeded at 100% confluence (1×104 cells) into 96 wells 
containing a round disk in the center, for creation of the detection zone, and allowed to adhere 
overnight. Disks were then removed, allowing cells to migrate to the center of the well. Cells 
were filmed at 37°C with a DeltaVision microscope (Olympus U Plan S-Apo×20/0.75 
numerical aperture) using softWoRx software equipped with a camera (CoolSNAP HQ2). 
Images were acquired every 20 min for 24 h. Tracking was performed on phase-contrast 
image series using ImageJ software (http://rsb.info.nih.gov/ij/). 
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RESULTS 
Identification of Gab2 as a substrate of the Ras/MAPK pathway. 
To determine if the Ras/MAPK pathway promotes Gab2 phosphorylation on basic consensus 
motifs, we used two phosphorylation site-specific antibodies directed against similar 
consensus sequences: Arg/Lys-X-X-pSer/Thr (RXXpS/T) and Arg/Lys-X-XpSer/Thr-X-Pro 
(RXXpS/TXP). These consensus sequences are often found in substrates of AGC family 
kinases, such as Akt, RSK, and S6K1 (37). HEK293 cells transfected with Myc-tagged mouse 
Gab2 were serum starved overnight and stimulated with different agonists. 
Immunoprecipitated Gab2 was then analyzed for phosphorylation by immunoblotting using 
the anti-RXXpS/T and anti-RXXpS/TXP antibodies. With this approach, we found that 
treatment of cells with agonists of the Ras/MAPK pathway, including the phorbol ester PMA, 
epidermal growth factor (EGF), and serum (10%), led to the phosphorylation of Gab2 on 
basic consensus motifs (Fig. 2.1A). Gab2 phosphorylation correlated with the phosphorylation 
of both ERK1/2 (T202/Y204) and RSK (S380), suggesting that this pathway converges on 
Gab2 to promote its phosphorylation. The involvement of the Ras/MAPK pathway was 
further confirmed using constitutively activated (G12V) and dominant-negative (S17N) forms 
of H-Ras. We found that expression of RasG12V strongly stimulated Gab2 phosphorylation in 
the absence of serum or growth factors (Fig. 2.1B), indicating that Ras-dependent signaling is 
sufficient to promote Gab2 phosphorylation. To determine if the Ras/MAPK pathway 
specifically targets the Gab2 isoform, we performed a similar analysis of Gab1 and Gab3, 
which display ~38% amino acid identity with Gab2. While we found that Gab3 is not 
sufficiently soluble to allow efficient immunoprecipitation, our results indicated that Gab1 is 
not significantly phosphorylated on basic consensus sites compared to the level of 
phosphorylation of Gab2 (Fig. 2.1C). To determine if endogenous Gab2 is also regulated by 
the Ras/MAPK pathway, we used the RBL-2H3 leukemic cell line, which was previously 
shown to express high levels of Gab2 (38). Importantly, we found that stimulation of the 
Ras/MAPK pathway in these cells using dinitrophenyl produced a robust increase in 
endogenous Gab2 phosphorylation on basic consensus sites (Fig. 2.1D). Together, these 
findings demonstrate that growth factors and mitogens promote the specific phosphorylation 
of Gab2 through a pathway that likely involves ERK1/2 signaling.  
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RSK phosphorylates Gab2 at basic consensus motifs in vivo and in vitro. 
RSK is the most likely basophilic protein kinase operating downstream of the MAPK pathway 
(5). To test its potential involvement in the regulation of Gab2 phosphorylation, we used a 
MEK1/2 inhibitor (PD184352), which prevents ERK1/2 from activating RSK, as well as an 
RSK inhibitor (BI-D1870) to directly block its activity (Fig. 2.2A). We found that treatment 
of cells with PD184352 or BI-D1870 strongly prevented Gab2 phosphorylation in response to 
PMA stimulation (Fig. 2.2B), suggesting that Gab2 is an RSK substrate in cells. The 
involvement of ERK/RSK signaling was further confirmed by expressing a constitutively 
activated form of MEK1 (MEK-DD; S212/218D), which was found to be sufficient to 
promote Gab2 phosphorylation in serum-starved cells (Fig. 2.2C). We found that treatment of 
these cells with PD184532 or BI-D1870 completely prevented Gab2 phosphorylation induced 
by MEK-DD expression, suggesting that RSK is the predominant basophilic kinase regulating 
Gab2 phosphorylation downstream of the MAPK pathway. Consistent with this, we found that 
knockdown of RSK1 and RSK2 significantly reduced Gab2 phosphorylation induced by 
expression of MEK-DD (Fig. 2.2D) or PMA stimulation (Fig. 2.2E), indicating that RSK1 and 
RSK2 are required for the phosphorylation of Gab2 in cells. 
To determine if RSK directly phosphorylates Gab2, we performed in vitro kinase assays 
with purified proteins and [λ-32P]ATP. HEK293 cells were transiently transfected with wt or 
kinase-deficient (K112/464R) HA-tagged RSK1, and purified RSK1 from unstimulated or 
PMA-treated cells was incubated in a reaction buffer with full-length Myc-Gab2 
immunopurified from serum-starved cells. Although low levels of 32P label incorporation were 
detected in purified Gab2 incubated with unstimulated RSK1, we found that activated RSK1 
robustly increased 32P label incorporation (~12-fold) in purified Gab2 (Fig. 2.2F). The 
phosphotransferase activity of RSK1 was found to be necessary for this effect, as the 
kinase-deficient form of RSK1, which retained some ability to autophosphorylate, did not 
have significantly increased 32P label incorporation in Gab2. Taken together, our results 
indicate that RSK directly promotes Gab2 phosphorylation in vivo and in vitro in response to 
Ras/MAPK pathway activation. 
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Identification of Ser160, Ser211, and Ser620 as RSK-dependent phosphorylation sites.  
To identify the RSK-dependent phosphorylation sites in Gab2, we analyzed the sequence 
surrounding all Ser/Thr residues for similarities to phosphorylation sites in known substrates 
of RSK (5). We located six potential consensus phosphorylation sites (RXXpS/T), consisting 
of Ser160, Ser211, Thr256, Thr388, Ser434, and Ser620 (according to mouse Gab2 
numbering). To determine whether RSK phosphorylates these sites in cells, each one was 
individually mutated to an unphosphorylatable alanine residue and Gab2 phosphorylation was 
assessed using phosphorylation site-specific antibodies against basic consensus sequences. 
While mutation of Thr256, Thr388, and Ser434 did not affect Gab2 phosphorylation, we 
found that mutation of Ser160, Ser211, and Ser620 partly prevented Gab2 phosphorylation 
induced by PMA stimulation, as detected by the anti-RXXpS/TXP or the anti-RXXpS/T 
antibodies (Fig. 2.3A). These results suggested that these three serine residues are directly 
phosphorylated by RSK in cells. 
To further validate the link between Gab2 phosphorylation and RSK, we made use of a 
phosphorylation site-specific antibody raised against Ser160 (Ser159 in human Gab2), a site 
previously shown to be regulated by Akt (17). HEK293 cells were transfected with wt or 
kinase-deficient RSK1 (K112/464R), and endogenous Gab2 phosphorylation at Ser160 was 
assessed by immunoblotting on total cell lysates. Compared to control cells, we found that 
expression of wt RSK1 specifically increased Gab2 phosphorylation at Ser160 after PMA 
stimulation (Fig. 2.3B), suggesting that Gab2 is a substrate of RSK in cells. Expression of wt 
RSK1 induced Gab2 phosphorylation even in the absence of serum and PMA stimulation, 
consistent with the idea that expression of the wt protein increases basal RSK activity (Fig. 
2.3B). RSK1 phosphotransferase activity was found to be required for stimulating Gab2 
phosphorylation, as an RSK1 mutant with inactivating mutations in both kinase domains 
(K112/464R) did not increase Gab2 phosphorylation to a level over the level already 
stimulated by endogenous RSK activity (Fig. 2.3B). In order to validate that ERK/RSK 
signaling is required for Gab2 phosphorylation at Ser160 in cells, we pretreated cells with 
MEK1/2 inhibitors (PD184352, U0126) or an RSK inhibitor (BI-D1870) prior to stimulation 
with PMA. We found that both MEK1/2 and RSK inhibitors almost completely abrogated 
PMA-induced Gab2 phosphorylation at Ser160 (Fig. 2.3C), suggesting that RSK activity is 
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required for Gab2 phosphorylation in cells. Residual levels of Ser160 phosphorylation may be 
due to other basophilic kinases, such as Akt, which was previously shown to phosphorylate 
this site in Gab2 (17). 
While there are no phosphorylation site-specific antibodies against Ser211 and Ser620, 
we sought to confirm that these RSKdependent phosphorylation sites are modulated in cells 
using a quantitative mass spectrometry (MS)-based approach. HEK293 cells were transfected 
with Myc-tagged Gab2, serum starved overnight, and pretreated with vehicle or the MEK1/2 
inhibitor PD184352, prior to being stimulated with PMA (Fig. 2.3D). Alternatively, cells were 
cotransfected with an empty vector or constitutively activated (G12V) or dominant-negative 
(S17N) Ras for 48 h prior to serum starvation and cell lysis (Fig. 2.3D). Immunoprecipitated 
Gab2 was then isolated via SDS-PAGE, digested in-gel with trypsin, and labeled with 6-plex 
isobaric tandem mass tags (TMT6), as done previously (28). Samples were then combined and 
analyzed by liquid chromatography-assisted tandem MS, and the relative abundances of all 
identified phosphopeptides were measured across experimental conditions (Fig. 2.3D). Using 
this approach, we found that two phosphopeptides containing basic consensus sequences 
showed significant changes (ANOVA; FDR<5%) between the activated (PMA or RasG12V) 
and inactive (PD184352 or RasS17N) conditions (Fig. 2.3E and F, insets). These 
phosphopeptides were found to contain Ser211 and Ser620, and identification of these 
residues as being phosphorylated was obtained by MS/MS sequencing, as depicted by the 
annotated high-resolution MS/MS spectra (Fig. 2.3E and F). While previous studies have 
reported Ser160 as being phosphorylated in cells, we were not able to identify this 
phosphopeptide in the current study, likely due to the large size of the tryptic peptide 
containing Ser160 (44 amino acids). Together, our data indicate that RSK regulates the 
phosphorylation of Ser160, Ser211, and Ser620.  
Next, we combined the three RSK-dependent phosphorylation sites identified as 
described above into a single Gab2 molecule (S3A) and determined its phosphorylation levels 
in cells treated with agonists of the Ras/MAPK pathway. Importantly, we found that mutation 
of the three sites completely abrogated Gab2 phosphorylation at basic consensus motifs in 
response to PMA (Fig. 2.4A) and EGF (Fig. 2.4B) stimulation, as well as MEK-DD 
expression (Fig. 2.4C), indicating that Ser160/211/620 are the predominant RSK-dependent 
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sites in Gab2. We performed in vitro kinase assays to confirm that RSK predominantly 
phosphorylates Ser160/211/620 in vitro. Importantly, we found that RSK-mediated 32P label 
incorporation was strongly reduced when mutant Gab2 (S3A) was used as the substrate (Fig. 
2.4D), indicating that RSK primarily promotes Gab2 phosphorylation on Ser160/211/620. 
Some level of phosphorylation was also detected with the Gab2 S3A mutant, suggesting that 
RSK may target additional residues in vitro. While Ser160 and Ser211 are located between the 
PH domain and the first Grb2-SH3 domain-binding site, it is interesting to note that Ser620 
lies between the two Shp2-SH2 domain-binding sites (Tyr603, and Tyr632) (Fig. 2.4E), 
suggesting that RSK may modulate Shp2 recruitment in response to growth factors. All three 
phosphorylation sites are evolutionarily conserved along with the basic residues forming the 
consensus motif for RSK phosphorylation (Fig. 2.4F), suggesting that they play important 
functions. 
The Ras/MAPK pathway modulates Shp2 recruitment in an RSK-dependent manner. 
To address whether RSK-mediated Gab2 phosphorylation modulates its interaction with 
protein partners, we analyzed Gab2 immunoprecipitates from HEK293 cells stimulated with 
EGF for different times. As expected, we identified Grb2 within Gab2 immunoprecipitates but 
did not find that their interaction was modulated by either EGF or inhibitor treatments (Fig. 
2.5A), consistent with the fact that this interaction is mediated via SH3 domains (10). 
Interestingly, we found that the EGF-dependent recruitment of Shp2 was significantly 
enhanced in cells exposed to PD184352, suggesting that the Ras/MAPK pathway negatively 
regulates Shp2 recruitment (Fig. 2.5A). To further address the role of Gab2 phosphorylation in 
the recruitment of Shp2, we pretreated HEK293 cells with PMA to promote Gab2 
phosphorylation at basic consensus motifs (as for Fig. 2.1A) and then exposed cells to EGF 
for 5 or 10 min prior to Gab2 immunoprecipitation. Whereas PMA treatment by itself did not 
promote Shp2 recruitment (Fig. 2.5B, first two lanes), we found that pretreatment of cells 
with PMA severely decreased the ability of Gab2 to associate with Shp2 in response to EGF 
stimulation (Fig. 2.5B). Consistent with a role for the MAPK pathway, we found that 
inhibition of MEK1/2 using PD184352 rescued the inhibitory effect of PMA on Shp2 
recruitment (Fig. 2.5B, last two lanes). The role of MEK1/2-dependent signaling was further 
addressed by expressing a constitutively activated form of MEK1 (MEK-DD) prior to EGF 
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stimulation. Using this approach, we found that the constitutive activation of the MAPK 
pathway decreased Gab2-mediated recruitment of Shp2 in response to EGF stimulation (Fig. 
2.5C). To determine if Shp2 recruitment to Gab2 was regulated in an RSK dependent manner, 
we pretreated HEK293 cells with the RSK inhibitor BI-D1870 prior to a time course of EGF 
stimulation. Importantly, we found that inhibition of endogenous RSK activity increased Shp2 
recruitment induced by EGF treatment (Fig. 2.5D), indicating that the Ras/MAPK pathway 
negatively regulates Gab2-mediated Shp2 recruitment in an RSK-dependent manner. Notably, 
inhibition of RSK activity using BI-D1870 was found to increase ERK1/2 phosphorylation in 
response to EGF stimulation, consistent with a previous report showing that RSK negatively 
regulates ERK1/2 signaling by directly phosphorylating SOS1 (39). 
Next, we wanted to determine whether Gab2 phosphorylation on Ser160/211/620 was 
directly responsible for the reduction in Shp2 recruitment. To assess this, HEK293 cells were 
transfected with wt Gab2 or the Gab2 S3A mutant (S160/211/620A), treated with EGF over a 
time course, and Gab2 immunoprecipitated. As shown in Fig. 2.6A, we found that the Gab2 
S3A mutant more efficiently recruited Shp2 in response to EGF treatment, suggesting that 
RSK-dependent phosphorylation of Ser160/211/620 regulates Shp2 binding. This effect 
appeared to be specific to Shp2, as no modulations were observed in the recruitment of p85 in 
response to EGF stimulation (Fig. 2.6B). The increase induced by the Gab2 S3A mutant was 
quantified by densitometry and found to be significantly different from that induced by wt 
Gab2 at the 5-, 10-, and 30-min time points (Fig. 2.6C). Interestingly, we also found that 
expression of the Gab2 S3A mutant potentiated ERK1/2 phosphorylation in response to EGF 
stimulation (Fig. 2.6A), consistent with the established role of Shp2 as a positive regulator of 
Ras/MAPK signaling. We also determined whether constitutive activation of the MAPK 
pathway using MEK-DD could similarly negatively regulate Shp2 recruitment to Gab2. 
Whereas MEK-DD expression strongly suppressed Shp2 recruitment to wt Gab2, we found 
that the Gab2 S3A mutant was mostly insensitive to the activation of the Ras/MAPK pathway 
(Fig. 2.6D). To further validate these findings, we made use of Gab2-deficient MEFs (25) to 
stably express Myc-tagged wt Gab2 or the Gab2 S3A mutant in a background without 
endogenous Gab2 expression (Fig. 2.6E). To determine the ability of exogenous Gab2 to 
recruit Shp2, we analyzed the levels of Myc-tagged Gab2 within endogenous Shp2 
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immunoprecipitates. Compared to wt Gab2, we found that the Gab2 S3A mutant recruited 
more Shp2 in response to EGF stimulation (Fig. 2.6F). We also determined which of the three 
RSK-dependent phosphorylation sites participated in the regulation of Shp2 binding and 
found that mutation of Ser211 or Ser620 was sufficient to increase Shp2 recruitment in 
response to EGF stimulation (Fig. 2.6G). Together, these results provide robust evidence that 
RSK-mediated phosphorylation of Gab2 on Ser211 and Ser620 impedes Shp2 recruitment and 
function in response to growth factors. 
RSK-mediated Gab2 phosphorylation impairs mammary epithelial cell migration. 
Gab2-mediated Shp2 recruitment has previously been shown to promote the migration of 
mammary epithelial cells (14, 16). We thus used this biological system to address the function 
of RSK-mediated Gab2 phosphorylation. We generated stable MCF-10A cells, which express 
very low endogenous levels of Gab2, to express an empty vector, wt Gab2, or the Gab2 S3A 
mutant. Upon generation of pooled populations of stably expressing cells, we readily 
observed a change in morphology between parental and Gab2-expressing cells (Fig. 2.7A). 
This change in morphology induced by the expression of wt Gab2 was previously shown to 
correlate with enhanced cell motility (16). Interestingly, we also observed a change in 
morphology between cells expressing wt Gab2 and the S3A mutant (Fig. 2.7A), with the latter 
having a more elongated cell shape reminiscent of mesenchymal morphology. 
Immunofluorescence experiments indicated that wt Gab2 and the S3A mutant were expressed 
at similar levels, which was confirmed by immunoblotting the total cell lysates of all three 
cell lines (Fig. 2.7B). The differences in morphology between the three stable cell lines were 
quantified, and the S3A Gab2-expressing cells were found to be 2 and 7 times more likely to 
have an elongated shape than wt Gab2 and empty vector-expressing cells, respectively (Fig. 
2.7C). We also performed an assay to verify whether Shp2 recruitment was modulated in 
MCF-10A cells and found that the Gab2 S3A mutant recruited more Shp2 than wt Gab2 in 
response to EGF stimulation (Fig. 2.7D). 
Based on the known role of Gab2 in cell motility, we determined whether Gab2 
phosphorylation affected MCF-10A cell migration using a Transwell assay. While we 
confirmed previous data by showing that expression of wt Gab2 increases MCF-10A 
migration (16), we found that cells expressing the Gab2 S3A mutant exhibited a significant 
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increase in cell migration (~1.5-fold compared to wt Gab2-expressing cells) (Fig. 2.8A and B). 
As shown in Fig. 2.8C, we confirmed that this effect was not a result of increased cell 
proliferation. To further characterize this apparent gain of function of mutant Gab2, we 
performed live-cell-imaging wound healing assays by tracking migrating cells. 
Quantifications of cell paths revealed that MCF-10A cells expressing the Gab2 S3A mutant 
exhibited a robust increase in displacement from the point of origin (Fig. 2.8D). Indeed, the 
speed of movement of Gab2 S3A expressing cells was found to be ~1.6-fold higher than that 
of wt Gab2-expressing cells, reaching 0.45 m/min (Fig. 2.8E). As shown in Fig. 2.7B and D, 
we found that cells expressing the Gab2 S3A mutant displayed increased ERK1/2 
phosphorylation, consistent with the role of Shp2 in the regulation of the Ras/MAPK pathway. 
To determine whether this pathway was partly responsible for the observed increased motility 
of cells expressing the Gab2 S3A mutant, we treated cells with the MEK1/2 inhibitor 
PD184352 during image acquisitions. As shown in Fig. 2.8E, we found that PD184352 
treatment abrogated the increased motility of Gab2 S3A-expressing cells, consistent with a 
role of the Ras/MAPK pathway. Taken together, our results indicate that RSK-mediated 
phosphorylation of Gab2 inhibits cell elongation and Gab2-dependent migration of mammary 
epithelial cells. These findings suggest that RSK-mediated regulation of Gab2 function 
represents a novel negative-feedback pathway that restricts cell migration occurring in 
response to Ras/MAPK signaling (Fig. 2.9). 
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DISCUSSION 
The role of the Gab2 adapter protein has been widely investigated in hematopoietic cells and 
in cancer progression, where it functions to regulate the activation of several signaling 
pathways, including Ras/MAPK and PI3K/Akt. In this study, we demonstrate in different cell 
types that Gab2 phosphorylation is regulated by the Ras/MAPK pathway in an 
RSK-dependent manner (Fig. 2.1 to 2.2). Using phosphomotif antibodies, mass spectrometry, 
and site-directed mutagenesis, we found that RSK phosphorylates Gab2 on three serine 
residues which fall into the RXXpS/T consensus sequence (Ser160, Ser211, Ser620), both in 
vivo and in vitro (Fig. 2.3 to 2.4). Of note, we found that the closely related Gab1 isoform is 
not significantly phosphorylated by RSK in response to growth factors (Fig. 2.1C), which is 
indicative of the specificity of the regulation of Gab2. Using both gain- and loss-of-function 
approaches, we showed that RSK-mediated Gab2 phosphorylation decreases Shp2 binding in 
response to EGF stimulation (Fig. 2.5 to 2.7), suggesting that RSK negatively regulates the 
Gab2-Shp2 axis. Using mammary epithelial cells that stably express exogenous Gab2 alleles, 
we found that Gab2 phosphorylation on Ser160/211/620 inhibits cell motility (Fig. 2.8), 
suggesting a model whereby RSK limits Gab2-dependent cell migration upon activation of 
the Ras/MAPK pathway. Based on the widespread role of Gab2 in receptor signaling, our 
results suggest that RSK may regulate Gab2 function in response to many types of growth 
factors and cytokines. 
Whereas Gab2 tyrosine phosphorylation and activation of downstream signaling 
pathways are well characterized, relatively little is known about the mechanisms involved in 
Gab2 inactivation by Ser/Thr phosphorylation. Our data demonstrate that the Ras/MAPK 
pathway and, more specifically, RSK phosphorylate Gab2 on three serine residues to inhibit 
Shp2 recruitment. A previous report has shown that Akt phosphorylates Gab2 on Ser159 
(Ser160 is the homologous site in mouse Gab2) and thereby reduces Gab2 tyrosine 
phosphorylation via unknown mechanisms (17). While Ser159 is one of the three 
phosphorylation sites that we found to be regulated by RSK, we did not observe that Ser159 
phosphorylation modulates Gab2 tyrosine phosphorylation in response to EGF stimulation. 
More recently, Gab2 was shown to be phosphorylated on two additional residues (Ser210 and 
Thr391, according to the human numbering) in response to growth factors, but the actual 
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protein kinase involved in these phosphorylation events remains elusive (19). Interestingly, 
phosphorylation of these sites was shown to mediate 14-3-3 binding and to inhibit Grb2 
binding, but again, the mechanisms involved have not been determined. While we found that 
Ser210 (Ser211 is the homologous site in mouse Gab2) is regulated by RSK (Fig. 2.3), we did 
not observe that RSK-mediated phosphorylation of Gab2 altered Grb2 or p85 binding (Fig. 
2.5A and 6B). Our results also indicate that Thr391 is not regulated by RSK, consistent with 
the idea that RSK is mostly a serine kinase and that very few substrates of RSK have been 
shown to be phosphorylated on threonine residues (5).  
We found that RSK phosphorylates a novel site in Gab2 (Ser620), which is located 
between the two SH2 domain-binding sites for Shp2 (Tyr603 and Tyr632) (Fig. 2.3 and 2.4). 
Our results indicate that RSK-mediated phosphorylation of Gab2 inhibits Shp2 recruitment, 
suggesting that phosphorylated Ser620 hinders Shp2 interaction to the SH2 domain-binding 
sites. Another possibility is that phosphorylation of Ser160/211/620 causes a conformational 
change in Gab2 that reduces its affinity for Shp2, but more experimentation will be required 
to fully understand the molecular events taking place upon RSK-mediated phosphorylation. 
Interestingly, ERK1/2 was also shown to modulate Shp2 recruitment in response to IL-2 
stimulation (18). ERK1/2 was found to phosphorylate Ser613, which is also located in close 
proximity to the SH2 domain-binding motif of Gab2. Although we have not been able to 
identify phosphorylated Ser613 in our MS experiments, these results suggest that RSK may 
collaborate with ERK1/2 to inhibit Shp2 recruitment in response to agonists of the 
Ras/MAPK pathway. Based on the fact that RSK-mediated phosphorylation of Gab2 does not 
perturb recruitment of the p85 subunit of PI3K or Grb2 binding, our results suggest that Gab2 
phosphorylation on Ser160/211/620 specifically regulates Shp2 recruitment. Our findings 
indicate that RSK is part of a negative feedback loop that restricts Gab2-Shp2 signaling, 
similar to the recently described loop involving RSK and SOS1 (39). Based on the established 
role of Shp2 in the regulation of Ras/MAPK signaling (40), our results highlight a second 
RSK-dependent inhibitory loop that negatively regulates ERK1/2 signaling. 
The mechanisms by which Gab2 contributes to breast cancer are not fully understood, but 
several studies implicated Shp2 in Gab2-dependent cell proliferation and motility (14, 16). 
Similar to our findings, expression of Gab2 in MCF-10A cells has been shown to promote a 
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change in morphology and cell motility (16), providing an excellent system to analyze the 
impact of Gab2 phosphorylation on its function. We found that mutation of Ser160/211/620 
potentiated the effect of wt Gab2 on cell motility, which is consistent with the important role 
that Shp2 plays in cytoskeletal organization and cell migration (16). In addition to regulating 
the Ras/MAPK pathway, Shp2 has recently been shown to modulate RhoA activation (16, 41). 
Indeed, the recruitment of Shp2 to the plasma membrane was found to promote the 
dephosphorylation of Rho kinase II (ROCKII), resulting in modulation of RhoA induced cell 
rounding (41). Based on the known roles of the Ras/MAPK pathway in cell motility in diverse 
systems (42), these findings indicate that RSK likely regulates the involvement of Shp2 in 
both of these pathways to promote a change in cell shape and cell motility. 
In summary, we have identified a novel mechanism by which growth factors regulate 
Gab2 function. Based on the involvement of Gab2 in the pathogenesis of breast cancer, our 
results provide important information about the complexity of its regulation. Our findings also 
have potential clinical implication, as RSK1 and RSK2 have been shown to be upregulated in 
both breast and prostate cancers (43). While these two RSK isoforms likely play important 
proproliferative functions (5, 6), our results indicate that they are also involved in the negative 
regulation of RTK signaling. 
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FIGURES 
 
Figure 2.1 Identification of Gab2 as a target of Ras/MAPK signaling.  
(A and C) HEK293 cells were transfected with an empty vector or Myc-tagged Gab1 or Gab2, serum starved 
overnight, and stimulated for 30 min with PMA (100 ng/ml) or 10 min with EGF (25 ng/ml) or fetal bovine 
serum (10%). Immunoprecipitated (IP) Myc-Gab1 or Myc-Gab2 was then assayed for phosphorylation with 
phosphomotif antibodies that recognize the RXXpS/T and RXXpS/TXP consensus motifs. Phosphorylated and 
total levels of RSK and ERK1/2 were assayed by immunoblotting on total cell lysates. SE, short exposure; LE, 
long exposure. (B) As for panel A, except that HEK293 cells were cotransfected with Myc-Gab2 and a 
constitutively active (G12V) or inactive (S17N) form of Ras. (D) RBL-2H3 cells were incubated overnight with 
anti-2,4-dinitrophenol IgE and stimulated with 2,4-dinitrophenol for 10 min prior to endogenous Gab2 
immunoprecipitation. Phosphorylation of endogenous Gab2 was assayed using a phosphomotif antibody that 
recognizes RXXpS/T sequences. 
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Figure 2.2 Activation of the Ras/MAPK pathway induces RSK-dependent phosphorylation of Gab2.  
(A) Schematic representation of the agonists and pharmacological inhibitors used in this study. (B) HEK293 
cells were transfected with an empty vector or Myc-tagged Gab2 and serum starved overnight. Cells were 
pretreated with PD184352 (10 μM) or BI-D1870 (10 μM) for 30 min prior to stimulation with PMA (100 
ng/ml) for 30 min. Immunoprecipitated Myc-Gab2 was then assayed for phosphorylation using phosphomotif 
antibodies that recognize the RXXpS/T and RXXpS/TXP consensus sequences. (C) As for panel B, except that 
cells were also cotransfected with a constitutively activated form of MEK1 (MEK-DD). (D) HEK293 cells 
were transfected with Flag-tagged MEK-DD and either a scrambled siRNA or siRNAs targeting RSK1 and/or 
RSK2. Cells were serum starved overnight, and immunoprecipitated Myc-Gab2 was assayed for 
phosphorylation using a phosphomotif antibody that recognizes the RXXpS/T consensus sequence. (E) As for 
panel D, except that cells were stimulated with PMAinstead of being transfected with MEK-DD. In addition, 
total cell lysates were immunoblotted with a phosphorylation site-specific antibody against Ser160. (F) 
Wild-type and kinase-deficient RSK1 (K112/464R) were immunoprecipitated from HEK293 cells stimulated 
with PMA (100 ng/ml), and the resulting immunoprecipitates were incubated in a kinase reaction with 
[γ-32P]ATP and immunopurified full-length Myc-Gab2. The resulting samples were run on 
SDS-polyacrylamide gels and analyzed by exposing dried film on an autoradiogram. Levels of both RSK1 and 
Gab2 are shown on the Coomassie-stained gel.  
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  Figure 2.3 Identification of Ser160, Ser211, and Ser620 as being regulated by Ras/MAPK signaling. 
(A) HEK293 cells were transfected with wt Gab2 or potential RSK phosphorylation site mutants (S160A, 
S211A, T256A, T388A, S434A, and S620A), serum starved overnight, and stimulated with PMA (100 
ng/ml) for 30 min. Immunoprecipitated Myc-Gab2 was then assayed for phosphorylation with 
phosphomotif antibodies that recognize the RXXpS/T and RXXpS/TXP consensus motifs. (B) HEK293 
cells were transfected with wt or a kinase-inactive form of RSK1, serum starved overnight, and stimulated 
with PMA (25 ng/ml) for 15 min. Endogenous Gab2 phosphorylation at Ser160 was determined with a  
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phosphorylation site-specific antibody. (C) As for panel B, except that phosphorylation of endogenous Gab2 at 
Ser160 was monitored in HEK293 cells pretreated with UO126 (20μM), PD184352 (10 μM), or BI-D1870 (10 
μM) for 30 min prior to PMA stimulation. (D) Phosphorylation of murine Gab2 was confirmed via 
high-resolution MS/MS sequencing. Gab2 was immunoprecipitated in biological duplicate from cells 
following either mock treatment, treatment with PMA, or treatment with PMA and PD184352. In a separate 
experiment, cells were either transfected with an empty vector or different activated (G12V) and inactivated 
(S17N) alleles of Ras. After subsequent SDS-PAGE separation, bands corresponding to Gab2 were excised 
and proteins were digested in gel with trypsin followed by TMT labeling for relative quantitation. (E) The 
spectrum identifies a tryptic peptide bearing phosphorylation at Ser620, as well as TMT labels on both lysine 
side chains and the peptide N terminus; localization of the phosphorylation site is indicated by the presence of 
the y9 ion, which matches its theoretical mass to approximately 1 ppm. (Inset) Relative abundance of Ser620 
across the six samples normalized with respect to overall Gab2 abundance. PD, PD184352. (F) The spectrum 
identifies a tryptic peptide bearing two TMT labels as well as phosphorylation of Ser211. Phosphorylation site 
localization is confirmed by the y5 and y6 ions and b1 and b2 ions, as well as the b3 and b4 ions with 
subsequent neutral loss of H3PO4. (Inset) Relative levels of Gab2 phosphorylation at Ser211, after 
normalization on the basis of overall Gab2 abundance. Red and blue lines within the peptide sequences 
indicate y and b ions, respectively. 
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Figure 2.4 RSK predominantly phosphorylates Ser160, Ser211, and Ser620 in cells and in vitro.  
(A) HEK293 cells were transfected with Myc-tagged wt Gab2 or a triple mutant with all three serine residues 
converted to alanines (S160/211/620A [S3A]), serum starved overnight, and stimulated with PMA (100 ng/ml) 
for 30 min. Immunoprecipitated Myc-Gab2 was then assayed for phosphorylation with phosphomotif 
antibodies that recognize the RXXpS/T and RXXpS/TXP consensus motifs. (B) As for panel A, except that 
cells were treated with EGF (25 ng/ml) for 10 min. (C) As for panel A, except that cells were transfected with 
MEK-DD prior to serum starvation and cell lysis. (D) Wild-type RSK1 was immunoprecipitated from 
HEK293 cells stimulated with PMA (100 ng/ml), and the resulting immunoprecipitates were incubated in a 
kinase reaction with [γ-32P]ATP and immunopurified wt or S3A Myc-Gab2. The resulting samples were run on 
SDS-polyacrylamide gels and analyzed by exposing dried film on an autoradiogram. Levels of both RSK1 and 
Gab2 are shown on the Coomassie-stained gel. (E) Schematic representation of Gab2 with known 
phosphorylation binding sites. The three phosphorylation sites identified in this study are shown with circles 
labeled P. (F) Alignment of Gab2 amino acid sequences from different vertebrate species which demonstrate 
evolutionary conservation of all three phosphorylation sites.  
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Figure 2.5 The Ras/MAPK pathway modulates Shp2 recruitment in an RSK-dependent manner.  
(A) HEK293 cells were transfected with Myc-Gab2, serum starved overnight, pretreated with PD184352 (10 
μM), and stimulated with EGF (25 ng/ml) over a time course. Associated endogenous Grb2 and Shp2 within 
Myc-Gab2 immunoprecipitates were assayed by immunoblotting. (B) HEK293 cells were transfected with 
Myc-tagged Gab2, serum starved overnight, and pretreated with PD184352 (10 μM) and/or PMA (100 ng/ml) 
for 30 min, prior to treatment with EGF (25 ng/ml) for 5 or 10 min. Associated Shp2 was assayed as described 
for panel A. (C) As for panel A, except that cells were cotransfected with MEK-DD, serum starved overnight, 
and stimulated with EGF over a time course. (D) As for panel A, except that cells were pretreated with the 
RSK inhibitor BI-D1870 (10 μM) for 30 min prior to EGF stimulation. 
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Figure 2.6 A Gab2 mutant that cannot be phosphorylated on Ser160/211/620 promotes Shp2 
recruitment.  
(A) HEK293 cells were transfected with wt Myc-Gab2 or the S3A mutant, serum starved overnight, and 
stimulated with EGF (25 ng/ml) over a time course. Associated Shp2 within Gab2 immunoprecipitates was 
evaluated by immunoblotting. (B) HEK293 cells were transfected with wt Myc-Gab2 or the S3A mutant, 
serum starved overnight, and stimulated with EGF (25 ng/ml) over a time course. Associated p85 was  
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evaluated within Gab2 immunoprecipitates by immunoblotting, as well as Akt phosphorylation at Ser473. (C) 
The bar graph shows the relative Shp2 recruitment quantified by densitometry (as described in Materials and 
Methods) from three independent experiments similar to the one whose results are shown in panel A. The data 
are expressed as the mean fold increase in Shp2 recruitment comparing immunoprecipitations with wt Gab2 
and the S3A mutant. Results are means SEMs. One-tailed unequal variance Student’s t test P values are 
indicated for a comparison of the means of the wt and mutant (S3A) Gab2 levels. *, P<0.01. (D) HEK293 cells 
were cotransfected with wt Myc-Gab2 or the S3A mutant, with or without MEK-DD, serum starved overnight, 
and stimulated with EGF (25 ng/ml) over a time course. Shp2 recruitment was evaluated as described for panel 
A. (E) Wild-type and Gab2-deficient MEFs were evaluated for the presence of endogenous Gab2 by 
immunoblotting on total cell lysates. (F) Gab2-deficient MEFs stably expressing wt Gab2 or the S3A mutant 
were seeded at a similar density and serum starved overnight, prior to EGF (25 ng/ml) stimulation over a time 
course. Associated Myc-Gab2 was assayed within endogenous Shp2 immunoprecipitates by immunoblotting. 
(G) HEK293 cells were transfected with wt Myc-Gab2 or each of the Gab2 mutants (S160A, S211A, or 
S620A), serum starved overnight, and stimulated with EGF (25 ng/ml) over a time course. Associated Shp2 
was evaluatedwithin Gab2 immunoprecipitates by immunoblotting. 
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Figure 2.7 Stable expression of the Gab2 S3A mutant alters MCF-10A cell morphology.  
(A) Confocal images of growing MCF-10A cells stably expressing an empty vector, wt Gab2, or the S3A 
mutant. Cells were stained with phalloidin to visualize the actin cytoskeleton, anti-Myc to monitor Gab2 
expression, and DAPI to visualize nuclei. (B) Stable MCF-10A cells were lysed and immunoblotted for Gab2 
(anti-Myc) to show equal expression levels between wt Gab2 and the S3A mutant, as well as phosphorylated 
ERK1/2 (T202/Y204) to show increased activation in Gab2 S3A-expressing cells. The ratio of ERK1/2 
phosphorylation over total ERK1/2 levels was calculated on the basis of densitometric values. EV, empty 
vector. (C) Quantification of elongated cells from immunostaining experiments similar to the one shown in 
panel A. (D) MCF-10A cells stably expressing an empty vector, wt Myc-Gab2, or the S3A mutant were serum 
starved overnight and stimulated with EGF (25 ng/ml) over a time course. Associated Myc-Gab2 within 
endogenous Shp2 immunoprecipitates was evaluated by immunoblotting. The ratio of ERK1/2 
phosphorylation over total ERK1/2 levels was calculated on the basis of densitometric values. 
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Figure 2.8 Stable expression of the Gab2 S3A mutant promotes MCF-10A cell migration.  
(A) MCF-10A cells stably expressing an empty vector, wt Gab2, or the S3A mutant were seeded on top of 
Boyden chambers in EGF-free medium. Cells were allowed to migrate toward 20 ng/ml EGF for 24 h, fixed, 
and stained using H&E. (B) Filters processed as described for panel A were scanned, and migrated cells were 
automatically counted, as described in Materials and Methods. (C) Analysis of the proliferation of stable 
MCF-10A cells using the MTS assay over a time course of 72 h. The data are expressed as the mean fold 
increase in cell proliferation. A.U., absorbance units. (D) Live-cell-imaging wound-healing assays were 
performed using MCF-10A cells stably expressing wt Gab2 or the S3A mutant. Tree graphs show the length 
(μm), direction, and displacement (distance from the origin) of more than 70 cell paths. (E) Quantification of 
cell speed (μm/min) based on the total displacement calculated in wound-healing assays. An unpaired 
Student’s t test was performed to determine that the differences between wt and S3A Gab2 conditions and the 
effect of PD184352 treatment were statistically significant (*, P <0.00001). 
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Figure 2.9 Schematic representation of Gab2 signaling and its negative regulation by RSK.  
While Gab2 phosphorylation at tyrosine residues promotes Shp2 recruitment and activation of the Ras/MAPK 
pathway, RSK-mediated phosphorylation of Gab2 on Ser/Thr residues inhibits Shp2 binding and 
Shp2-dependent signaling. RSK-mediated phosphorylation of Gab2 likely plays a role in tightly regulating 
Gab2-dependent biological functions, such as the regulation of cell motility. 
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Preface to Chapter 3 
Deregulation of ERK1/2 activity causes a number of human diseases, such as cancer, 
inflammatory diseases and severe bone disorders. Hence, understanding the contribution of 
ERK1/2 to these diseases has become an attractive research field. Indeed, this question can be 
addressed by the identification of ERK1/2 substrates, which participate in numerous 
biological events, such as cell proliferation, apoptosis, transformation and migration. Several 
years ago, Gab2 was identified as an ERK1/2 substrate, and overexpression of Gab2 has been 
found to promote cell proliferation and migration. However, one question concerning how 
ERK1/2 regulate Gab2 function still remains elusive. Using a combination of genetics and 
biochemistry tool, we asked (a) How ERK1/2 mediate Gab2 phosphorylation. (b) Whether 
these phosphorylation events affect Gab2 association with different binding partners, such as 
Shp2 and p85. (c) If mitogen-induced Gab2 phosphorylation by ERK1/2 affects its biological 
functions, such as cell proliferation and cell motility.  
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ABSTRACT 
The scaffolding adapter protein Gab2 (Grb2-associated binder) promotes cell proliferation, 
survival and motility by engaging several signaling pathways downstream of growth factor 
and cytokine receptors. The involvement of Gab2 in the activation of different signaling 
pathways is well documented, but very little is known about the molecular mechanisms that 
potentiate or attenuate its function. Here we show that Gab2 becomes phosphorylated on 
Ser/Thr-Pro residues upon stimulation of the Ras/MAPK pathway. More specifically, we 
demonstrate that the protein kinases ERK1 and ERK2 directly phosphorylate Gab2 in vitro 
and in cells. We find that ERK1/2 interact with Gab2 via a novel docking domain which 
appears to be important for subsequent Gab2 phosphorylation by these protein kinases. Using 
site-directed mutagenesis, we identified five ERK1/2-dependent phosphorylation sites in 
Gab2 that are conserved amongst vertebrate Gab2 orthologues. We show that mutation of 
ERK1/2-dependent phosphorylation sites promotes p85 recruitment, suggesting that the 
Ras/MAPK pathway negatively regulates Gab2-dependent signaling. Taken together, our 
results provide a novel regulatory mechanism by which ERK1/2 participates in a negative 
feedback loop that limits the signaling response of growth factor and cytokine receptors. 
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INTRODUCTION 
The Ras/mitogen-activated protein kinase (MAPK) pathway plays a central role in 
transducing extracellular signals to intracellular target proteins involved in cell growth, 
survival and proliferation (1-4). As such, this pathway is deregulated in a variety of human 
disorders and diseases, including many types of cancer (5-7). Activation of the Ras/MAPK 
pathway is often initiated at the plasma membrane, where the binding of growth factors to 
receptor tyrosine kinases (RTKs) promotes the recruitment of several adaptor proteins, such 
as Grb2 (growth factor receptor-bound protein 2). Using its SH3 (Src homology 3) domains, 
Grb2 interacts with the Ras-specific guanine nucleotide exchange factor (GEF) SOS (son of 
sevenless) to promote the activation of Ras GTPases at the plasma membrane (8, 9). These 
events trigger the Ras-dependent activation of Raf, resulting in the sequential activation of 
MEK1/2 (MAPK/ERK kinase 1/2) and the MAPKs ERK1 and ERK2 (extracellular 
signal-regulated kinase 1/2) (10). ERK1/2 are proline-directed Ser/Thr kinases that 
phosphorylate substrate protein sequences containing, at minimum, a proline at the +1 
position (S/T-P). Upon activation, ERK1/2 phosphorylate many cellular targets involved in 
cell growth, survival and proliferation (1, 3). ERK1/2-mediated phosphorylation is often 
facilitated by docking domains (D-domains) located in protein substrates (11), which consist 
of two or more basic residues and a cluster of hydrophobic residues separated by a short 
peptide linker (R/K-R/K-X2-6-Ф -X-Φ, where Φ is a hydrophobic residue, such as Leu, Iso or 
Val, and X is any amino acids). ERK1/2 contain a common docking (CD) domain, which 
includes aspartate residues (D316 and D319 in ERK2), that mediate interactions with 
D-domains (12, 13). 
In addition to SOS, Grb2 associates with many adaptor proteins, including Gab 
(Grb2-associated binding protein) family members (Gab1-3) (14, 15). Gab proteins are devoid 
of enzymatic activity, but act as signaling platforms downstream of several RTKs and non-TK 
receptors, such as cytokine and G protein-coupled receptors. The Gab proteins have a similar 
topology, including an N-terminal pleckstrin homology (PH) domain, multiple proline-rich 
domains, and several phosphotyrosine residues. While the PH domain binds 
membrane-associated phospholipids and mediates the rapid membrane localization of Gab 
proteins, the proline-rich domains (PXXP) of Gab proteins constitutively associate with the 
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SH3 domains of Grb2 (14). Grb2 binding also participates in plasma membrane localization, 
but this interaction appears to be more important for the long-term residency of Gab proteins 
in this cellular compartment (16). Upon recruitment to the plasma membrane, Gab proteins 
become tyrosine phosphorylated and interact with SH2 domain-containing proteins, such as 
Shp2 (SH2 domain-containing protein tyrosine phosphatase 2) and the p85 regulatory subunit 
of PI3K (phosphoinositide 3-kinase), which stimulate the Ras/MAPK and PI3K/Akt signaling 
pathways, respectively (14). 
Amongst Gab family proteins, the Gab2 isoform has received much attention due to its 
emerging role in human cancer (17). The GAB2 gene is amplified in 10-15% of ovarian (18) 
and breast (19) tumors, suggesting its potential contribution to tumorigenesis. Overexpression 
of Gab2 in human mammary epithelial cells was shown to increase cell proliferation and 
invasion, and these effects were associated with enhanced and/or more sustained activation of 
the Ras/MAPK and PI3K/Akt signaling pathways (20, 21). Gab2 was shown to collaborate 
with HER2 (ErbB2 or Neu) in promoting breast epithelial cell transformation, suggesting its 
role in signal amplification downstream of this RTK (22). The mechanisms by which Gab2 
contributes to cancer development are ill-defined, but the effect of Gab2 on cell proliferation 
was shown to be dependent on intact Shp2 and Grb2 binding motifs, and was enhanced by its 
potential to recruit PI3K (20). 
In addition to being positively regulated by tyrosine phosphorylation, Gab2 was shown to 
be phosphorylated on several Ser/Thr residues in response to agonists of the Ras/MAPK and 
PI3K/Akt pathways (23). Akt phosphorylates Gab2 on Ser159 (according to mouse 
numbering), which in turn abrogates its phosphorylation on tyrosine residues (23). Additional 
PI3K-dependent phosphorylation sites exist on Gab2 (Ser210 and Thr391), but the identity of 
the protein kinase involved in their regulation remains unknown (24). Nonetheless, these 
phosphorylation sites were shown to mediate 14-3-3 binding, which in turn disrupt Grb2 
binding and Gab2 tyrosine phosphorylation (24). With regards to the Ras/MAPK pathway, 
one study has shown that ERK1/2 phosphorylates Gab2 on Ser612 and thereby inhibits Shp2 
recruitment (25). More recently, the MAPK-activated protein kinase RSK (p90 ribosomal S6 
kinase) was shown to phosphorylate Gab2 on three residues (Ser159, Ser210, Ser620) that 
also impair Shp2 recruitment (26), suggesting that ERK and RSK collaborate to inhibit Gab2 
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function. Evidence suggests that Gab2 is phosphorylated by ERK1/2 on multiple additional 
residues (25), but the identity of these phosphorylation sites as well as their functions remain 
unknown. 
In the current study, we characterized Gab2 phosphorylation in response to agonists of 
the Ras/MAPK pathway and identified multiple Ser/Thr residues that are directly 
phosphorylated by ERK1/2 in vitro and in cells. We found that ERK1/2 directly interact with 
Gab2 through a D-domain located near one of the Grb2-SH3 binding domains. Mutation to 
ERK1/2-dependent phosphorylation sites resulted in increased Gab2 tyrosine phosphorylation 
and association with p85, suggesting that ERK1/2 negatively regulate Gab2 function. 
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MATERIALS AND METHODS 
DNA constructs and recombinant proteins. The plasmids encoding hemagglutinin 
(HA)-tagged murine Gab1 and Gab2 were graciously provided by Drs. Morag Park (McGill 
University, Canada) and Isabelle Royal (University of Montreal, Canada), respectively, and 
described previously (27, 28). The vectors encoding constitutively active forms of Ras (G12V) 
and MEK1 (MEK-DD) and the inactive form of Ras (S17N) were described previously (29, 
30). All HA-tagged ERK1 constructs were provided by Dr. Sylvain Meloche (IRIC, 
University of Montreal, Canada). To subclone murine Gab1 and Gab2 into pcDNA3.0-6myc, 
HA-tagged Gab1 and Gab2 were amplified by PCR and described previously (26). All murine 
Gab2 mutants were generated using the QuikChange methodology (Stratagene, La Jolla, CA). 
To subclone murine Gab2 into pBabe-puro and produce retroviral particles used in the 
generation of stable cell lines, myc-tagged wild-type (wt) and mutant Gab2 were amplified by 
PCR as described previously (26). 
Antibodies. Antibodies targeted against pSer/Thr-Pro residues, Gab2, phospho-Akt 
(S473), Akt, p85, ERK1/2, phospho-ERK1/2 (T202/Y204), S6 and phospho-S6 (S235/236) 
were purchased from Cell Signaling Technologies (Beverly, MA). The Gab2 antibody used 
for immunoprecipitation and phospho-Tyr (PY99) were purchased from Santa Cruz 
Biotechnologies (Santa Cruz, CA). Anti-Myc, anti-HA and anti-Tubulin monoclonal 
antibodies were purchased from Sigma-Aldrich (Oakville, Ontario, Canada). All secondary 
horseradish peroxidase (HRP)-conjugated antibodies used for immunoblotting were 
purchased from Chemicon (Temecula, CA). 
Cell culture and transfection. HEK293 cells were maintained at 37°C in Dulbecco’s 
modified Eagle’s medium (DMEM) with 4.5 g/liter glucose supplemented with 10% fetal 
bovine serum (FBS) and antibiotics. HEK293 cells were transfected by calcium phosphate 
precipitation as previously described (31). Cells were grown for 24h after transfection and 
serum-starved using serum-free DMEM where indicated for 16 to 18h. Starved cells were 
pretreated with PD184352 (10 μM), U0126 (20 μM), or BI-D1870 (10 μM) (Biomol, 
Plymouth Meeting, PA), where indicated, and stimulated with FBS (10%), phorbol 
12-myristate 13-acetate (PMA; 100 ng/ml), or EGF (25 ng/ml) before being harvested. Unless 
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indicated otherwise, all drugs and growth factors were purchased from Invitrogen (Burlington, 
Ontario, Canada). 
RNA interference. For small interfering RNA (siRNA)-mediated knockdown of ERK1 
and ERK2, validated 21-nucleotide cRNAs with symmetrical two-nucleotide overhangs were 
obtained from Qiagen. HEK293 cells were transfected using calcium phosphate and 50 nM 
siRNA per dish. At 24 h following transfection, cells were serum starved overnight before 
being harvested. 
Immunoprecipitations and immunoblotting. Cell lysates were prepared as previously 
described (31). Briefly, cells were washed three times with ice-cold phosphate-buffered saline 
(PBS) and lysed in BLB (10 mM K3PO4, 1 mM EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM 
β-glycerophosphate, 0.5% Nonidet P-40, 0.1% Brij 35, 0.1% deoxycholic acid, 1 mM sodium 
orthovanadate [Na3VO4], 1 mM phenylmethylsulfonyl fluoride, and a cOmplete protease 
inhibitor cocktail tablet [Roche]). For immunoprecipitations, cell lysates were incubated with 
the indicated antibodies for 2h, followed by a 1h incubation with protein A-Sepharose CL-4B 
beads (GE Healthcare). Unless they were used for kinase assays, immunoprecipitates were 
washed three times in lysis buffer and beads were eluted and boiled in 2×reducing sample 
buffer (5×buffer is 60 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 14.4 mM 
2-mercaptoethanol, 0.1% bromophenol blue). For λ-phosphatase assay, exogenous myc-Gab2 
immunoprecipitates were washed twice in lysis buffer and incubated for 1h at 30°C with 
λ-phosphatase (New England BioLabs, Beverly, MA) in the supplied buffer. The reaction was 
stopped by adding 2×reducing sample buffer. Eluates and total cell lysates were subjected to 8 
to 12% SDS-PAGE, and resolved proteins were transferred onto polyvinylidene difluoride 
(PVDF) membranes for immunoblotting. The data presented are representative of at least 
three independent experiments. 
Protein phosphotransferase assays. Recombinant activated ERK1 purchased from 
Millipore was used for kinase assays, which were performed with immunopurified full-length 
myc-tagged Gab2 or the S143/469/532/612/614A mutant (from here on termed the S5A 
mutant) as substrates, under linear assay conditions. Assays were performed for 20 min at 
30°C in kinase buffer supplemented with ATP. The data presented are representative of at 
least three independent experiments. 
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RESULTS 
Gab2 is phosphorylated in response to agonists of the Ras/MAPK pathway 
To determine whether the Ras/MAPK or the PI3K/Akt pathways could alter the 
electrophoretic properties of Gab2, we analyzed endogenous Gab2 from HEK293 cells by 
SDS-PAGE. We found that strong agonists of the Ras/MAPK pathway, such as the phorbol 
ester PMA (phorbol 12-myristate 13-acetate) and EGF (epidermal growth factor), induced a 
robust electrophoretic shift in Gab2 which correlated with the phosphorylation of ERK1/2 
(Fig. 3.1A). Conversely, treatment of cells with insulin or serum, which are potent agonists of 
the PI3K/Akt pathway, did not significantly alter Gab2 mobility on SDS-PAGE. To determine 
if the mobility shift of Gab2 was indeed due to protein phosphorylation, we 
immunoprecipitated transfected myc-tagged Gab2 from cells stimulated with PMA and 
treated immunoprecipitates with λ-phosphatase. With this approach, we found that 
phosphatase treatment completely abolished the mobility shift of Gab2 induced by PMA 
stimulation (Fig. 3.1B), demonstrating that stimulation of the Ras/MAPK pathway promotes 
direct Gab2 phosphorylation. Next, we sought to delineate the protein kinase(s) involved in 
Gab2 phosphorylation using pharmacological inhibitors of MEK1/2 (PD184352 and U0126) 
to prevent ERK1/2 activation (Fig. 3.1C). We also tested a RSK inhibitor (BI-D1870), as we 
have previously shown that this kinase directly phosphorylates Gab2 in response to agonists 
of the Ras/MAPK pathway (Fig. 3.1C). While RSK inhibition did not significantly affect the 
mobility shift of Gab2 induced by PMA, we found that treatment of cells with MEK1/2 
inhibitors efficiently blocked Gab2 phosphorylation (Fig. 3.1D). As ERK1/2 are the only 
known MEK1/2 substrates, these results suggest that ERK1/2, or a kinase other than RSK 
downstream of ERK1/2, regulates Gab2 phosphorylation. Finally, to confirm the direct 
involvement of ERK1/2 in Gab2 phosphorylation, we used small interfering RNA (siRNA) 
mediated RNAi (RNA interference) to specifically reduce endogenous expression of ERK1 
and ERK2. We found that depletion of endogenous ERK1 and ERK2 resulted in a strong 
inhibition of the mobility shift in Gab2 upon PMA stimulation (Fig. 3.1E), suggesting that 
endogenous ERK1/2 are required for Gab2 phosphorylation. 
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ERK1/2 phosphorylate Gab2 in vitro and in cells 
To determine if Gab2 is a direct substrate of ERK1/2, which are proline-directed kinases (10), 
we took advantage of a phospho-motif antibody that recognizes potential ERK1/2 
phosphorylation sites (pS/T-P), as done previously (32). HEK293 cells transfected with 
myc-tagged Gab2 were serum-starved overnight and stimulated over a time-course of EGF. 
Immunoprecipitated Gab2 was then analyzed for phosphorylation by immunoblotting using 
the anti-pS/T-P antibody. Using this approach, we found that EGF treatment rapidly 
stimulated Gab2 phosphorylation on the pS/T-P consensus motif, which correlated well with 
the phosphorylation status of ERK1/2 (Fig. 3.2A). The requirement for ERK1/2 activity was 
confirmed by showing that treatment of cells with MEK1/2 inhibitors (PD184352) completely 
abrogated Gab2 phosphorylation on the pS/T-P consensus motif (Fig. 3.2B). RSK was 
excluded from these effects by showing that two different pharmacological inhibitors 
(BI-D1870 and SL-0101) did not affect Gab2 phosphorylation on the pS/T-P consensus motif 
(Fig. 3.2C). To confirm the direct involvement of ERK1/2 in the regulation of Gab2 
phosphorylation on the pS/T-P consensus motif, we used siRNAs to specifically knockdown 
endogenous ERK1 and/or ERK2 in HEK293 cells. As shown with the mobility shift (Fig. 
3.1E), we found that knockdown of endogenous ERK1 and ERK2 significantly reduced Gab2 
phosphorylation on the pS/T-P consensus motif (Fig. 3.2D), indicating that Gab2 is targeted 
by both ERK1 and ERK2. To determine whether endogenous Gab2 is also subject to a similar 
regulation, we immunoprecipitated endogenous Gab2 in HEK293 cells and detected its 
phosphorylation using the anti-pS/T-P antibody. Compared to unstimulated cells, we found 
that PMA stimulation increased endogenous Gab2 phosphorylation on the pS/T-P consensus 
motif (Fig. 3.2E). This effect was completely inhibited by the addition of a MEK1/2 inhibitor 
(PD184352), suggesting that ERK1/2 phosphorylates endogenous Gab2 in cells. Finally, to 
investigate whether Gab2 is a direct substrate of ERK1/2, we performed in vitro kinase assays 
using recombinant activated ERK1 and immunopurified wild-type Gab2 as substrate. While 
no phosphate incorporation was seen in purified Gab2 in the absence of ATP or recombinant 
ERK1, we found a significant induction of Gab2 phosphorylation in the presence of both ATP 
and recombinant ERK1 (Fig. 3.2F). Taken together, these results demonstrate that ERK1/2 
directly phosphorylate Gab2 in vitro and in cells. 
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ERK1/2 are recruited to Gab2 in a MEK1/2-dependent manner 
To determine if ERK1/2 physically interact with Gab2, HEK293 cells were transfected with 
myc-tagged Gab2 and immunoprecipitates were assayed for the presence of endogenous 
ERK1/2 over a time-course of EGF treatment. While Gab2 and ERK1/2 did not appear to 
interact in unstimulated cells, we found that EGF stimulation potently induced their 
association in cells (Fig. 3.3A). The interaction between Gab2 and ERK1/2 correlated very 
well with the levels of ERK1/2 phosphorylation, suggesting that ERK1/2 activation was 
necessary for its association with Gab2. To determine this, we pretreated cells with the 
MEK1/2 inhibitor PD184352 prior to PMA or EGF stimulation, and found that MEK1/2 
inhibition completely abrogates ERK1/2 interaction (Fig. 3.3B). We confirmed the 
requirement for ERK1/2 activation by expressing an activated form of MEK1 (S212/218D), 
which resulted in the association of Gab2 and ERK1/2 in the absence of growth factors or 
serum (Fig. 3.3C). Having demonstrated that Gab2 interacts with ERK1/2 in response to 
MEK1/2 activation, we next determined whether ERK1/2 activity was required for this 
association. For this, myc-tagged Gab2 was cotransfected with wild-type ERK1 or an 
unphosphorylatable ERK1 mutant (T202A/Y204F; AEF). While exogenous wild-type ERK1 
was found to interact with Gab2 in response to PMA stimulation (Fig. 3.3D), the AEF mutant 
of ERK1 did not, suggesting that ERK1/2 needs to be in an activated conformational state to 
associate with Gab2. We confirmed that endogenous Gab2 also interact with ERK1/2 in a 
stimulation-dependent manner, by looking at ERK1/2 association within endogenous Gab2 
immunoprecipitates from HEK293 cells (Fig. 3.3E). The Gab1 isoform was previously shown 
to interact with ERK1/2 (33). We thus compared Gab1 and Gab2 in their ability to interact 
with ERK1/2 in response to stimulation of the Ras/MAPK pathway. While we found that 
Gab1 appeared to interact with ERK1/2 to some degree, we did not see evidence for a 
regulated interaction as shown for Gab2 (Fig. 3.3F). Together, these results demonstrate that 
Gab2, but not Gab1, specifically interacts with ERK1/2 in response to agonists of the 
Ras/MAPK pathway. 
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Identification of a D-domain in Gab2 involved in ERK1/2 binding 
Next, we sought to determine whether Gab2 directly interacts with activated ERK1/2. 
ERK1/2 often associate with substrate proteins using specialized docking motifs, termed 
D-domains (34). These domains specifically interact with residues within the CD domain of 
ERK1/2, which includes aspartate residues (D328 in ERK1) (12, 13). To determine if the CD 
domain of ERK1 is involved in Gab2 binding, we performed co-immunoprepicipation 
experiments with wild-type Gab2 and wild-type ERK1 or the ERK1 D328N mutant (Fig. 
3.4A). Compared to wild-type ERK1, we found that the ERK1 D328N mutant was impaired 
in its ability to associate with Gab2, suggesting that Gab2 possess a D-domain. Using the 
bioinformatics tool Scansite (35), we analyzed the Gab2 sequence for the presence of a 
potential D-domain. Notably, this search led to the high-confidence identification of a 
potential D-domain (score 0.377; percentile 0.031%) located between residues 510 and 524 of 
mouse Gab2 (RKAKPTPLDLRNNTV, where the important residues are shown in boldface). 
Sequence alignment revealed that this motif is conserved within vertebrate orthologues of 
Gab2, but appears to contain some substitutions in the Gab1 and Gab3 isoforms (Fig. 3.4B). 
To determine if this putative D-domain was functional, we individually mutated all charged 
residues within this motif and assayed Gab2 association to ERK1/2. As shown in Fig. 3.4C, 
we found that mutation of Arg510, Lys511, Lys513, Leu517 and Leu519 resulted in 
decreased association with ERK1/2. We also evaluated Gab2 phosphorylation on pS/T-P 
consensus motifs, and found that mutation of Leu517 and Leu519 had the greatest impact (Fig. 
3.4C), consistent with the idea that protein-protein interaction mediated by hydrophobic 
residues usually results in tighter binding than salt bonds (36). Mutation of Leu506 had no 
effect on ERK1/2 association and Gab2 phosphorylation, demonstrating that this hydrophobic 
residue is not part of the newly identified D-domain. To determine the respective role of 
Leu517 and Leu519, we generated a double mutant (L517/519A) and analyzed its ability to 
interact with ERK1/2 and become phosphorylated by these protein kinases. As shown in Fig. 
3.4D, we did not find additive effects of mutating these two residues, indicating that they are 
both core constituents of the D-domain (Fig. 3.4D). We also analyzed the ability of the Gab2 
L517A mutant to interact with ERK1/2 during a time-course of EGF stimulation. As shown in 
Fig. 4E, we found that this mutant is impaired in ERK1/2 recruitment and also becomes less 
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efficiently phosphorylated by these enzymes. Having demonstrated that the D-domain in 
Gab2 is functional, we next determined whether Ile537 in Gab1, which corresponds to 
Leu519 in Gab2, was responsible for the reduced association of this isoform to ERK1/2. For 
this, we mutated Leu519 in Gab2 to Ile and determined the ability of this mutant to interact 
with ERK1/2 compared to wild-type Gab2. Notably, we found that the L519I mutant of Gab2 
was impaired in its ability to interact with ERK1/2 (Fig. 3.4F), providing a potential 
explanation for the observed differences between Gab1 and Gab2. Together, these results 
indicate that ERK1/2 directly interact and phosphorylate Gab2 in response to stimulation of 
the Ras/MAPK pathway. 
Identification of ERK1/2 phosphorylation sites in Gab2 
To identify ERK1/2-dependent phosphorylation sites in Gab2, we analyzed the sequence 
surrounding all Ser/Thr-Pro residues for similarities to phosphorylation sites in known 
substrates of ERK1/2 (10). We located five potential phosphorylation sites, consisting of 
Ser143, Ser469, Ser532, Ser612, and Ser614 (according to the Gab2 mouse numbering), 
which were previously found in proteomics studies to be phosphorylated in cells (Fig. 3.5A) 
(37). Amongst these, Ser143, Ser469, Ser532, Ser612 were shown to be modulated by EGF 
stimulation by quantitative mass spectrometry (24). Given the lack of phosphorylation 
site-specific antibodies, we mutated all five residues to unphosphorylatable alanines, and 
assayed Gab2 phosphorylation in response to PMA stimulation. While the mutation of each 
individual site did not noticeably reduce overall Gab2 phosphorylation, the combination of 
multiple mutations resulted in reduced electrophoretic mobility and phosphorylation as 
assessed with the anti-pS/T-P antibody (Fig. 3.5B). Indeed, our results indicate that the S2A 
(S612/614A), S3A1 (S143/469/532A) and S3A2 (S532/612/614A) mutants of Gab2 had 
reduced electrophoretic mobility in response to PMA stimulation (Fig. 3.5B). The 
combination of all these mutations into a single Gab2 protein (S5A) appeared to almost 
completely prevent Gab2 phosphorylation in response to EGF (Fig. 3.5C), PMA (Fig. 3.5D) 
and MEK-DD expression (Fig. 3.5E), suggesting that these resides are the predominant 
ERK1/2 phosphorylation sites in Gab2. Furthermore, we performed in vitro kinase assays to 
confirm that ERK1/2 directly phosphorylate Ser143/469/532/612/614. As shown in Fig. 3.5F, 
we found that ERK1-mediated phosphate incorporation was robustly decreased in the Gab2 
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S5A mutant compared to wild-type Gab2, indicating that these residues are directly 
phosphorylated by Gab2. These phosphorylation sites, as well as the following proline residue, 
appear to be conserved amongst vertebrate species, suggesting that they play important 
biological functions (Fig. 3.5G). Notably, many of these sites appear to cluster around the 
p85-SH2 binding sites (Fig. 3.5A), suggesting that they may be involved a feedback 
regulation of p85 and/or Shp2 binding. 
ERK1/2 negatively regulate Gab2-dependent signaling by restricting p85 recruitment 
To assess whether ERK1/2-mediated Gab2 phosphorylation affects p85 recruitment to Gab2, 
we first analyzed immunoprecipitated Gab2 from HEK293 cells transfected with MEK-DD, 
to constitutively stimulate Gab2 Ser/Thr phosphorylation at ERK1/2 sites. In response to EGF 
stimulation, we found that cells expressing MEK-DD and having increased Gab2 
phosphorylation on Ser/Thr residues showed reduced association between Gab2 and p85, as 
well as reduced Gab2 tyrosine phosphorylation (Fig. 3.6A). These results suggest that the 
Ras/MAPK pathway negatively regulates p85 recruitment to Gab2, possibly due to 
ERK1/2-dependent phosphorylation of Gab2. To test this, HEK293 cells transfected with 
wild-type Gab2 or the S5A Gab2 mutant were treated with EGF over a time course, prior to 
Gab2 immunoprecipitation. As shown in Fig. 3.6B, we found that p85 was more efficiently 
recruited to the Gab2 S5A mutant compared to wild-type Gab2 in response to EGF 
stimulation. These results suggest that ERK1/2-dependent phosphorylation of Gab2 on 
Ser143/469/532/612/614 negatively regulates p85 recruitment, possibly due to a local steric 
effect of Ser/Thr phosphorylation. These feedback regulatory mechanisms appear to be 
specific to p85, as we did not see differences between wild-type Gab2 and the S5A mutant in 
their ability to recruit and interact with Shp2 and Grb2, respectively. Taken together, these 
results suggest a model in which ERK1/2 negatively regulates Gab2 function by reducing p85 
association. 
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DISCUSSION 
While the physiological functions of Gab2 during mouse development and in human cancer 
have been largely elucidated, much less is known about the molecular mechanisms involved 
in its regulation. As for other Gab isoforms, the role and regulation of Gab2 tyrosine 
phosphorylation is relatively well understood and is usually associated with increased 
Gab2-dependent signaling in response to growth factors and cytokines. Conversely, Ser/Thr 
phosphorylation is usually associated with reduced Gab2-dependent signaling, but the protein 
kinases involved and the exact molecular functions of these phosphorylation events are only 
partially understood. Our study brings new evidence that ERK1/2 is an important binding 
partner of Gab2 that mediates its phosphorylation on multiple Ser/Thr residues. These 
phosphorylation events occur in a feedback paradigm where EGF stimulation promotes 
ERK1/2 signaling, but also following heterologous activation of ERK1/2, such as in response 
to phorbol esters and the expression of activated components of the Ras/MAPK pathway. 
These findings suggest that ERK1/2 may serve to limit Gab2 activation following stimulation, 
but also indicate that cancer cells harboring activating mutations in components of the 
Ras/MAPK pathway may have perturbed Gab2-dependent signaling. The fact that Gab2 
participates in the signaling response of many types of receptors, including several RTKs and 
cytokine receptors, suggests that our results may be applicable to a large number of biological 
situations. 
Our results indicate that ERK1/2-mediated Gab2 phosphorylation inhibits the recruitment 
of p85, possibly by affecting Gab2 tyrosine phosphorylation. The mechanism by which 
ERK1/2 may affect Gab2 tyrosine phosphorylation remains unknown, but our results suggest 
that Grb2 binding to Gab2 is not affected by ERK1/2-mediated phosphorylation. Previous 
reports have shown that Shp2 may dephosphorylate Gab2 on tyrosine residues (38), but our 
results indicate that Shp2 recruitment is also not affected by ERK1/2-mediated 
phosphorylation. This is in contrast to a previous study which indicated that 
ERK1/2-mediated Gab2 phosphorylation on Ser612 inhibits Shp2 recruitment (25). These 
discrepancies may be explained by results showing that the ERK1/2-activated protein kinase 
RSK directly phosphorylates Gab2 and thereby inhibits Shp2 recruitment (26). In this 
scenario, it may not be the direct action of ERK1/2 that affects Shp2 recruitment, but rather 
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the activation of RSK which depends on the Ras/MAPK pathway. Together, these results 
suggest that ERK1/2 and RSK may collaborate in the inhibition of Gab2 function by 
promoting site-specific phosphorylation events that prevents the recruitment of both Shp2 and 
p85. These results are consistent with the idea that the Ras/MAPK pathway participates in 
feedback loops that inhibits its own activation and that of the PI3K/Akt pathway, as shown in 
a number of studies using MEK1/2 inhibitors. Our results suggest that Gab2 may be an 
important signaling node that synthesizes upstream and downstream signals. 
One of the interesting observations that arise from our work is the identification of a new 
ERK1/2-docking domain within Gab2 (RKAKPTPLDL), which appears to be required for 
efficient Gab2 phosphorylation by ERK1/2. While comparing Gab1 and Gab2, we found that 
growth factors specifically promote the recruitment of ERK1/2 to Gab2, suggesting that Gab1 
does not have a functional ERK1/2-docking domain. Consistent with this, we found that the 
corresponding sequence in Gab1 contains an amino acid change that reduces the affinity to 
ERK1/2, which likely explains differences in ERK1/2 binding. Curiously, a previous study 
has reported that Gab1 interacts with ERK1/2 with a higher affinity than Gab2 (39). This 
interaction was shown to depend on the Met-binding domain (MBD) of Gab1, which 
interestingly contains part of the identified ERK1/2-docking domain. These discrepancies 
likely results from the type of bait proteins used in GST pull-downs (39), which for Gab2 
consisted of a deletion mutant that only contained part of the ERK1/2-docking domain that we 
identified in this study. Together, these results suggest that ERK1/2 plays an important role in 
the regulation of Gab2 function, whereas the role of ERK1/2 in the regulation of Gab1 
remains to be determined. 
Based on its frequent amplification in breast cancer, Gab2 has been characterized as a 
potential oncogene that appears to collaborate with HER2 (21, 40). The deletion of Gab2 was 
shown to reduce HER2-mediated tumorigenesis (21), suggesting that Gab2 participates in the 
signaling response elicited by HER2. Our results suggest that ERK1/2 limits Gab2-dependent 
signaling by inhibiting its association with key binding partners. These findings suggest that 
mutation of ERK1/2 phosphorylation sites in Gab2 may increase its ability to collaborate with 
HER2, but more experiments will be required to directly address this. We have looked at 
databases of cancer somatic mutations, but did not find evidence of Gab2 mutation at ERK1/2 
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phosphorylation sites. Nonetheless, it is probable that ERK1/2-dependent phosphorylation of 
Gab2 may impede its ability to participate in HER2-mediated tumorigenesis. 
In summary, our study provides evidence for a new mechanism by which ERK1/2 
negatively regulate Gab2 function. We propose a model whereby the Ras/MAPK pathway has 
a dual role in determining the strength and duration of Gab2-dependent signaling, namely via 
ERK1/2- and RSK-mediated phosphorylation. Based on the involvement of Gab2 in several 
types of cancer, including breast cancer and melanoma, our results provide important 
information regarding the complexity of RTK signaling. 
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FIGURES  
 
Figure 3.1 Gab2 is phosphorylated in response to agonists of the Ras/MAPK pathway. 
(A) HEK293 cells were serum-starved overnight, and stimulated for 30 min with PMA (100 ng/ml; 30 min), 
EGF (25 ng/ml; 10 min), fetal bovine serum (10%; 15 min), or insulin (100 nM; 20 min). Total and 
phosphorylated forms of endogenous ERK1/2, Gab2, Akt and S6 were determined by immunoblotting. (B) 
HEK293 cells were transfected with myc-tagged murine Gab2, serum-starved overnight, and stimulated for 
with PMA (100 ng/ml) for 30 min. Immunoprecipitated (IP) Gab2 was then treated with 400 units 
λ-phosphatase for 60 min at 30 °C, and Gab2 phosphorylation was assayed by mobility shift assay. (C) 
Schematic representation of the agonists and pharmacological inhibitors used in this study. (D) HEK293 cells 
were serum-starved overnight, pretreated with PD184352 (10 µM), U0126 (20 µM), or BI-D1870 (10 µM) for 
30 min prior to PMA (100 ng/ml) stimulation. Phosphorylation of endogenous Gab2 was assayed by mobility 
shift assay. (E) As for panel (D), except that HEK293 cells were transfected with a constitutively active form 
of MEK1 (MEK-DD) rather than being stimulated with PMA. (F) HEK293 cells were transfected with either a 
scrambled siRNA or siRNAs targeting ERK1 and/or ERK2, serum-starved overnight, and stimulated for 30 
min with PMA (100 ng/ml). Again, phosphorylation of endogenous Gab2 was assayed by mobility shift assay.  
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Figure 3.2 ERK1/2 phosphorylate Gab2 in vitro and in cells.  
(A) HEK293 cells were transfected with myc-Gab2, serum-starved overnight, and stimulated with EGF (25 
ng/ml) over a time course (0-60 min). Immunoprecipitated (IP) Gab2 was then assayed for phosphorylation 
with a phospho-motif antibody that recognizes the pS/T-P motif. Total and phosphorylated forms of ERK1/2 
were assayed by immunoblotting on total cell lysates. (B and C) HEK293 cells were transfected with 
myc-Gab2 and serum-starved overnight. Cells were pre-treated with MEK1/2 (PD184352) or RSK (BI-D1870 
and SL0101) inhibitors prior to stimulation with PMA (100 ng/ml) for 30 min. Immunoprecipitated (IP) Gab2 
was assayed for phosphorylation using a phospho-motif antibody which recognizes the pS/T-P sequence. (D) 
HEK293 cells were transfected with flag-tagged MEK-DD and either a scrambled siRNA or siRNAs targeting 
ERK1 and/or ERK2. Cells were serum-starved overnight, and immunoprecipitated (IP) Gab2 was assayed for 
phosphorylation using a phospho-motif antibody which recognizes the pS/T-P sequence. (E) As for panel (A), 
except that endogenous Gab2 was immunoprecipitated. (F) Recombinant activated ERK1 was incubated with 
immunopurified wt Gab2 in a kinase reaction, and the resulting samples were immunoblotted for Gab2 
phosphorylation using a phospho-motif antibody which recognizes the pS/T-P sequence.   
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Figure 3.3 ERK1/2 interact with Gab2 in a MEK1/2-dependent manner.  
(A) HEK293 cells were transfected with myc-Gab2, serum-starved overnight, and stimulated with EGF (25 
ng/ml) over a time course. Associated endogenous ERK1/2 within myc-Gab2 immunoprecipitates was assayed 
by immunoblotting. (B) HEK293 cells were transfected with myc-Gab2, serum-starved overnight, pre-treated 
with PD184352 (10 µM) prior to stimulation with EGF (25 ng/ml) for 10 min, or PMA (100 ng/ml) for 30 min. 
The presence of endogenous ERK1/2 was assayed as described in (A). (C) As for panel (B), except that cells 
were transfected with MEK-DD instead of being stimulated with PMA. (D) HEK293 cells were co-transfected 
with myc-Gab2, and wt HA-ERK1 or the AEF (T202A/Y204F) mutant. Cells were serum-starved overnight 
and stimulated with PMA for 30 min. Associated exogenous ERK1within myc-Gab2 immunoprecipitates was 
assayed as described in (A). Total and phosphorylated forms of ERK1/2 (endogenous and exogenous) were 
assayed by immunoblotting on total cell lysates. (E) As for panel (B), except that endogenous Gab2 was 
immunoprecipitated, and the presence of endogenous phosphorylated ERK1/2 within Gab2 
immunoprecipitates was assayed by immunoblotting. (F) HEK293 cells were transfected with myc-Gab1 or 
myc-Gab2, serum-starved overnight, and stimulated with EGF or PMA. Associated endogenous ERK1/2 was 
assayed as described for panel (A).  
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Figure 3.4 Identification of a D-domain in Gab2 involved in ERK1/2 binding. 
(A) HEK293 cells were co-transfected with myc-Gab2, and wt HA-ERK1 or the D328N mutant (CD domain 
mutant), with or without MEK-DD, and serum-starved overnight. Associated exogenous ERK1 within 
myc-Gab2 immunoprecipitates was assayed by immunoblotting. Total and phosphorylated forms of ERK1/2 
(endogenous and exogenous) were assayed by immunoblotting on total cell lysates. (B) Alignment of known 
D-domains with the potential D-domain found in Gab2 from different vertebrate species, as well as Gab1 and 
Gab3. (C) HEK293 cells were transfected with myc-Gab2, or potential ERK-binding site mutants (L506A, 
R510A, K511A, K513A, L517A, L519A), serum-starved overnight, and stimulated with PMA (100 ng/ml) for 
30 min. Immunoprecipitated (IP) Gab2 was then assayed for phosphorylation with the phospho-motif antibody 
which recognizes the pS/T-P sequence, and also endogenous ERK1/2 association. (D) As for panel (C), except 
that cells were transfected with myc-Gab2, or potential ERK-binding site mutants (L517/519A, L517A, 
L519A). (E) HEK293 cells were transfected with myc-Gab2 or the Gab2 L517A mutant, serum-starved  
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overnight, and stimulated with PMA over a time over a time course. Immunoprecipitated (IP) Gab2 was then 
assayed as described for panel (C). (F) HEK293 cells were transfected with myc-Gab2 or the Gab2 L519I 
mutant (mimicking the putative Gab1 D-domain), serum-starved overnight, and stimulated with PMA or EGF. 
Associated exogenous ERK1/2 within myc-Gab2 immunoprecipitates were assayed by immunoblotting.  
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Figure 3.5 Identification of ERK1/2 phosphorylation sites in Gab2.  
(A) Schematic representation of Gab2 with known tyrosine phosphorylation sites and domains. (B) HEK293 
cells were transfected with myc-tagged wt Gab2 or various combination mutants, including S2A (S612/614A), 
S3A1 (S143/469/532A), S3A2 (S532/612/614A) and S5A (S143/469/532/612/614A). Cells were 
serum-starved overnight, and stimulated with PMA (100 ng/ml) for 20 min. Immunoprecipitated (IP) Gab2 
was then assayed for phosphorylation with the phospho-motif antibody which recognizes pS/T-P sequences. (C) 
HEK293 cells were transfected with myc-tagged wt Gab2 or a quintuple mutant with all five serine residues 
converted to alanines S5A (S143/469/532/612/614A), serum-starved overnight, and stimulated with EGF (25 
ng/ml) for 10 min. Immunoprecipitated (IP) Gab2 was then assayed for phosphorylation with the 
phospho-motif antibody. (D) As for panel (C), except that cells were treated with PMA (100 ng/ml) for 30 min. 
(E) As for panel (C), except that cells were transfected with MEK-DD prior to serum-starvation.   
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(F) Recombinant activated ERK1 was incubated with immunopurified wt Gab2 or the Gab2 S5A mutant in a 
kinase reaction, and the resulting samples were immunoblotted for Gab2 phosphorylation using the 
phospho-motif antibody. (G) Alignment of the five potential ERK1/2 phosphorylation sites in Gab2 from 
different vertebrate species and also from different Gab isoforms. 
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Figure 3.6 ERK1/2 negatively regulate Gab2-dependent signaling by reducing p85 recruitment.  
(A) HEK293 cells were co-transfected with myc-Gab2, an empty vector or MEK-DD, serum-starved overnight, 
and treated with EGF (25 ng/ml) over a time course. Associated endogenous p85 within myc-Gab2 
immunoprecipitates was assayed by immunoblotting. Total tyrosine phosphorylation and proline-directed 
serine/threonine phosphorylation in Gab2 were immunoblotted using the PY99 antibody and the pS/T-P 
phospho-motif antibodies, respectively. (B) As in panel (A), except that cells were transfected with wt 
myc-Gab2 or the unphosphorylatable Gab2 S5A mutant. Associated endogenous p85, total tyrosine 
phosphorylation, and the pS/T-P motif were assayed as described previously. 
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Figure 3.7 Schematic representation of Gab2 regulation by the Ras/MAPK pathway.  
Schematic representation of the molecular mechanisms by which the Ras/MAPK pathway regulates 
Gab2-dependent signaling in response to EGF treatment. (A) Without EGF, Gab2 and its binding partners are 
cytoplasmic. (B) Upon activation of the EGF receptor, Gab2 is recruited to the plasma membrane where it 
becomes tyrosine phosphorylated and participates in the activation of the Ras/MAPK and PI3K/Akt signaling 
pathways. (C) Finally, activated ERK1/2 is recruited to Gab2 via its D-domain, which promotes the 
ERK1/2-dependent phosphorylation of Gab2 on sites that negatively regulate p85 recruitment.    
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4.1 Regulation of Gab2 by RSK kinases 
    4.1.1 Phosphorylation of Gab2 by RSK impacts the recruitment of its binding 
partners   
In this thesis, using different approaches, we identified Ser160, Ser211 and Ser620 
(according to mouse Gab2 numbering) as three phosphorylation sites in Gab2 with basic 
residues at the -5 and -3 positions. Among these sites, phosphorylation of Ser211 was suggested 
to be regulated by an unknown PI3K-dependent protein kinase (Brummer et al., 2008), and 
Ser160 was previously found to be directly phosphorylated by Akt1 (Lynch and Daly, 2002). 
Although the ability to phosphorylate substrates on the basic consensus motif: 
R/K-X-R/K-X-X-pS/T is a common characteristic of the AGC family of kinases, some 
members have their own additional preferences for selecting substrates, such as Akt. It was 
shown that Akt additionally prefers to select substrates with Ser/Thr at -2 position and Phe at 
+1 position (Obata et al., 2000). Moreover, maintaining a Pro residue at the +2 position to 
form a tight turn is a feature of Akt distinct from PKC, because the latter is likely to select 
basic or aromatic residues at this position (Datta et al., 1997). Interestingly, although the 
substrate specificities of certain AGC kinases have been characterized, Akt and RSK are 
considered likely to target similar sequences. Several lines of evidence support this thought. 
First, using PSPL (positional scanning peptide library), Galan et al. recently showed that RSK 
not only selects substrates with Arg at -5 and -3 positions, but also prefers them to have Ser 
and Pro residues at the -2 and -1 positions, respectively, matching the optimized sequence 
targeted by Akt (Galan et al., 2014). Second, numerous common substrates of Akt and RSK 
have been identified, such as PDCD4, TSC2, Bad and Chk1 (Datta et al., 1997; Fang et al., 
1999; Inoki et al., 2002; King et al., 2004; Roux et al., 2004; Palamarchuk et al., 2005; 
Ray-David et al., 2012; Galan et al., 2014). Hence, the phospho-motif antibodies (RXXpS/T 
& RXXpS/TXP) for selecting Akt substrates can also be used to detect potential RSK 
substrates. Given that PMA and RasG12V (an activated form of Ras) do not significantly 
activate the PI3K/Akt pathway, we strongly believe that mitogen-induced phosphorylation of 
Gab2 recognized by these two phospho-motif antibodies is dependent on RSK (Chapter 2, 
Figure 2.1A and B). On the basis of our current study and a previous report which have 
clearly characterized that Gab2 acts as both upstream and a substrate of RSK and Akt, these 
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findings indicate that crosstalk between the Ras/MAPK and PI3K/Akt pathways converge on 
Gab2.  
It has been characterized that Gab2 tyrosine phosphorylation by RTK creates numerous 
binding sites responsible for protein interactions, such as Shp2 and p85 (Gu and Neel, 2003). 
Ser620, a novel phosphorylation site identified in our study, falls between the two 
Shp2-binding residues (Tyr603 and Tyr632) (Chapter 2, Figure 2.4E). Although it is unclear how 
these two phospho-tyrosine residues modulate Gab2-Shp2 interaction allosterically, it is still 
possible that RSK-mediated phosphorylation may impede Shp2 recruitment to Gab2. Indeed, 
we show that the MAPK pathway through RSK restricts Shp2 recruitment to Gab2 in 
HEK293 and MCF-10A cells (Chapter 2, Figure 2.6A and 2.7D). Given that Shp2 is a 
membrane receptor-associated protein and that Gab2 transiently localizes at the plasma 
membrane upon EGF stimulation, it is possible that phosphorylation of Gab2 by RSK alters 
its localization at the plasma membrane, where Gab2-Shp2 interaction occurs. Moreover, 
since the RSK phosphorylation consensus motif (RXXpS/T) matches the minimum 14-3-3 
binding motif (Galan et al., 2014), it is possible that RSK-dependent Gab2 phosphorylation 
leads to the recruitment of 14-3-3 proteins. Given that phosphorylation of Ser211 has been 
characterized as a 14-3-3 binding site in Gab2 (Brummer et al., 2008), it would be interesting 
to investigate whether other sites, likely Ser160 or Ser620, are involved in Gab2/14-3-3 
interaction. A previous study identified Ser160 as an Akt phosphorylation site, and mutation of 
Ser to Ala led to increased Gab2 tyrosine phosphorylation, as well as Shc and ErbB2 
association (Lynch and Daly, 2002). However, we have not observed an increased tyrosine 
phosphorylation level in the Gab2 S160A mutant in our experimental system. The reason for 
these discrepancies may be due to the distinct agonists used in respective studies. Whereas 
EGF (an ErbB1 ligand) was used in our experiments, the previous report took advantage of 
Heregulin (HRG; ErbB3 and ErbB4 ligand) to stimulate cells. It is possible that different 
expression levels of receptors (ErbB1, ErbB3 and ErbB4) in respective cell types and their 
affinity to a specific ligand may lead to distinct downstream signal transduction. 
    4.1.2 Potential roles of phosphorylated Gab2 by RSK in signal transduction  
Having demonstrated the crucial contribution of Gab2 to cancer development, several 
studies indicated that the Gab2-Shp2 axis is required for Gab2-induced cell proliferation and 
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motility (Bentires-Alj et al., 2006; Brummer et al., 2006; Herrera Abreu et al., 2010). In 
MCF-10A cells co-expressing ErbB2 and Gab2, it was shown that disruption of Gab2-Shp2 
association inhibited cell proliferation and migration (Bentires-Alj et al., 2006). In line with 
these findings, we observed that expression of the unphosphorylatable Gab2 S3A 
(S160/211/620A) mutant which displays sustained association with Shp2, led to increased cell 
motility (Chapter 2, Figure 2.8D). Our data suggest that RSK attenuates Gab2-mediated cell 
motility through inhibition of Shp2 recruitment. Being one of the critical adaptor binder 
proteins to Gab2, Shp2 has been well characterized as an oncogene in tumor progression. 
Upon RTK activation, Shp2 is recruited to the plasma membrane, where it dephosphorylates 
p120-RasGAP, leading to the upregulation of the Ras-Raf-MEK1/2-ERK1/2 signaling cascade 
(Montagner et al., 2005; Matozaki et al., 2009). Our data fit this model, whereby sustained 
Shp2 recruitment to Gab2 S3A increases ERK1/2 activity. However, other potential molecular 
mechanisms concerning the Gab2-Shp2 axis regulation of the downstream signaling cascades 
cannot be excluded. It was shown that Gab2 cooperated with other proto-oncogenes, such as 
Src, to transform primary human MCF-10A mammary epithelial cells, leading to an invasive 
multiacinar phenotype in a three-dimensional culture system (Bennett et al., 2008). However, 
it is unclear by which mechanism Gab2 is involved in Src signaling. One possible explanation 
is that Gab2 recruits Shp2 to an inhibitory site of Src. Indeed, it was found that 
Gab2-mediated Shp2 recruitment to Lyn (a predominant Src kinase in myeloid cells) 
increased Lyn activity by dephosphorylating its inhibitory site Tyr507 (Futami et al., 2011). 
Another potential mechanism of RSK modulating Gab2 function in cell motility is through the 
reorganization of cytoskeleton. It has been shown that Gab2 modulates RhoA activity 
(Herrera Abreu et al., 2010). Given that Shp2 regulates Rho kinase II (ROCK II) activity and 
further acts on the cytoskeleton, we can reasonably hypothesize that increased Shp2 
recruitment to the Gab2 S3A mutant may promote cell motility by modulating RhoA/ROCK 
II activity (Lee and Chang, 2008). Based on these statements, measuring Shp2-modulated 
downstream effector activities in the Gab2 S3A mutant overexpressed MCF-10A cells, such 
as Src and ROCK II, would be helpful to expand our knowledge of RSK-modulated Gab2 
actions on multiple downstream signaling cascades.      
    4.1.3 The potential role of Gab2 phosphorylation by RSK in primary mast cells 
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and the allergic response 
The physiological function of Gab2 in the immune system has been studied using GAB2 
knockout mice. As we described in Chapter 1.4.1, GAB2-deficient mice are viable and fertile, 
but were found to have decreased circulating mast cells, suggesting that Gab2 is involved in 
the allergic response through transducing signals from c-Kit (stem cell factor receptor) to the 
downstream signaling cascades, such as the Ras/MAPK or Rac/JNK pathways (Nishida et al., 
2002; Yu et al., 2006; Sharma et al., 2014). Here, by using rat basophilic leukemia(RBL)-2H3 
cells with high expression levels of Gab2, we show that endogenous Gab2 is phosphorylated 
by RSK upon dinitrophenyl treatment (Chapter 2, Figure 2.1D). Because our data showed that 
RSK through Gab2 participates in the negative feedback loop of MAPK signaling in HEK293 
cells (Chapter 2, Figure 2.9), it is reasonable to think that RSK may also affect Kit signaling 
in mast cells. Experiments that are specifically performed in bone marrow-derived mast cells 
(BMMCs) purified GAB2-deficient mice, will be helpful to confirm this assumption. To do 
this, we can re-express Gab2 wild-type or S3A mutant (S159/211/620A) in the Gab2-/- 
BMMCs cells by retroviral vector infections. The contribution of Gab2 S3A mutant to 
Kit-induced signal transduction to downstream effectors, such as ERK1/2 or JNK activities, 
will be assayed upon stimulation of dose-dependent SCF (stem cell factor; Kit ligand) 
treatment. Moreover, given that RSK participates in the regulation of Gab2 functions and 
Gab2-/- mice have decreased circulating mast cells in a number of tissues, we can reasonably 
assume that RSK may play a role in an allergic response. Notably, different isoforms of RSK 
have distinct functions. Therefore, we expect that certain RSK isoforms may be involved in 
the regulation of mast cell proliferation and the allergic response. This hypothesis can be 
addressed by evaluating the allergic response in RSK1-3 knockout animals subjected to mast 
cell activation through antigen induced aggregation of FcεRI. Collectively, this work will be 
helpful to understand the potential role of RSK in the allergic response.  
4.2 Regulation of Gab2 functions by MAP kinases 
    4.2.1 ERK1/2 bind to Gab2 and further regulate its phosphorylation 
One of the fascinating observations deriving from our work is the identification a new 
ERK1/2-docking domain in Gab2. To increase the fidelity and duration of Ras/MAPK 
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signaling, ERK1/2 specifically bind to specific sequences in protein substrates, such as the 
D-domain (Roskoski, 2012). It was shown that hydrophobic interactions were crucial for 
activated ERK1/2(p-ERK1/2)-substrate binding to occur, which either attracts substrates 
surrounding the kinases or ensures the correct orientation of substrates in the kinase active site 
(Ubersax and Ferrell, 2007). Since our data demonstrated that Gab2 only interacts with 
activated ERK1/2 (p-ERK1/2) rather than the inactivated form, we reasonably thought that 
Gab2 association with p-ERK1/2 is modulated by hydrophobic contact. Although we lack the 
crystal structure support of Gab2, several lines of evidence suggest that the identified Gab2 
D-domain forms a hydrophobic bond with activated ERK1/2. Firstly, in our 
co-immunoprecipitation assays, both ERK1/2 activity and ERK1/2 CD-domain are crucial for 
Gab2-ERK1/2 association, raising the possibility of physical interaction of ERK and Gab2 in 
cells (Chapter 3, Figure 3.3D and 3.4A). Secondly, mutation of each positively charged amino 
acid and hydrophobic amino acids to alanine residues within the Gab2 D-domain disrupts 
Gab2-ERK1/2 interaction (Chapter 3, Figure 3.4C), which is accompanied with a significant 
reduction of Gab2 phosphorylation. This result implicates that Gab2 directly interacts with 
ERK1/2 in cells. Most importantly, among these residues, mutation of the hydrophobic amino 
acids L517 and L519 have the greatest impact on ERK1/2 association, indicating an essential 
role for the L-X-L motif in Gab2. Indeed, the same crucial function of L-X-L has been 
characterized in the transcription factor Ets-1, in which a ERK1/2 docking site is also located 
on the C-terminus and regulates Ets-1 transcription activity (Seidel and Graves, 2002). 
Although Gab1 is relatively similar to Gab2, we were not able to observe Gab1-ERK1/2 
interaction upon the activation of the MAPK pathway, indicating the specificity action of 
ERK1/2 on Gab2 (Chapter, Figure 3.3F). This result is controversial with a previous report 
that Gab1, rather than Gab2, associated with activated ERK2 (Roshan et al., 1999). It was 
shown that Gab1 associated with ERK2 via its Met-binding domain (MBD), which 
interestingly contains part of the identified ERK1/2-docking domain. The reasons for these 
discrepancies are likely due to the respective assays, because we mostly monitored 
protein-protein interaction under physical conditions, rather than GST-pull downs using only 
MBD in Gab1 or the corresponding sequence in Gab2 as a bait protein. 
    4.2.2 Potential functions of ERK1/2-dependent phosphorylation sites in Gab2  
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Another outstanding question that arises from our work is the identification of potential 
ERK-phosphorylation sites in Gab2. To date, we cannot rule out which phosphorylation site in 
Gab2 is dependent on ERK1/2 interaction. Although several reports indicated that there are 
numerous proline-directed phospho-Ser/Thr sites in Gab2, including S143, S469, S532, S612, 
S614 (Arnaud et al., 2004; Halbach et al., 2013), no systematic analysis was performed to 
fully characterize the exact functions of these phosphorylation sites. Our work shows that 
ERK1/2 phosphorylate Gab2 on these five Ser/Thr-Pro residues both in vitro and in cells. A 
previous report showed that phosphorylation of Gab2 on Ser623 (Ser612 is the homologous site 
in mouse Gab2) by ERK1/2 inhibited Shp2 recruitment (Arnaud et al., 2004). We did not 
observe that Gab2 phosphorylation on Ser143/469/532/612/614 had any effect on Shp2 
recruitment in HEK293 cells. However, our previous report showed that phosphorylated Gab2 
by RSK impeded Shp2 association (Zhang et al., 2013). Given that RSK is regulated by 
ERK1/2, it raises the possibility that the previous observation of ERK1/2-modulated Shp2 
recruitment is due to RSK. Most notably, among these five phosphorylation sites, S469 in 
Gab2 is located adjacent to one of the p85 binding sites (465YXXM468). To date, three tyrosine 
phosphorylation sites in Gab2 responsible for p85 recruitment have been established, 
including Tyr452, Tyr476 and Tyr584 (Crouin et al., 2001). Unlike Shp2 which preferentially 
associates with tyrosine residue 614 in Gab2 rather than tyrosine 643 (it is the same case in 
Gab1) (Rocchi et al., 1998; Crouin et al., 2001), all three tyrosine residues responsible for p85 
binding have been confirmed to function equally (Crouin et al., 2001). Moreover, Yu et al. 
found that ERK1/2 negatively regulated the p85 subunit of PI3K interaction with Gab1 upon 
EGF stimulation (Yu et al., 2002). Although they did not characterize any ERK1/2-dependent 
phosphorylation sites in Gab1 involved in limiting p85 association, this result still raises the 
possibility that ERK1/2 affect p85-Gab1 interaction through certain pS/T-P sites. Based on 
these statements, we assume that phosphorylation of Gab2 by ERK1/2 on certain sites, likely 
S469, induces a conformational change in Gab that reduces its affinity for p85. Alternatively, 
Gab2 phosphorylation by ERK1/2 provokes steric hindrance for the recruitment of p85.  
        Is p85 a negative or positive regulator in the PI3K/Akt pathway? 
A critical question we next sought to answer was how the feedback regulation of Gab2 
mediated by ERK1/2 affected the activity of downstream effector proteins. Our results 
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indicate that Gab2 phosphorylation by ERK1/2 limits p85 recruitment. p85 is a regulatory 
subunit of PI3K and constitutively binds to the PI3K catalytic subunit p110, leading to 
increased PIP3 levels and Akt activation. However, accumulating evidence suggest that p85 
should be considered carefully when analyzing the activity of Akt induced by PI3K. p85 
appears to have dual functions in the activation of the catalytic subunit p110 of PI3K: (1) 
Stabilization of p110; (2) Inhibition of p110 lipid kinase activity (Yu et al., 1998). Aside from 
having this dual function in regulating p110 activity, p85 also directly binds to the tumor 
suppressor PTEN and negatively regulates PIP3 lipid products, raising the possibility that 
more p85 recruitment to the Gab2 S5A mutant may in fact lead to a dysregulation of the 
balance action between the reciprocal actions of PTEN and p110 (Chagpar et al., 2010). 
Moreover, it was shown that p85 acts as a negative regulator of the insulin-induced signaling 
cascade. In p85 knockout (p85-/-) mice, Akt activity was found to be significantly increased in 
the presence of insulin, suggesting that cells depleted of p85 are more sensitive to insulin 
treatment (Terauchi et al., 1999). Furthermore, Luo et al. found that p85 restricted 
insulin-induced signal transduction by associating with IRS1, resulting in sequestered p110 
from potential p85/p110 complexes (Luo et al., 2005). In addition, a recent study indicated 
that localization of p85 at the plasma membrane, rather than its expression level, is crucial for 
PI3K activity (Chiu et al., 2014). Given the complexity of p85-mediated signal transduction, 
the measurement of PI3K activity by ELISA (enzyme-linked immunosorbent assay) in the 
Gab2 S5A mutant will be helpful in understanding the role of ERK1/2 in regulating Gab2 
function. To address this, the PI3-kinase will be purified from cells by the 
immunoprecipitation method and further react with PI(4,5)P2 substrate. After completing the 
PI3-Kinase reaction, the PI(3,4,5)P3 product will be detected by ELISA as described in the 
protocol of PI3-Kinase Activity ELISA: Pico. 
One possible effect of ERK1/2 on Gab2 function is to alter its PH domain-mediated 
localization at the plasma membrane. Ser532, which was identified by our group as an ERK1/2 
phosphorylation site in Gab2, was also characterized as an ERK1/2-modulated 
phosphorylation site in Gab1 (Ser551 in mouse Gab1). Most intriguingly, Eulenfeld et al. found 
that ERK1/2 phosphorylation of Gab1 on Ser551 was required for Gab1 residency at the 
plasma membrane, where Gab1-mediated protein interactions is initiated (Eulenfeld and 
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Schaper, 2009). Given the relatively high homology between Gab1 and Gab2, these findings 
raise the possibility that ERK1/2 may have the same effect on Gab2 PH-domain localization 
to the plasma membrane, leading to altered downstream effector activities. Nevertheless, 
future work will be required to identify the exact mechanisms by which ERK1/2 regulate 
Gab2 function, either through p85 recruitment or PH domain-mediated localization.  
4.3 Other potential mechanisms of Gab2-mediated cell motility  
While the involvement of Gab2 in cell motility has been characterized, the molecular 
mechanisms underlying this process still remain elusive. Our work has showed that increased 
ERK1/2 activity induced by an unphosphorylatable Gab2 S3A (S160/211/620A) mutant 
promoted MCF-10A cell motility. Aside from classical Gab2 downstream effectors, such as 
ERK1/2, which have been shown to play important roles in cell migration, others, such as 
members of the Rho family were also reported to play a role downstream of Gab2 (Herrera 
Abreu et al., 2010). Hence, other potential mechanisms regarding how Gab2 promotes cell 
migration should be considered. At this point in time, identifying whether phosphorylated 
Gab2 by ERK1/2 participates in the activation of small Rho GTPases would be helpful to 
address this question. It has been shown that Gab2 directly binds to GC-GAP, a novel Rho 
family GTPases-activating protein which decreases Rac1 and Cdc42 activity (Zhao et al., 
2003). Given that Rac1 and Cdc42 modulate cytoskeletal reorganization and also filopodia 
and lamellipodia formation, this finding raises the possibility that ERK1/2-mediated 
phosphorylation of Gab2 may affect GC-GAP recruitment, leading to altered cell motility. 
Another possibility is that phosphorylation of Gab2 by ERK1/2 may regulate RhoA activity. 
This hypothesis is supported by a previous report that Gab2 negatively regulates RhoA 
activity resulting in enhanced cell migration and motility (Brummer et al., 2008). Moreover, 
Gab2-induced cell motility may also involve the engagement of actin-nucleating protein 
N-WASP. It has been shown that Gab1 directly binds to WASP and enhances dorsal ruffle 
formation in MDCK cells (Abella et al., 2010). Most notably, the Park group found that 
disruption of the Gab1-Shp2 interaction had no effect on dorsal ruffle formation, indicating 
that Gab1 modulates actin reorganization independently of the classical Gab1-Shp2-ERK1/2 
cascade. Given the high similarity between Gab1 and Gab2 topology, it is probable that 
ERK1/2 may affect the ability of Gab2 to induce actin reorganization via N-WASP. More 
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work will be required to fully understand the exact mechanisms by which Gab2 promotes cell 
motility.    
4.4 Deciphering the role of the MAPK pathway in the regulation of 
Gab2-dependent function 
In this thesis, I systematically analyzed the feedback regulation of Gab2-dependent 
signaling by the MAPK pathway. Upon RTK activation, Gab2 becomes tyrosine 
phosphorylated and mediates the recruitment of different binding proteins, such as Shp2 and 
p85, which are involved in the amplification of downstream pathways. In addition, our data 
indicate that Gab2 is a substrate of the MAPK pathway. Indeed, our results suggest that 
post-translational modification of Gab2 occurs in both ERK1/2- and RSK-dependent manners. 
We suggest that while ERK1/2 associate and phosphorylate Gab2, and thereby decrease p85 
recruitment, RSK negatively regulates MAPK signaling by restricting Shp2 recruitment.  
Given that hyperactive RSK signaling has been implicated in a number of human cancers, 
including breast cancer and melanoma, it raises the possibility that RSK could be a potential 
therapeutic target for these cancers, which have inappropriate activation of the MAPK 
pathway. To address this question, in 2005, the Lannigan group developed the first 
RSK-specific inhibitor, SL0101 (Smith et al., 2005). Furthermore, they found that this 
inhibitor selectively suppresses breast cancer cell growth (MCF-7 cells) rather than normal 
breast epithelial cells (MCF-10A cells) (Smith et al., 2005). Based on these statements, it 
appears that administering RSK inhibitors to patients may be a potential powerful approach to 
treat cancers. However, some studies show that RSK inhibitors should be used with caution 
because they may upregulate ERK1/2 activity. One piece of evidence is that inhibition of RSK 
activity by pharmacological inhibitors upregulates ERK1/2 activity in certain types of cells 
(Saha et al., 2012). Consistent with this result, it was found that ERK1/2 activity is increased 
in skeletal muscle tissue of RSK2 knockout mice (Dufresne et al., 2001). To date, several 
possible molecular mechanisms have been characterized to explain this negative feedback 
regulation of MAPK signaling by RSK. In 2012, collaboration between the Ballif group and 
our group indicated that RSK phosphorylates the Ras-GEF SOS1, leading to Grb2 
dissociation and thereby preventing ERK1/2 activity (Saha et al., 2012). Moreover, my work 
suggests an alternative mechanism whereby RSK negatively regulates ERK1/2 activity by 
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restricting Gab2 functions. Since RSK negatively regulates ERK1/2 activity, it raises the 
possibility that RSK inhibitors may lead to cancer development by increasing ERK1/2 
signaling. In this regard, drug combinations consisting of RSK and ERK1/2 inhibitors may be 
an effective cancer-targeted therapy. This proposal is reminiscent a clinical treatment for 
PTEN-deficient glioblastoma patients with both the mTORC1 and PI3K pathway inhibitors 
(Cloughesy et al., 2008). Taken together, our findings expand the repertoire of actions 
mediated by Gab2, and also highlight the development of novel therapeutic approaches for 
cancer treatments.  
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Chapter 5 Conclusions and Perspectives 
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Gab2 has been characterized as a potential oncogene in breast cancer. Tyrosine 
phosphorylation of Gab2 by RTKs plays a crucial role in signal transduction from the receptor 
to the Ras/MAPK and PI3K/Akt pathways, leading to cell proliferation, migration and 
invasion. Interestingly, Gab2 is also found to be phosphorylated on Ser/Thr residues, but less 
is known about this post-translational modification. In this context, our work led to a better 
understanding of the mechanisms by which Gab2 is regulated by the MAPK pathway, which 
may help us in the design of novel therapeutic approaches for breast cancer.  
The most fascinating finding arising from our work is the demonstration that the MAPK 
pathway plays a dual role in the regulation of Gab2 function. On the one hand, we found for 
the first time that Gab2 is a novel substrate of RSK. Gab2 phosphorylation by RSK restricts 
Shp2 recruitment and downregulates ERK1/2 activity. Using live-cell-imaging wound-healing 
assays with in intro cellular model, we have investigated the impact of RSK on 
Gab2-mediated biological functions. Our findings helped characterize a novel negative 
feedback loop, whereby RSK through Gab2 negatively regulates MAPK signaling, leading to 
decreased cell motility. Given the widespread role of RTKs in signal transduction, our work 
also suggests that RSK may play a regulatory function in diverse receptor systems. On the 
other hand, we determined a novel ERK1/2 docking domain in Gab2. This observation 
provides us with a more detailed understanding of how ERK1/2 regulate Gab2 function at the 
molecular level. Our study of the effect of the MAPK pathway on Gab2 allows us to show 
that phosphorylation of Gab2 by ERK1/2 inhibits p85 recruitment. Given the complex 
functions of p85 in the regulation of PI3K/Akt signaling, future studies are required to fully 
characterize whether phosphorylated Gab2 by ERK1/2 results in altered Akt activity as well 
as other possible downstream effectors, such as RhoA and Rac. Lastly, given that Gab2 is 
known to participate in HER2-mediated tumorigenesis, our results also suggest that 
phosphorylated Gab2 by ERK1/2 may affect its ability to collaborate with HER2 in breast 
cancer development, but more experiments will be required to directly address this.  
    Our study has important clinical implications because RSK has been established as a 
major effector of the Ras/MAPK pathway and is constitutively activated in a large number of 
human tumors. For this reason, RSK may be a potential therapeutic target in cancer treatment 
(Romeo et al., 2012). However, based on our observations, we suggest that RSK inhibitors 
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should be used in with caution because RSK negatively regulates MAPK signaling through by 
modulating upstream inducers of Ras, such as SOS and Gab2 (Saha et al., 2012; Zhang et al., 
2013). Given that RSK inhibitors may thus promote the hyperactivation of ERK1/2, it is 
possible that co-treatment using ERK1/2 and RSK inhibitors in cancer may be more effective 
than either of them alone.  
Finally, given accumulating evidence showing that Gab2 is the key molecule in cancer, 
understanding how Gab2 is regulated at the molecular level will help us define its role in 
certain biological contexts. Based on our data, we show a more complete mechanistic 
illustration of Gab2 regulation by the MAPK pathway, which will allow us to control cancer 
progression in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 156 
 
Bibliography 
Abe, M. K., K. T. Kahle, et al. (2001). "ERK7 is an autoactivated member of the MAPK 
family." J Biol Chem 276(24): 21272-9. 
Abella, J. V., R. Vaillancourt, et al. (2010). "The Gab1 scaffold regulates RTK-dependent 
dorsal ruffle formation through the adaptor Nck." J Cell Sci 123(Pt 8): 1306-19. 
Abraham, D., K. Podar, et al. (2000). "Raf-1-associated protein phosphatase 2A as a positive 
regulator of kinase activation." J Biol Chem 275(29): 22300-4. 
Acharyya, S., T. Oskarsson, et al. (2012). "A CXCL1 paracrine network links cancer 
chemoresistance and metastasis." Cell 150(1): 165-78. 
Adelaide, J., G. Monges, et al. (1995). "Oesophageal cancer and amplification of the human 
cyclin D gene CCND1/PRAD1." Br J Cancer 71(1): 64-8. 
Agazie, Y. M. and M. J. Hayman (2003). "Molecular mechanism for a role of SHP2 in 
epidermal growth factor receptor signaling." Mol Cell Biol 23(21): 7875-86. 
Alexandropoulos, K., G. Cheng, et al. (1995). "Proline-rich sequences that bind to Src 
homology 3 domains with individual specificities." Proc Natl Acad Sci U S A 92(8): 
3110-4. 
Allen, L. F., J. Sebolt-Leopold, et al. (2003). "CI-1040 (PD184352), a targeted signal 
transduction inhibitor of MEK (MAPKK)." Semin Oncol 30(5 Suppl 16): 105-16. 
Alonso, M., M. Melani, et al. (2004). "Mitochondrial extracellular signal-regulated kinases 
1/2 (ERK1/2) are modulated during brain development." J Neurochem 89(1): 248-56. 
Anjum, R., P. P. Roux, et al. (2005). "The tumor suppressor DAP kinase is a target of 
RSK-mediated survival signaling." Curr Biol 15(19): 1762-7. 
Appel, S. and K. G. Morgan (2010). "Scaffolding proteins and non-proliferative functions of 
ERK1/2." Commun Integr Biol 3(4): 354-6. 
Appelmann, I., R. Liersch, et al. (2009). "Angiogenesis inhibition in cancer therapy: 
platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) 
 157 
 
and their receptors: biological functions and role in malignancy." Recent Results Cancer 
Res 180: 51-81. 
Arencibia, J. M., D. Pastor-Flores, et al. (2013). "AGC protein kinases: from structural 
mechanism of regulation to allosteric drug development for the treatment of human 
diseases." Biochim Biophys Acta 1834(7): 1302-21. 
Arnaud, M., C. Crouin, et al. (2004). "Phosphorylation of Grb2-associated binder 2 on serine 
623 by ERK MAPK regulates its association with the phosphatase SHP-2 and decreases 
STAT5 activation." J Immunol 173(6): 3962-71. 
Aronchik, I., B. A. Appleton, et al. (2014). "Novel Potent and Selective Inhibitors of p90 
Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK Driven 
Cancers." Mol Cancer Res. 
Arthur, J. S. and P. Cohen (2000). "MSK1 is required for CREB phosphorylation in response 
to mitogens in mouse embryonic stem cells." FEBS Lett 482(1-2): 44-8. 
Babu, G. J., M. J. Lalli, et al. (2000). "Phosphorylation of elk-1 by MEK/ERK pathway is 
necessary for c-fos gene activation during cardiac myocyte hypertrophy." J Mol Cell 
Cardiol 32(8): 1447-57. 
Badve, S., D. J. Dabbs, et al. (2010). "Basal-like and triple-negative breast cancers: a critical 
review with an emphasis on the implications for pathologists and oncologists." Mod 
Pathol 24(2): 157-67. 
Batzer, A. G., P. Blaikie, et al. (1995). "The phosphotyrosine interaction domain of Shc binds 
an LXNPXY motif on the epidermal growth factor receptor." Mol Cell Biol 15(8): 
4403-9. 
Bayascas, J. R., S. Wullschleger, et al. (2008). "Mutation of the PDK1 PH domain inhibits 
protein kinase B/Akt, leading to small size and insulin resistance." Mol Cell Biol 28(10): 
3258-72. 
Bennett, H. L., T. Brummer, et al. (2008). "Gab2 and Src co-operate in human mammary 
epithelial cells to promote growth factor independence and disruption of acinar 
 158 
 
morphogenesis." Oncogene 27(19): 2693-704. 
Bentires-Alj, M., S. G. Gil, et al. (2006). "A role for the scaffolding adapter GAB2 in breast 
cancer." Nat Med 12(1): 114-21. 
Bignone, P. A., K. Y. Lee, et al. (2007). "RPS6KA2, a putative tumour suppressor gene at 
6q27 in sporadic epithelial ovarian cancer." Oncogene 26(5): 683-700. 
Bocanegra, M., A. Bergamaschi, et al. (2009). "Focal amplification and oncogene dependency 
of GAB2 in breast cancer." Oncogene 29(5): 774-9. 
Bolos, V., H. Peinado, et al. (2003). "The transcription factor Slug represses E-cadherin 
expression and induces epithelial to mesenchymal transitions: a comparison with Snail 
and E47 repressors." J Cell Sci 116(Pt 3): 499-511. 
Bone, H. and M. J. Welham (2000). "Shc associates with the IL-3 receptor beta subunit, SHIP 
and Gab2 following IL-3 stimulation. Contribution of Shc PTB and SH2 domains." Cell 
Signal 12(3): 183-94. 
Boulton, T. G., J. S. Gregory, et al. (1991). "Purification and properties of extracellular 
signal-regulated kinase 1, an insulin-stimulated microtubule-associated protein 2 kinase." 
Biochemistry 30(1): 278-86. 
Boulton, T. G., S. H. Nye, et al. (1991). "ERKs: a family of protein-serine/threonine kinases 
that are activated and tyrosine phosphorylated in response to insulin and NGF." Cell 
65(4): 663-75. 
Boulton, T. G., G. D. Yancopoulos, et al. (1990). "An insulin-stimulated protein kinase 
similar to yeast kinases involved in cell cycle control." Science 249(4964): 64-7. 
Breitschopf, K., J. Haendeler, et al. (2000). "Posttranslational modification of Bcl-2 facilitates 
its proteasome-dependent degradation: molecular characterization of the involved 
signaling pathway." Mol Cell Biol 20(5): 1886-96. 
Bridges, D. and G. B. Moorhead (2005). "14-3-3 proteins: a number of functions for a 
numbered protein." Sci STKE 2005(296): re10. 
Brose, M. S., P. Volpe, et al. (2002). "BRAF and RAS mutations in human lung cancer and 
 159 
 
melanoma." Cancer Res 62(23): 6997-7000. 
Brown, L. A., S. E. Kalloger, et al. (2008). "Amplification of 11q13 in ovarian carcinoma." 
Genes Chromosomes Cancer 47(6): 481-9. 
Brummer, T., M. Larance, et al. (2008). "Phosphorylation-dependent binding of 14-3-3 
terminates signalling by the Gab2 docking protein." EMBO J 27(17): 2305-16. 
Brummer, T., H. Naegele, et al. (2003). "Identification of novel ERK-mediated feedback 
phosphorylation sites at the C-terminus of B-Raf." Oncogene 22(55): 8823-34. 
Brummer, T., D. Schramek, et al. (2006). "Increased proliferation and altered growth factor 
dependence of human mammary epithelial cells overexpressing the Gab2 docking 
protein." J Biol Chem 281(1): 626-37. 
Brunet, A., D. Roux, et al. (1999). "Nuclear translocation of p42/p44 mitogen-activated 
protein kinase is required for growth factor-induced gene expression and cell cycle 
entry." EMBO J 18(3): 664-74. 
Bruning, J. C., J. A. Gillette, et al. (2000). "Ribosomal subunit kinase-2 is required for growth 
factor-stimulated transcription of the c-Fos gene." Proc Natl Acad Sci U S A 97(6): 
2462-7. 
Buck, M. and M. Chojkier (2007). "C/EBPbeta associates with caspase 8 complex proteins 
and modulates apoptosis in hepatic stellate cells." J Clin Gastroenterol 41 Suppl 3: 
S295-9. 
Burkhard, K. A., F. Chen, et al. (2010). "Quantitative analysis of ERK2 interactions with 
substrate proteins: roles for kinase docking domains and activity in determining binding 
affinity." J Biol Chem 286(4): 2477-85. 
Burkhard, S. J. and J. A. Traugh (1983). "Changes in ribosome function by cAMP-dependent 
and cAMP-independent phosphorylation of ribosomal protein S6." J Biol Chem 258(22): 
14003-8. 
Camps, M., A. Nichols, et al. (1998). "Catalytic activation of the phosphatase MKP-3 by 
ERK2 mitogen-activated protein kinase." Science 280(5367): 1262-5. 
 160 
 
Cano, A., M. A. Perez-Moreno, et al. (2000). "The transcription factor snail controls 
epithelial-mesenchymal transitions by repressing E-cadherin expression." Nat Cell Biol 
2(2): 76-83. 
Carey, L. A., C. M. Perou, et al. (2006). "Race, breast cancer subtypes, and survival in the 
Carolina Breast Cancer Study." JAMA 295(21): 2492-502. 
Cargnello, M. and P. P. Roux (2011). "Activation and function of the MAPKs and their 
substrates, the MAPK-activated protein kinases." Microbiol Mol Biol Rev 75(1): 50-83. 
Carracedo, A., L. Ma, et al. (2008). "Inhibition of mTORC1 leads to MAPK pathway 
activation through a PI3K-dependent feedback loop in human cancer." J Clin Invest 
118(9): 3065-74. 
Carriere, A., M. Cargnello, et al. (2008). "Oncogenic MAPK signaling stimulates mTORC1 
activity by promoting RSK-mediated raptor phosphorylation." Curr Biol 18(17): 
1269-77. 
Carriere, A., Y. Romeo, et al. (2010). "ERK1/2 phosphorylate Raptor to promote 
Ras-dependent activation of mTOR complex 1 (mTORC1)." J Biol Chem 286(1): 
567-77. 
Chagpar, R. B., P. H. Links, et al. (2010). "Direct positive regulation of PTEN by the p85 
subunit of phosphatidylinositol 3-kinase." Proc Natl Acad Sci U S A 107(12): 5471-6. 
Chatterjee, S., L. C. Heukamp, et al. (2013). "Tumor VEGF:VEGFR2 autocrine feed-forward 
loop triggers angiogenesis in lung cancer." J Clin Invest 123(4): 1732-40. 
Chen, B., C. Tardell, et al. (2012). "BRAFV600E negatively regulates the AKT pathway in 
melanoma cell lines." PLoS One 7(8): e42598. 
Chen, R. H., C. Abate, et al. (1993). "Phosphorylation of the c-Fos transrepression domain by 
mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase." Proc Natl Acad Sci 
U S A 90(23): 10952-6. 
Chen, R. H., S. Corbalan-Garcia, et al. (1997). "The role of the PH domain in the 
signal-dependent membrane targeting of Sos." EMBO J 16(6): 1351-9. 
 161 
 
Chen, R. H., C. Sarnecki, et al. (1992). "Nuclear localization and regulation of erk- and 
rsk-encoded protein kinases." Mol Cell Biol 12(3): 915-27. 
Cheung, M., A. Sharma, et al. (2008). "Akt3 and mutant V600E B-Raf cooperate to promote 
early melanoma development." Cancer Res 68(9): 3429-39. 
Chiu, Y. H., J. Y. Lee, et al. (2014). "BRD7, a Tumor Suppressor, Interacts with p85alpha and 
Regulates PI3K Activity." Mol Cell 54(1): 193-202. 
Chong, H., H. G. Vikis, et al. (2003). "Mechanisms of regulating the Raf kinase family." Cell 
Signal 15(5): 463-9. 
Chu, C. T., D. J. Levinthal, et al. (2004). "Oxidative neuronal injury. The dark side of 
ERK1/2." Eur J Biochem 271(11): 2060-6. 
Chu, S., L. Li, et al. (2007). "BCR-tyrosine 177 plays an essential role in Ras and Akt 
activation and in human hematopoietic progenitor transformation in chronic 
myelogenous leukemia." Cancer Res 67(14): 7045-53. 
Chuderland, D., A. Konson, et al. (2008). "Identification and characterization of a general 
nuclear translocation signal in signaling proteins." Mol Cell 31(6): 850-61. 
Chung, J., R. H. Chen, et al. (1991). "Coordinate regulation of pp90rsk and a distinct 
protein-serine/threonine kinase activity that phosphorylates recombinant pp90rsk in 
vitro." Mol Cell Biol 11(4): 1868-74. 
Cloughesy, T. F., K. Yoshimoto, et al. (2008). "Antitumor activity of rapamycin in a Phase I 
trial for patients with recurrent PTEN-deficient glioblastoma." PLoS Med 5(1): e8. 
Cohen-Armon, M. (2007). "PARP-1 activation in the ERK signaling pathway." Trends 
Pharmacol Sci 28(11): 556-60. 
Cohen, M. S., C. Zhang, et al. (2005). "Structural bioinformatics-based design of selective, 
irreversible kinase inhibitors." Science 308(5726): 1318-21. 
Colanzi, A. and D. Corda (2007). "Mitosis controls the Golgi and the Golgi controls mitosis." 
Curr Opin Cell Biol 19(4): 386-93. 
 162 
 
Conway, A. M., S. Rakhit, et al. (1999). "Platelet-derived-growth-factor stimulation of the 
p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of 
pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 
3-kinase." Biochem J 337 ( Pt 2): 171-7. 
Crouin, C., M. Arnaud, et al. (2001). "A yeast two-hybrid study of human p97/Gab2 
interactions with its SH2 domain-containing binding partners." FEBS Lett 495(3): 
148-53. 
Crozier, J. A., A. Swaika, et al. (2014). "Adjuvant chemotherapy in breast cancer: To use or 
not to use, the anthracyclines." World J Clin Oncol 5(3): 529-38. 
Cush, J. J., J. B. Splawski, et al. (1995). "Elevated interleukin-10 levels in patients with 
rheumatoid arthritis." Arthritis Rheum 38(1): 96-104. 
Dance, M., A. Montagner, et al. (2008). "The molecular functions of Shp2 in the 
Ras/Mitogen-activated protein kinase (ERK1/2) pathway." Cell Signal 20(3): 453-9. 
Datta, S. R., H. Dudek, et al. (1997). "Akt phosphorylation of BAD couples survival signals 
to the cell-intrinsic death machinery." Cell 91(2): 231-41. 
De Cesare, D., S. Jacquot, et al. (1998). "Rsk-2 activity is necessary for epidermal growth 
factor-induced phosphorylation of CREB protein and transcription of c-fos gene." Proc 
Natl Acad Sci U S A 95(21): 12202-7. 
De Luca, A., M. R. Maiello, et al. (2012). "The RAS/RAF/MEK/ERK and the PI3K/AKT 
signalling pathways: role in cancer pathogenesis and implications for therapeutic 
approaches." Expert Opin Ther Targets 16 Suppl 2: S17-27. 
De Mesquita, D. D., Q. Zhan, et al. (2001). "p90-RSK and Akt may promote rapid 
phosphorylation/inactivation of glycogen synthase kinase 3 in 
chemoattractant-stimulated neutrophils." FEBS Lett 502(3): 84-8. 
Delcourt, N., J. Bockaert, et al. (2007). "GPCR-jacking: from a new route in RTK signalling 
to a new concept in GPCR activation." Trends Pharmacol Sci 28(12): 602-7. 
Deleris, P., M. Trost, et al. (2010). "Activation loop phosphorylation of ERK3/ERK4 by 
 163 
 
group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated 
protein kinase 5 signaling pathway." J Biol Chem 286(8): 6470-8. 
Deschenes-Simard, X., F. Kottakis, et al. (2014). "ERKs in cancer: friends or foes?" Cancer 
Res 74(2): 412-9. 
Ding, J., J. Romani, et al. (2013). "Inhibition of PI3K/mTOR overcomes nilotinib resistance 
in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2." 
PLoS One 8(12): e83510. 
Doehn, U., C. Hauge, et al. (2009). "RSK is a principal effector of the RAS-ERK pathway for 
eliciting a coordinate promotile/invasive gene program and phenotype in epithelial 
cells." Mol Cell 35(4): 511-22. 
Dong, C., S. B. Waters, et al. (1996). "SOS phosphorylation and disassociation of the 
Grb2-SOS complex by the ERK and JNK signaling pathways." J Biol Chem 271(11): 
6328-32. 
Dong, Z., R. Kumar, et al. (1997). "Macrophage-derived metalloelastase is responsible for the 
generation of angiostatin in Lewis lung carcinoma." Cell 88(6): 801-10. 
Doppler, H. and P. Storz (2014). "Regulation of VASP by phosphorylation: consequences for 
cell migration." Cell Adh Migr 7(6): 482-6. 
Doyon, P. and M. J. Servant (2010). "Tumor necrosis factor receptor-associated factor-6 and 
ribosomal S6 kinase intracellular pathways link the angiotensin II AT1 receptor to the 
phosphorylation and activation of the IkappaB kinase complex in vascular smooth 
muscle cells." J Biol Chem 285(40): 30708-18. 
Draber, P., V. Sulimenko, et al. (2012). "Cytoskeleton in mast cell signaling." Front Immunol 
3: 130. 
Dufresne, S. D., C. Bjorbaek, et al. (2001). "Altered extracellular signal-regulated kinase 
signaling and glycogen metabolism in skeletal muscle from p90 ribosomal S6 kinase 2 
knockout mice." Mol Cell Biol 21(1): 81-7. 
Dumaz, N. and R. Marais (2003). "Protein kinase A blocks Raf-1 activity by stimulating 
 164 
 
14-3-3 binding and blocking Raf-1 interaction with Ras." J Biol Chem 278(32): 
29819-23. 
Dummler, B. A., C. Hauge, et al. (2005). "Functional characterization of human RSK4, a new 
90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types." J Biol 
Chem 280(14): 13304-14. 
Dunn, G. P., H. W. Cheung, et al. (2014). "In vivo multiplexed interrogation of amplified 
genes identifies GAB2 as an ovarian cancer oncogene." Proc Natl Acad Sci U S A 111(3): 
1102-7. 
Dunn, J. M., R. A. Phillips, et al. (1988). "Identification of germline and somatic mutations 
affecting the retinoblastoma gene." Science 241(4874): 1797-800. 
Elshamy, W. M. and R. J. Duhe (2013). "Overview: cellular plasticity, cancer stem cells and 
metastasis." Cancer Lett 341(1): 2-8. 
Erhardt, P., E. J. Schremser, et al. (1999). "B-Raf inhibits programmed cell death downstream 
of cytochrome c release from mitochondria by activating the MEK/Erk pathway." Mol 
Cell Biol 19(8): 5308-15. 
Erikson, E. and J. L. Maller (1985). "A protein kinase from Xenopus eggs specific for 
ribosomal protein S6." Proc Natl Acad Sci U S A 82(3): 742-6. 
Eulenfeld, R. and F. Schaper (2009). "A new mechanism for the regulation of Gab1 
recruitment to the plasma membrane." J Cell Sci 122(Pt 1): 55-64. 
Fang, X., S. Yu, et al. (1999). "Regulation of BAD phosphorylation at serine 112 by the 
Ras-mitogen-activated protein kinase pathway." Oncogene 18(48): 6635-40. 
Fanger, G. R., C. Widmann, et al. (1998). "14-3-3 proteins interact with specific MEK 
kinases." J Biol Chem 273(6): 3476-83. 
Fantz, D. A., D. Jacobs, et al. (2001). "Docking sites on substrate proteins direct extracellular 
signal-regulated kinase to phosphorylate specific residues." J Biol Chem 276(29): 
27256-65. 
Favata, M. F., K. Y. Horiuchi, et al. (1998). "Identification of a novel inhibitor of 
 165 
 
mitogen-activated protein kinase kinase." J Biol Chem 273(29): 18623-32. 
Fisher, T. L. and J. Blenis (1996). "Evidence for two catalytically active kinase domains in 
pp90rsk." Mol Cell Biol 16(3): 1212-9. 
Foley, J., N. K. Nickerson, et al. (2010). "EGFR signaling in breast cancer: bad to the bone." 
Semin Cell Dev Biol 21(9): 951-60. 
Forsythe, J. A., B. H. Jiang, et al. (1996). "Activation of vascular endothelial growth factor 
gene transcription by hypoxia-inducible factor 1." Mol Cell Biol 16(9): 4604-13. 
Foulkes, W. D. and A. Y. Shuen (2013). "In brief: BRCA1 and BRCA2." J Pathol 230(4): 
347-9. 
Franzoso, G., L. Carlson, et al. (1997). "Requirement for NF-kappaB in osteoclast and B-cell 
development." Genes Dev 11(24): 3482-96. 
Freeman, A. K. and D. K. Morrison (2011). "14-3-3 Proteins: diverse functions in cell 
proliferation and cancer progression." Semin Cell Dev Biol 22(7): 681-7. 
Frodin, M., C. J. Jensen, et al. (2000). "A phosphoserine-regulated docking site in the protein 
kinase RSK2 that recruits and activates PDK1." EMBO J 19(12): 2924-34. 
Fujita, N., S. Sato, et al. (2003). "Phosphorylation of p27Kip1 at threonine 198 by p90 
ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic 
localization." J Biol Chem 278(49): 49254-60. 
Futami, M., Q. S. Zhu, et al. (2011). "G-CSF receptor activation of the Src kinase Lyn is 
mediated by Gab2 recruitment of the Shp2 phosphatase." Blood 118(4): 1077-86. 
Galan, J. A., K. M. Geraghty, et al. (2014). "Phosphoproteomic analysis identifies the tumor 
suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3." Proc Natl Acad 
Sci U S A 111(29): E2918-27. 
Galanis, A., S. H. Yang, et al. (2001). "Selective targeting of MAPKs to the ETS domain 
transcription factor SAP-1." J Biol Chem 276(2): 965-73. 
Galli, S., O. Jahn, et al. (2009). "A new paradigm for MAPK: structural interactions of 
 166 
 
hERK1 with mitochondria in HeLa cells." PLoS One 4(10): e7541. 
Gannon, L. M., M. B. Cotter, et al. (2013). "The classification of invasive carcinoma of the 
breast." Expert Rev Anticancer Ther 13(8): 941-54. 
Gao, S. P., K. G. Mark, et al. (2007). "Mutations in the EGFR kinase domain mediate STAT3 
activation via IL-6 production in human lung adenocarcinomas." J Clin Invest 117(12): 
3846-56. 
Gao, T. and A. C. Newton (2002). "The turn motif is a phosphorylation switch that regulates 
the binding of Hsp70 to protein kinase C." J Biol Chem 277(35): 31585-92. 
Gavin, A. C. and A. R. Nebreda (1999). "A MAP kinase docking site is required for 
phosphorylation and activation of p90(rsk)/MAPKAP kinase-1." Curr Biol 9(5): 281-4. 
Ghosh, S., M. Basu, et al. (2012). "ETS-1 protein regulates vascular endothelial growth 
factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in 
human ovarian carcinoma cell line SKOV-3." J Biol Chem 287(18): 15001-15. 
Grady, W. M. (2005). "Transforming growth factor-beta, Smads, and cancer." Clin Cancer 
Res 11(9): 3151-4. 
Gressner, A. M. and I. G. Wool (1974). "The phosphorylation of liver ribosomal proteins in 
vivo. Evidence that only a single small subunit protein (S6) is phosphorylated." J Biol 
Chem 249(21): 6917-25. 
Gu, H., H. Maeda, et al. (2000). "New role for Shc in activation of the phosphatidylinositol 
3-kinase/Akt pathway." Mol Cell Biol 20(19): 7109-20. 
Gu, H. and B. G. Neel (2003). "The "Gab" in signal transduction." Trends Cell Biol 13(3): 
122-30. 
Gu, H., J. C. Pratt, et al. (1998). "Cloning of p97/Gab2, the major SHP2-binding protein in 
hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation." Mol 
Cell 2(6): 729-40. 
Gu, H., K. Saito, et al. (2001). "Essential role for Gab2 in the allergic response." Nature 
412(6843): 186-90. 
 167 
 
Guo, C. and A. J. Whitmarsh (2008). "The beta-arrestin-2 scaffold protein promotes c-Jun 
N-terminal kinase-3 activation by binding to its nonconserved N terminus." J Biol Chem 
283(23): 15903-11. 
Gupta, P. B., S. Mani, et al. (2005). "The evolving portrait of cancer metastasis." Cold Spring 
Harb Symp Quant Biol 70: 291-7. 
Gupta, S., A. R. Ramjaun, et al. (2007). "Binding of ras to phosphoinositide 3-kinase 
p110alpha is required for ras-driven tumorigenesis in mice." Cell 129(5): 957-68. 
Halbach, S., K. T. Rigbolt, et al. (2013). "Alterations of Gab2 signalling complexes in 
imatinib and dasatinib treated chronic myeloid leukaemia cells." Cell Commun Signal 
11(1): 30. 
Hanahan, D. and R. A. Weinberg (2011). "Hallmarks of cancer: the next generation." Cell 
144(5): 646-74. 
Hart, M., J. P. Concordet, et al. (1999). "The F-box protein beta-TrCP associates with 
phosphorylated beta-catenin and regulates its activity in the cell." Curr Biol 9(4): 207-10. 
Herbst, R., P. M. Carroll, et al. (1996). "Daughter of sevenless is a substrate of the 
phosphotyrosine phosphatase Corkscrew and functions during sevenless signaling." Cell 
85(6): 899-909. 
Herrera Abreu, M. T., W. E. Hughes, et al. (2010). "Gab2 regulates cytoskeletal organization 
and migration of mammary epithelial cells by modulating RhoA activation." Mol Biol 
Cell 22(1): 105-16. 
Hille, B. (1994). "Modulation of ion-channel function by G-protein-coupled receptors." 
Trends Neurosci 17(12): 531-6. 
Holgado-Madruga, M., D. R. Emlet, et al. (1996). "A Grb2-associated docking protein in 
EGF- and insulin-receptor signalling." Nature 379(6565): 560-4. 
Hollander, M. C., G. M. Blumenthal, et al. (2011). "PTEN loss in the continuum of common 
cancers, rare syndromes and mouse models." Nat Rev Cancer 11(4): 289-301. 
Hollestelle, A., F. Elstrodt, et al. (2007). "Phosphatidylinositol-3-OH kinase or RAS pathway 
 168 
 
mutations in human breast cancer cell lines." Mol Cancer Res 5(2): 195-201. 
Horst, B., S. K. Gruvberger-Saal, et al. (2009). "Gab2-mediated signaling promotes 
melanoma metastasis." Am J Pathol 174(4): 1524-33. 
Hu, P., B. Margolis, et al. (1992). "Interaction of phosphatidylinositol 3-kinase-associated p85 
with epidermal growth factor and platelet-derived growth factor receptors." Mol Cell 
Biol 12(3): 981-90. 
Hu, X., S. D. Chakravarty, et al. (2008). "Regulation of interferon and Toll-like receptor 
signaling during macrophage activation by opposing feedforward and feedback 
inhibition mechanisms." Immunol Rev 226: 41-56. 
Huang, C. K., L. Zhan, et al. (1997). "LSP1 is the major substrate for mitogen-activated 
protein kinase-activated protein kinase 2 in human neutrophils." J Biol Chem 272(1): 
17-9. 
Inoki, K., Y. Li, et al. (2002). "TSC2 is phosphorylated and inhibited by Akt and suppresses 
mTOR signalling." Nat Cell Biol 4(9): 648-57. 
Ishibe, S., D. Joly, et al. (2003). "Phosphorylation-dependent paxillin-ERK association 
mediates hepatocyte growth factor-stimulated epithelial morphogenesis." Mol Cell 12(5): 
1275-85. 
Ishitani, S., K. Inaba, et al. (2010). "Homodimerization of Nemo-like kinase is essential for 
activation and nuclear localization." Mol Biol Cell 22(2): 266-77. 
Itoh, M., Y. Yoshida, et al. (2000). "Role of Gab1 in heart, placenta, and skin development 
and growth factor- and cytokine-induced extracellular signal-regulated kinase 
mitogen-activated protein kinase activation." Mol Cell Biol 20(10): 3695-704. 
Itoh, S., F. Yoshitake, et al. (2007). "Gab2 plays distinct roles in bone homeostasis at different 
time points." J Bone Miner Metab 25(2): 81-5. 
Jacobs, D., G. J. Beitel, et al. (1998). "Gain-of-function mutations in the Caenorhabditis 
elegans lin-1 ETS gene identify a C-terminal regulatory domain phosphorylated by ERK 
MAP kinase." Genetics 149(4): 1809-22. 
 169 
 
Jadeski, L., J. M. Mataraza, et al. (2008). "IQGAP1 stimulates proliferation and enhances 
tumorigenesis of human breast epithelial cells." J Biol Chem 283(2): 1008-17. 
Jesch, S. A., T. S. Lewis, et al. (2001). "Mitotic phosphorylation of Golgi reassembly stacking 
protein 55 by mitogen-activated protein kinase ERK2." Mol Biol Cell 12(6): 1811-7. 
Jiang, X. and X. Wang (2004). "Cytochrome C-mediated apoptosis." Annu Rev Biochem 73: 
87-106. 
Jin, J., F. D. Smith, et al. (2004). "Proteomic, functional, and domain-based analysis of in 
vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular 
organization." Curr Biol 14(16): 1436-50. 
Johnson, N., V. Speirs, et al. (2008). "A comparative study of genome-wide SNP, CGH 
microarray and protein expression analysis to explore genotypic and phenotypic 
mechanisms of acquired antiestrogen resistance in breast cancer." Breast Cancer Res 
Treat 111(1): 55-63. 
Jones, S. W., E. Erikson, et al. (1988). "A Xenopus ribosomal protein S6 kinase has two 
apparent kinase domains that are each similar to distinct protein kinases." Proc Natl 
Acad Sci U S A 85(10): 3377-81. 
Jorissen, R. N., F. Walker, et al. (2003). "Epidermal growth factor receptor: mechanisms of 
activation and signalling." Exp Cell Res 284(1): 31-53. 
Kant, S., S. Schumacher, et al. (2006). "Characterization of the atypical MAPK ERK4 and its 
activation of the MAPK-activated protein kinase MK5." J Biol Chem 281(46): 35511-9. 
Kaur, S., G. Martin-Manso, et al. (2010). "Thrombospondin-1 inhibits VEGF receptor-2 
signaling by disrupting its association with CD47." J Biol Chem 285(50): 38923-32. 
Ke, Y., D. Wu, et al. (2007). "Role of Gab2 in mammary tumorigenesis and metastasis." 
Oncogene 26(34): 4951-60. 
Kesler, S. R., R. J. Simensen, et al. (2007). "Altered neurodevelopment associated with 
mutations of RSK2: a morphometric MRI study of Coffin-Lowry syndrome." 
Neurogenetics 8(2): 143-7. 
 170 
 
Kim, J., A. B. Parrish, et al. (2012). "Rsk-mediated phosphorylation and 14-3-3varepsilon 
binding of Apaf-1 suppresses cytochrome c-induced apoptosis." EMBO J 31(5): 
1279-92. 
Kim, M. J., J. Y. Ro, et al. (2006). "Clinicopathologic significance of the basal-like subtype of 
breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing 
phenotypes." Hum Pathol 37(9): 1217-26. 
King, F. W., J. Skeen, et al. (2004). "Inhibition of Chk1 by activated PKB/Akt." Cell Cycle 
3(5): 634-7. 
Kinkade, C. W., M. Castillo-Martin, et al. (2008). "Targeting AKT/mTOR and ERK MAPK 
signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model." J 
Clin Invest 118(9): 3051-64. 
Klemke, R. L., S. Cai, et al. (1997). "Regulation of cell motility by mitogen-activated protein 
kinase." J Cell Biol 137(2): 481-92. 
Kojima, Y., A. Acar, et al. (2010). "Autocrine TGF-beta and stromal cell-derived factor-1 
(SDF-1) signaling drives the evolution of tumor-promoting mammary stromal 
myofibroblasts." Proc Natl Acad Sci U S A 107(46): 20009-14. 
Komis, G., P. Illes, et al. (2011). "Microtubules and mitogen-activated protein kinase 
signalling." Curr Opin Plant Biol 14(6): 650-7. 
Kosako, H., N. Yamaguchi, et al. (2009). "Phosphoproteomics reveals new ERK MAP kinase 
targets and links ERK to nucleoporin-mediated nuclear transport." Nat Struct Mol Biol 
16(10): 1026-35. 
Kroczynska, B., S. Joshi, et al. (2010). "Regulatory effects of ribosomal S6 kinase 1 (RSK1) 
in IFNlambda signaling." J Biol Chem 286(2): 1147-56. 
Kurokawa, H., A. E. Lenferink, et al. (2000). "Inhibition of HER2/neu (erbB-2) and 
mitogen-activated protein kinases enhances tamoxifen action against 
HER2-overexpressing, tamoxifen-resistant breast cancer cells." Cancer Res 60(20): 
5887-94. 
 171 
 
Lau, M. T., W. K. So, et al. (2013). "Fibroblast growth factor 2 induces E-cadherin 
down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer 
cells." PLoS One 8(3): e59083. 
Lavoie, C., J. F. Mercier, et al. (2002). "Beta 1/beta 2-adrenergic receptor heterodimerization 
regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy." J Biol 
Chem 277(38): 35402-10. 
Lawler, P. R. and J. Lawler (2012). "Molecular basis for the regulation of angiogenesis by 
thrombospondin-1 and -2." Cold Spring Harb Perspect Med 2(5): a006627. 
Lawrence, M. C., A. Jivan, et al. (2008). "The roles of MAPKs in disease." Cell Res 18(4): 
436-42. 
Le Gallic, L., L. Virgilio, et al. (2004). "ERF nuclear shuttling, a continuous monitor of Erk 
activity that links it to cell cycle progression." Mol Cell Biol 24(3): 1206-18. 
Lee, H. H. and Z. F. Chang (2008). "Regulation of RhoA-dependent ROCKII activation by 
Shp2." J Cell Biol 181(6): 999-1012. 
Lee, S., M. Warthaka, et al. (2011). "A model of a MAPK*substrate complex in an active 
conformation: a computational and experimental approach." PLoS One 6(4): e18594. 
Lee, S. H., J. W. Lee, et al. (2003). "BRAF and KRAS mutations in stomach cancer." 
Oncogene 22(44): 6942-5. 
Lefloch, R., J. Pouyssegur, et al. (2008). "Single and combined silencing of ERK1 and ERK2 
reveals their positive contribution to growth signaling depending on their expression 
levels." Mol Cell Biol 28(1): 511-27. 
Lehr, S., J. Kotzka, et al. (2004). "Identification of major ERK-related phosphorylation sites 
in Gab1." Biochemistry 43(38): 12133-40. 
Lemmon, M. A. and J. Schlessinger (2010). "Cell signaling by receptor tyrosine kinases." Cell 
141(7): 1117-34. 
Leung, W. H. and S. Bolland (2007). "The inositol 5'-phosphatase SHIP-2 negatively 
regulates IgE-induced mast cell degranulation and cytokine production." J Immunol 
 172 
 
179(1): 95-102. 
Li, D., L. Jin, et al. (2013). "The prometastatic ribosomal S6 kinase 2-cAMP response 
element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding 
protein fascin-1 to promote tumor metastasis." J Biol Chem 288(45): 32528-38. 
Li, S., D. D. Hsu, et al. (2012). "Dual faces of SH2-containing protein-tyrosine phosphatase 
Shp2/PTPN11 in tumorigenesis." Front Med 6(3): 275-9. 
Li, S. G. and L. Li (2014). "Targeted therapy in HER2-positive breast cancer." Biomed Rep 
1(4): 499-505. 
Ling, H., M. Fabbri, et al. (2013). "MicroRNAs and other non-coding RNAs as targets for 
anticancer drug development." Nat Rev Drug Discov 12(11): 847-65. 
Liu, Y. and L. R. Rohrschneider (2002). "The gift of Gab." FEBS Lett 515(1-3): 1-7. 
Lopez-Vicente, L., G. Armengol, et al. (2009). "Regulation of replicative and stress-induced 
senescence by RSK4, which is down-regulated in human tumors." Clin Cancer Res 
15(14): 4546-53. 
Lorenzen, J. A., S. E. Baker, et al. (2001). "Nuclear import of activated D-ERK by DIM-7, an 
importin family member encoded by the gene moleskin." Development 128(8): 1403-14. 
Luo, J., S. J. Field, et al. (2005). "The p85 regulatory subunit of phosphoinositide 3-kinase 
down-regulates IRS-1 signaling via the formation of a sequestration complex." J Cell 
Biol 170(3): 455-64. 
Lynch, D. K. and R. J. Daly (2002). "PKB-mediated negative feedback tightly regulates 
mitogenic signalling via Gab2." EMBO J 21(1-2): 72-82. 
Ma, L., Z. Chen, et al. (2005). "Phosphorylation and functional inactivation of TSC2 by Erk 
implications for tuberous sclerosis and cancer pathogenesis." Cell 121(2): 179-93. 
Ma, Q., S. Guin, et al. (2011). "Ribosomal protein S6 kinase (RSK)-2 as a central effector 
molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition 
induced by macrophage-stimulating protein." Mol Cancer 10: 66. 
 173 
 
Mao, D., H. Epple, et al. (2006). "PLCgamma2 regulates osteoclastogenesis via its interaction 
with ITAM proteins and GAB2." J Clin Invest 116(11): 2869-79. 
Mao, Y. and A. W. Lee (2005). "A novel role for Gab2 in bFGF-mediated cell survival during 
retinoic acid-induced neuronal differentiation." J Cell Biol 170(2): 305-16. 
Margolis, B. and E. Y. Skolnik (1994). "Activation of Ras by receptor tyrosine kinases." J Am 
Soc Nephrol 5(6): 1288-99. 
Maroun, C. R., M. Holgado-Madruga, et al. (1999). "The Gab1 PH domain is required for 
localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis 
downstream from the met receptor tyrosine kinase." Mol Cell Biol 19(3): 1784-99. 
Matozaki, T., Y. Murata, et al. (2009). "Protein tyrosine phosphatase SHP-2: a 
proto-oncogene product that promotes Ras activation." Cancer Sci 100(10): 1786-93. 
Mehlen, P. and A. Puisieux (2006). "Metastasis: a question of life or death." Nat Rev Cancer 
6(6): 449-58. 
Mendoza, M. C., E. E. Er, et al. (2011). "The Ras-ERK and PI3K-mTOR pathways: cross-talk 
and compensation." Trends Biochem Sci 36(6): 320-8. 
Meng, J., B. Dai, et al. (2010). "Combination treatment with MEK and AKT inhibitors is 
more effective than each drug alone in human non-small cell lung cancer in vitro and in 
vivo." PLoS One 5(11): e14124. 
Menzies, A. M. and G. V. Long (2014). "Dabrafenib and Trametinib, alone and in 
combination for BRAF-mutant metastatic melanoma." Clin Cancer Res. 
Meyuhas, O. and A. Dreazen (2009). "Ribosomal protein S6 kinase from TOP mRNAs to cell 
size." Prog Mol Biol Transl Sci 90: 109-53. 
Mira, A., C. Isella, et al. (2009). "The GAB2 signaling scaffold promotes anchorage 
independence and drives a transcriptional response associated with metastatic 
progression of breast cancer." Oncogene 28(50): 4444-55. 
Moelling, K., K. Schad, et al. (2002). "Regulation of Raf-Akt Cross-talk." J Biol Chem 
277(34): 31099-106. 
 174 
 
Moller, D. E., C. H. Xia, et al. (1994). "Human rsk isoforms: cloning and characterization of 
tissue-specific expression." Am J Physiol 266(2 Pt 1): C351-9. 
Montagner, A., A. Yart, et al. (2005). "A novel role for Gab1 and SHP2 in epidermal growth 
factor-induced Ras activation." J Biol Chem 280(7): 5350-60. 
Murphy, L. O., S. Smith, et al. (2002). "Molecular interpretation of ERK signal duration by 
immediate early gene products." Nat Cell Biol 4(8): 556-64. 
Mustonen, M. V., S. Pyrhonen, et al. (2014). "Toremifene in the treatment of breast cancer." 
World J Clin Oncol 5(3): 393-405. 
Nakajima, T., A. Fukamizu, et al. (1996). "The signal-dependent coactivator CBP is a nuclear 
target for pp90RSK." Cell 86(3): 465-74. 
Nakaoka, Y. and I. Komuro (2013). "Gab docking proteins in cardiovascular disease, cancer, 
and inflammation." Int J Inflam 2013: 141068. 
Nam, H. J., S. Kim, et al. (2008). "The ERK-RSK1 activation by growth factors at G2 phase 
delays cell cycle progression and reduces mitotic aberrations." Cell Signal 20(7): 
1349-58. 
Naor, Z., O. Benard, et al. (2000). "Activation of MAPK cascades by G-protein-coupled 
receptors: the case of gonadotropin-releasing hormone receptor." Trends Endocrinol 
Metab 11(3): 91-9. 
Nardozzi, J. D., K. Lott, et al. (2010). "Phosphorylation meets nuclear import: a review." Cell 
Commun Signal 8: 32. 
Neufeld, G., T. Cohen, et al. (1999). "Vascular endothelial growth factor (VEGF) and its 
receptors." FASEB J 13(1): 9-22. 
Newton, A. C. (2003). "Regulation of the ABC kinases by phosphorylation: protein kinase C 
as a paradigm." Biochem J 370(Pt 2): 361-71. 
Ni, S., C. Zhao, et al. (2007). "A novel Stat3 binding motif in Gab2 mediates transformation 
of primary hematopoietic cells by the Stk/Ron receptor tyrosine kinase in response to 
Friend virus infection." Mol Cell Biol 27(10): 3708-15. 
 175 
 
Nishida, K., L. Wang, et al. (2002). "Requirement of Gab2 for mast cell development and 
KitL/c-Kit signaling." Blood 99(5): 1866-9. 
Nowak, G. (2002). "Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, 
decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells." J Biol 
Chem 277(45): 43377-88. 
Obata, T., M. B. Yaffe, et al. (2000). "Peptide and protein library screening defines optimal 
substrate motifs for AKT/PKB." J Biol Chem 275(46): 36108-15. 
Onder, T. T., P. B. Gupta, et al. (2008). "Loss of E-cadherin promotes metastasis via multiple 
downstream transcriptional pathways." Cancer Res 68(10): 3645-54. 
Pages, G., S. Guerin, et al. (1999). "Defective thymocyte maturation in p44 MAP kinase (Erk 
1) knockout mice." Science 286(5443): 1374-7. 
Palamarchuk, A., A. Efanov, et al. (2005). "Akt phosphorylates and regulates Pdcd4 tumor 
suppressor protein." Cancer Res 65(24): 11282-6. 
Papkoff, J., R. H. Chen, et al. (1994). "p42 mitogen-activated protein kinase and p90 
ribosomal S6 kinase are selectively phosphorylated and activated during 
thrombin-induced platelet activation and aggregation." Mol Cell Biol 14(1): 463-72. 
Patan, S. (2004). "Vasculogenesis and angiogenesis." Cancer Treat Res 117: 3-32. 
Pawson, T. and J. Schlessingert (1993). "SH2 and SH3 domains." Curr Biol 3(7): 434-42. 
Pende, M., S. H. Um, et al. (2004). "S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and 
rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a 
mitogen-activated protein kinase-dependent S6 kinase pathway." Mol Cell Biol 24(8): 
3112-24. 
Peng, C., Y. Y. Cho, et al. (2010). "RSK2 mediates NF-{kappa}B activity through the 
phosphorylation of IkappaBalpha in the TNF-R1 pathway." FASEB J 24(9): 3490-9. 
Poirier, R., S. Jacquot, et al. (2007). "Deletion of the Coffin-Lowry syndrome gene Rsk2 in 
mice is associated with impaired spatial learning and reduced control of exploratory 
behavior." Behav Genet 37(1): 31-50. 
 176 
 
Porter, A. C. and R. R. Vaillancourt (1998). "Tyrosine kinase receptor-activated signal 
transduction pathways which lead to oncogenesis." Oncogene 17(11 Reviews): 1343-52. 
Prat, A., J. S. Parker, et al. (2010). "Phenotypic and molecular characterization of the 
claudin-low intrinsic subtype of breast cancer." Breast Cancer Res 12(5): R68. 
Pruett, W., Y. Yuan, et al. (1995). "Association between GRB2/Sos and insulin receptor 
substrate 1 is not sufficient for activation of extracellular signal-regulated kinases by 
interleukin-4: implications for Ras activation by insulin." Mol Cell Biol 15(3): 1778-85. 
Qian, P., Z. Zuo, et al. (2011). "Pivotal role of reduced let-7g expression in breast cancer 
invasion and metastasis." Cancer Res 71(20): 6463-74. 
Rak, J., Y. Mitsuhashi, et al. (1995). "Mutant ras oncogenes upregulate VEGF/VPF 
expression: implications for induction and inhibition of tumor angiogenesis." Cancer Res 
55(20): 4575-80. 
Ranganathan, A., M. N. Yazicioglu, et al. (2006). "The nuclear localization of ERK2 occurs 
by mechanisms both independent of and dependent on energy." J Biol Chem 281(23): 
15645-52. 
Rasola, A., M. Sciacovelli, et al. (2010). "Activation of mitochondrial ERK protects cancer 
cells from death through inhibition of the permeability transition." Proc Natl Acad Sci U 
S A 107(2): 726-31. 
Ray-David, H., Y. Romeo, et al. (2012). "RSK promotes G2 DNA damage checkpoint 
silencing and participates in melanoma chemoresistance." Oncogene 32(38): 4480-9. 
Rebecchi, M. J. and S. Scarlata (1998). "Pleckstrin homology domains: a common fold with 
diverse functions." Annu Rev Biophys Biomol Struct 27: 503-28. 
Richards, S. A., V. C. Dreisbach, et al. (2001). "Characterization of regulatory events 
associated with membrane targeting of p90 ribosomal S6 kinase 1." Mol Cell Biol 21(21): 
7470-80. 
Richards, S. A., J. Fu, et al. (1999). "Ribosomal S6 kinase 1 (RSK1) activation requires 
signals dependent on and independent of the MAP kinase ERK." Curr Biol 9(15): 
 177 
 
810-20. 
Robertson, S. E., S. R. Setty, et al. (2006). "Extracellular signal-regulated kinase regulates 
clathrin-independent endosomal trafficking." Mol Biol Cell 17(2): 645-57. 
Robinson, M. J., S. A. Stippec, et al. (1998). "A constitutively active and nuclear form of the 
MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation." Curr Biol 
8(21): 1141-50. 
Rocchi, S., S. Tartare-Deckert, et al. (1998). "Determination of Gab1 (Grb2-associated 
binder-1) interaction with insulin receptor-signaling molecules." Mol Endocrinol 12(7): 
914-23. 
Rodrigues, G. A., M. Falasca, et al. (2000). "A novel positive feedback loop mediated by the 
docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor 
receptor signaling." Mol Cell Biol 20(4): 1448-59. 
Rodriguez-Manzaneque, J. C., T. F. Lane, et al. (2001). "Thrombospondin-1 suppresses 
spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and 
mobilization of vascular endothelial growth factor." Proc Natl Acad Sci U S A 98(22): 
12485-90. 
Romeo, Y., J. Moreau, et al. (2012). "RSK regulates activated BRAF signalling to mTORC1 
and promotes melanoma growth." Oncogene 32(24): 2917-26. 
Romeo, Y., X. Zhang, et al. (2011). "Regulation and function of the RSK family of protein 
kinases." Biochem J 441(2): 553-69. 
Roshan, B., C. Kjelsberg, et al. (1999). "Activated ERK2 interacts with and phosphorylates 
the docking protein GAB1." J Biol Chem 274(51): 36362-8. 
Roskoski, R., Jr. (2012). "ERK1/2 MAP kinases: structure, function, and regulation." 
Pharmacol Res 66(2): 105-43. 
Roux, P. P., B. A. Ballif, et al. (2004). "Tumor-promoting phorbol esters and activated Ras 
inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 
kinase." Proc Natl Acad Sci U S A 101(37): 13489-94. 
 178 
 
Roux, P. P., S. A. Richards, et al. (2003). "Phosphorylation of p90 ribosomal S6 kinase (RSK) 
regulates extracellular signal-regulated kinase docking and RSK activity." Mol Cell Biol 
23(14): 4796-804. 
Roux, P. P., D. Shahbazian, et al. (2007). "RAS/ERK signaling promotes site-specific 
ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent 
translation." J Biol Chem 282(19): 14056-64. 
Sachs, M., H. Brohmann, et al. (2000). "Essential role of Gab1 for signaling by the c-Met 
receptor in vivo." J Cell Biol 150(6): 1375-84. 
Saha, M., A. Carriere, et al. (2012). "RSK phosphorylates SOS1 creating 14-3-3-docking sites 
and negatively regulating MAPK activation." Biochem J 447(1): 159-66. 
Salazar, L., T. Kashiwada, et al. (2009). "A novel interaction between fibroblast growth factor 
receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent 
regulation of ERK by p85 in multiple myeloma cells." Hum Mol Genet 18(11): 1951-61. 
Sapkota, G. P., L. Cummings, et al. (2007). "BI-D1870 is a specific inhibitor of the p90 RSK 
(ribosomal S6 kinase) isoforms in vitro and in vivo." Biochem J 401(1): 29-38. 
Sattler, M., M. G. Mohi, et al. (2002). "Critical role for Gab2 in transformation by 
BCR/ABL." Cancer Cell 1(5): 479-92. 
Schaeffer, H. J., A. D. Catling, et al. (1998). "MP1: a MEK binding partner that enhances 
enzymatic activation of the MAP kinase cascade." Science 281(5383): 1668-71. 
Schechter, A. L., D. F. Stern, et al. (1984). "The neu oncogene: an erb-B-related gene 
encoding a 185,000-Mr tumour antigen." Nature 312(5994): 513-6. 
Scherr, M., A. Chaturvedi, et al. (2006). "Enhanced sensitivity to inhibition of SHP2, STAT5, 
and Gab2 expression in chronic myeloid leukemia (CML)." Blood 107(8): 3279-87. 
Schuler, M. and D. R. Green (2001). "Mechanisms of p53-dependent apoptosis." Biochem Soc 
Trans 29(Pt 6): 684-8. 
Schutzman, J. L., C. Z. Borland, et al. (2001). "The Caenorhabditis elegans EGL-15 signaling 
pathway implicates a DOS-like multisubstrate adaptor protein in fibroblast growth factor 
 179 
 
signal transduction." Mol Cell Biol 21(23): 8104-16. 
Schwartz, G. K. and M. A. Shah (2005). "Targeting the cell cycle: a new approach to cancer 
therapy." J Clin Oncol 23(36): 9408-21. 
Schwartz, M. (2004). "Rho signalling at a glance." J Cell Sci 117(Pt 23): 5457-8. 
Seidel, J. J. and B. J. Graves (2002). "An ERK2 docking site in the Pointed domain 
distinguishes a subset of ETS transcription factors." Genes Dev 16(1): 127-37. 
Seiffert, M., J. M. Custodio, et al. (2003). "Gab3-deficient mice exhibit normal development 
and hematopoiesis and are immunocompetent." Mol Cell Biol 23(7): 2415-24. 
Senechal, K., J. Halpern, et al. (1996). "The CRKL adaptor protein transforms fibroblasts and 
functions in transformation by the BCR-ABL oncogene." J Biol Chem 271(38): 
23255-61. 
Shahbazian, D., P. P. Roux, et al. (2006). "The mTOR/PI3K and MAPK pathways converge 
on eIF4B to control its phosphorylation and activity." EMBO J 25(12): 2781-91. 
Sharma, C., T. Vomastek, et al. (2005). "MEK partner 1 (MP1): regulation of oligomerization 
in MAP kinase signaling." J Cell Biochem 94(4): 708-19. 
Sharma, N., S. Everingham, et al. (2014). "SHP2 phosphatase promotes mast cell chemotaxis 
toward stem cell factor via enhancing activation of the Lyn/Vav/Rac signaling axis." J 
Immunol 192(10): 4859-66. 
Shaul, Y. D. and R. Seger (2006). "ERK1c regulates Golgi fragmentation during mitosis." J 
Cell Biol 172(6): 885-97. 
Shaulian, E. and M. Karin (2001). "AP-1 in cell proliferation and survival." Oncogene 20(19): 
2390-400. 
Sherr, C. J. and F. McCormick (2002). "The RB and p53 pathways in cancer." Cancer Cell 
2(2): 103-12. 
Shin, S., C. A. Dimitri, et al. (2010). "ERK2 but not ERK1 induces epithelial-to-mesenchymal 
transformation via DEF motif-dependent signaling events." Mol Cell 38(1): 114-27. 
 180 
 
Shweiki, D., A. Itin, et al. (1992). "Vascular endothelial growth factor induced by hypoxia 
may mediate hypoxia-initiated angiogenesis." Nature 359(6398): 843-5. 
Smith, J. A., C. E. Poteet-Smith, et al. (1999). "Identification of an extracellular 
signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical 
for activation by ERK in vivo." J Biol Chem 274(5): 2893-8. 
Smith, J. A., C. E. Poteet-Smith, et al. (2005). "Identification of the first specific inhibitor of 
p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell 
proliferation." Cancer Res 65(3): 1027-34. 
Smolen, G. A., J. Zhang, et al. (2010). "A genome-wide RNAi screen identifies multiple 
RSK-dependent regulators of cell migration." Genes Dev 24(23): 2654-65. 
Somasundaram, K. (2003). "Breast cancer gene 1 (BRCA1): role in cell cycle regulation and 
DNA repair--perhaps through transcription." J Cell Biochem 88(6): 1084-91. 
Song, T., K. Sugimoto, et al. (2007). "p90 RSK-1 associates with and inhibits neuronal nitric 
oxide synthase." Biochem J 401(2): 391-8. 
Sonnenblick, A., C. Levy, et al. (2004). "Interplay between MITF, PIAS3, and STAT3 in 
mast cells and melanocytes." Mol Cell Biol 24(24): 10584-92. 
Sturgill, T. W., L. B. Ray, et al. (1988). "Insulin-stimulated MAP-2 kinase phosphorylates and 
activates ribosomal protein S6 kinase II." Nature 334(6184): 715-8. 
Sulzmaier, F. J. and J. W. Ramos (2013). "RSK isoforms in cancer cell invasion and 
metastasis." Cancer Res 73(20): 6099-105. 
Sun, Y., G. Nie, et al. (2014). "Luminal breast cancer classification according to proliferative 
indices: clinicopathological characteristics and short-term survival analysis." Med Oncol 
31(7): 55. 
Taki, M., N. Kamata, et al. (2003). "Down-regulation of Wnt-4 and up-regulation of Wnt-5a 
expression by epithelial-mesenchymal transition in human squamous carcinoma cells." 
Cancer Sci 94(7): 593-7. 
Takino, T., H. Tsuge, et al. (2010). "MT1-MMP promotes cell growth and ERK activation 
 181 
 
through c-Src and paxillin in three-dimensional collagen matrix." Biochem Biophys Res 
Commun 396(4): 1042-7. 
Tamimi, R. M., H. J. Baer, et al. (2008). "Comparison of molecular phenotypes of ductal 
carcinoma in situ and invasive breast cancer." Breast Cancer Res 10(4): R67. 
Tan, Y., H. Ruan, et al. (1999). "p90(RSK) blocks bad-mediated cell death via a protein 
kinase C-dependent pathway." J Biol Chem 274(49): 34859-67. 
Tanoue, T., R. Maeda, et al. (2001). "Identification of a docking groove on ERK and p38 
MAP kinases that regulates the specificity of docking interactions." EMBO J 20(3): 
466-79. 
Tanoue, T. and E. Nishida (2003). "Molecular recognitions in the MAP kinase cascades." Cell 
Signal 15(5): 455-62. 
Tanoue, T., T. Yamamoto, et al. (2001). "A Novel MAPK phosphatase MKP-7 acts 
preferentially on JNK/SAPK and p38 alpha and beta MAPKs." J Biol Chem 276(28): 
26629-39. 
Teis, D., N. Taub, et al. (2006). "p14-MP1-MEK1 signaling regulates endosomal traffic and 
cellular proliferation during tissue homeostasis." J Cell Biol 175(6): 861-8. 
Terauchi, Y., Y. Tsuji, et al. (1999). "Increased insulin sensitivity and hypoglycaemia in mice 
lacking the p85 alpha subunit of phosphoinositide 3-kinase." Nat Genet 21(2): 230-5. 
Thakur, A., K. W. Rahman, et al. (2007). "Aberrant expression of X-linked genes RbAp46, 
Rsk4, and Cldn2 in breast cancer." Mol Cancer Res 5(2): 171-81. 
Therrien, M., H. C. Chang, et al. (1995). "KSR, a novel protein kinase required for RAS 
signal transduction." Cell 83(6): 879-88. 
Thomas, G. M., G. R. Rumbaugh, et al. (2005). "Ribosomal S6 kinase 2 interacts with and 
phosphorylates PDZ domain-containing proteins and regulates AMPA receptor 
transmission." Proc Natl Acad Sci U S A 102(42): 15006-11. 
Tohgo, A., K. L. Pierce, et al. (2002). "beta-Arrestin scaffolding of the ERK cascade enhances 
cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin 
 182 
 
AT1a receptor stimulation." J Biol Chem 277(11): 9429-36. 
Topham, C. H. and S. S. Taylor (2013). "Mitosis and apoptosis: how is the balance set?" Curr 
Opin Cell Biol 25(6): 780-5. 
Torii, S., M. Kusakabe, et al. (2004). "Sef is a spatial regulator for Ras/MAP kinase 
signaling." Dev Cell 7(1): 33-44. 
Tunquist, B. J., M. S. Schwab, et al. (2002). "The spindle checkpoint kinase bub1 and cyclin 
e/cdk2 both contribute to the establishment of meiotic metaphase arrest by cytostatic 
factor." Curr Biol 12(12): 1027-33. 
Turke, A. B., Y. Song, et al. (2012). "MEK inhibition leads to PI3K/AKT activation by 
relieving a negative feedback on ERBB receptors." Cancer Res 72(13): 3228-37. 
Ubersax, J. A. and J. E. Ferrell, Jr. (2007). "Mechanisms of specificity in protein 
phosphorylation." Nat Rev Mol Cell Biol 8(7): 530-41. 
Ucuzian, A. A., A. A. Gassman, et al. (2010). "Molecular mediators of angiogenesis." J Burn 
Care Res 31(1): 158-75. 
Vaidyanathan, H. and J. W. Ramos (2003). "RSK2 activity is regulated by its interaction with 
PEA-15." J Biol Chem 278(34): 32367-72. 
Vasiljeva, O., A. Papazoglou, et al. (2006). "Tumor cell-derived and macrophage-derived 
cathepsin B promotes progression and lung metastasis of mammary cancer." Cancer Res 
66(10): 5242-50. 
Vesuna, F., P. van Diest, et al. (2008). "Twist is a transcriptional repressor of E-cadherin gene 
expression in breast cancer." Biochem Biophys Res Commun 367(2): 235-41. 
Vik, T. A. and J. W. Ryder (1997). "Identification of serine 380 as the major site of 
autophosphorylation of Xenopus pp90rsk." Biochem Biophys Res Commun 235(2): 
398-402. 
Vu, T. H. and Z. Werb (2000). "Matrix metalloproteinases: effectors of development and 
normal physiology." Genes Dev 14(17): 2123-33. 
 183 
 
Wada, T., T. Nakashima, et al. (2005). "The molecular scaffold Gab2 is a crucial component 
of RANK signaling and osteoclastogenesis." Nat Med 11(4): 394-9. 
Wang, L. and L. J. Di (2014). "BRCA1 And Estrogen/Estrogen Receptor In Breast Cancer: 
Where They Interact?" Int J Biol Sci 10(5): 563-573. 
Wang, R., S. Y. Jung, et al. (2010). "Direct roles of the signaling kinase RSK2 in Cdc25C 
activation during Xenopus oocyte maturation." Proc Natl Acad Sci U S A 107(46): 
19885-90. 
Wang, Y. and R. Prywes (2000). "Activation of the c-fos enhancer by the erk MAP kinase 
pathway through two sequence elements: the c-fos AP-1 and p62TCF sites." Oncogene 
19(11): 1379-85. 
Wang, Y., Q. Sheng, et al. (2011). "Gab2 regulates the migratory behaviors and E-cadherin 
expression via activation of the PI3K pathway in ovarian cancer cells." Oncogene 31(20): 
2512-20. 
Wang, Z., H. Yang, et al. (2006). "Phosphatase-mediated crosstalk control of ERK and p38 
MAPK signaling in corneal epithelial cells." Invest Ophthalmol Vis Sci 47(12): 5267-75. 
Wei, J. H. and J. Seemann (2009). "Remodeling of the Golgi structure by ERK signaling." 
Commun Integr Biol 2(1): 35-6. 
Welsh, G. I., C. M. Miller, et al. (1998). "Regulation of eukaryotic initiation factor eIF2B: 
glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes 
dephosphorylation in response to insulin." FEBS Lett 421(2): 125-30. 
Williams, M. R., J. S. Arthur, et al. (2000). "The role of 3-phosphoinositide-dependent protein 
kinase 1 in activating AGC kinases defined in embryonic stem cells." Curr Biol 10(8): 
439-48. 
Wohrle, F. U., R. J. Daly, et al. (2009). "Function, regulation and pathological roles of the 
Gab/DOS docking proteins." Cell Commun Signal 7: 22. 
Wohrle, F. U., S. Halbach, et al. (2012). "Gab2 signaling in chronic myeloid leukemia cells 
confers resistance to multiple Bcr-Abl inhibitors." Leukemia 27(1): 118-29. 
 184 
 
Wolf, I., B. J. Jenkins, et al. (2002). "Gab3, a new DOS/Gab family member, facilitates 
macrophage differentiation." Mol Cell Biol 22(1): 231-44. 
Woo, M. S., Y. Ohta, et al. (2004). "Ribosomal S6 kinase (RSK) regulates phosphorylation of 
filamin A on an important regulatory site." Mol Cell Biol 24(7): 3025-35. 
Wortzel, I. and R. Seger (2011). "The ERK Cascade: Distinct Functions within Various 
Subcellular Organelles." Genes Cancer 2(3): 195-209. 
Wu, C. F., S. Liu, et al. (2013). "RSK promotes G2/M transition through activating 
phosphorylation of Cdc25A and Cdc25B." Oncogene. 
Wu, J. and R. Janknecht (2002). "Regulation of the ETS transcription factor ER81 by the 
90-kDa ribosomal S6 kinase 1 and protein kinase A." J Biol Chem 277(45): 42669-79. 
Wu, J., F. Meng, et al. (2008). "Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation 
and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells." 
Blood 111(7): 3821-9. 
Xie, Z. H., I. Ambudkar, et al. (2002). "The adapter molecule Gab2 regulates Fc epsilon 
RI-mediated signal transduction in mast cells." J Immunol 168(9): 4682-91. 
Xing, H., K. Kornfeld, et al. (1997). "The protein kinase KSR interacts with 14-3-3 protein 
and Raf." Curr Biol 7(5): 294-300. 
Xing, J., D. D. Ginty, et al. (1996). "Coupling of the RAS-MAPK pathway to gene activation 
by RSK2, a growth factor-regulated CREB kinase." Science 273(5277): 959-63. 
Xing, J., J. M. Kornhauser, et al. (1998). "Nerve growth factor activates extracellular 
signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate 
CREB serine 133 phosphorylation." Mol Cell Biol 18(4): 1946-55. 
Xu, J., S. Lamouille, et al. (2009). "TGF-beta-induced epithelial to mesenchymal transition." 
Cell Res 19(2): 156-72. 
Yamada, K., K. Nishida, et al. (2001). "Comparative FISH mapping of Gab1 and Gab2 genes 
in human, mouse and rat." Cytogenet Cell Genet 94(1-2): 39-42. 
 185 
 
Yamazaki, T., K. Zaal, et al. (2002). "Role of Grb2 in EGF-stimulated EGFR internalization." 
J Cell Sci 115(Pt 9): 1791-802. 
Yamnik, R. L. and M. K. Holz (2009). "mTOR/S6K1 and MAPK/RSK signaling pathways 
coordinately regulate estrogen receptor alpha serine 167 phosphorylation." FEBS Lett 
584(1): 124-8. 
Yang, J. Y., C. S. Zong, et al. (2008). "ERK promotes tumorigenesis by inhibiting FOXO3a 
via MDM2-mediated degradation." Nat Cell Biol 10(2): 138-48. 
Yang, S., M. Ji, et al. (2013). "Phosphorylation of KIBRA by the extracellular 
signal-regulated kinase (ERK)-ribosomal S6 kinase (RSK) cascade modulates cell 
proliferation and migration." Cell Signal 26(2): 343-51. 
Yang, Y., J. Wu, et al. (2012). "GAB2 induces tumor angiogenesis in NRAS-driven 
melanoma." Oncogene 32(31): 3627-37. 
Yarden, Y. (2001). "The EGFR family and its ligands in human cancer. signalling 
mechanisms and therapeutic opportunities." Eur J Cancer 37 Suppl 4: S3-8. 
Yasuda, J., A. J. Whitmarsh, et al. (1999). "The JIP group of mitogen-activated protein kinase 
scaffold proteins." Mol Cell Biol 19(10): 7245-54. 
You, J. S. and P. A. Jones (2012). "Cancer genetics and epigenetics: two sides of the same 
coin?" Cancer Cell 22(1): 9-20. 
Yu, C. F., Z. X. Liu, et al. (2002). "ERK negatively regulates the epidermal growth 
factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase." J Biol Chem 
277(22): 19382-8. 
Yu, C. F., B. Roshan, et al. (2001). "ERK regulates the hepatocyte growth factor-mediated 
interaction of Gab1 and the phosphatidylinositol 3-kinase." J Biol Chem 276(35): 
32552-8. 
Yu, J., Y. Zhang, et al. (1998). "Regulation of the p85/p110 phosphatidylinositol 3'-kinase: 
stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory 
subunit." Mol Cell Biol 18(3): 1379-87. 
 186 
 
Yu, M., J. Luo, et al. (2006). "The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked 
mast cell proliferation by activating the Rac/JNK pathway." J Biol Chem 281(39): 
28615-26. 
Yu, Y., S. O. Yoon, et al. (2011). "Phosphoproteomic analysis identifies Grb10 as an 
mTORC1 substrate that negatively regulates insulin signaling." Science 332(6035): 
1322-6. 
Zeniou, M., T. Ding, et al. (2002). "Expression analysis of RSK gene family members: the 
RSK2 gene, mutated in Coffin-Lowry syndrome, is prominently expressed in brain 
structures essential for cognitive function and learning." Hum Mol Genet 11(23): 
2929-40. 
Zhang, H. S., A. A. Postigo, et al. (1999). "Active transcriptional repression by the Rb-E2F 
complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition." 
Cell 97(1): 53-61. 
Zhang, J., L. S. Barak, et al. (1997). "A central role for beta-arrestins and clathrin-coated 
vesicle-mediated endocytosis in beta2-adrenergic receptor resensitization. Differential 
regulation of receptor resensitization in two distinct cell types." J Biol Chem 272(43): 
27005-14. 
Zhang, X., G. Lavoie, et al. (2013). "Gab2 phosphorylation by RSK inhibits Shp2 recruitment 
and cell motility." Mol Cell Biol 33(8): 1657-70. 
Zhao, C., H. Ma, et al. (2003). "GC-GAP, a Rho family GTPase-activating protein that 
interacts with signaling adapters Gab1 and Gab2." J Biol Chem 278(36): 34641-53. 
Zhao, C., D. H. Yu, et al. (1999). "Gab2, a new pleckstrin homology domain-containing 
adapter protein, acts to uncouple signaling from ERK kinase to Elk-1." J Biol Chem 
274(28): 19649-54. 
Zhao, J., X. Yuan, et al. (2003). "ERK-dependent phosphorylation of the transcription 
initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth." 
Mol Cell 11(2): 405-13. 
 187 
 
Zhao, Y., C. Bjorbaek, et al. (1995). "RSK3 encodes a novel pp90rsk isoform with a unique 
N-terminal sequence: growth factor-stimulated kinase function and nuclear 
translocation." Mol Cell Biol 15(8): 4353-63. 
Zhu, J., J. Blenis, et al. (2008). "Activation of PI3K/Akt and MAPK pathways regulates 
Myc-mediated transcription by phosphorylating and promoting the degradation of 
Mad1." Proc Natl Acad Sci U S A 105(18): 6584-9. 
Zilfou, J. T. and S. W. Lowe (2009). "Tumor suppressive functions of p53." Cold Spring 
Harb Perspect Biol 1(5): a001883. 
 
  
 
